<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LFMD="http://lifemd.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lfmd-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockParValue.01PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue.01PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TelehealthRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:TelehealthRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TelehealthRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:TelehealthRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkSimpliRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:WorkSimpliRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkSimpliRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:WorkSimpliRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="AsOf2016-04-01_custom_ImmudynePrLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ImmudynePrLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-01</instant>
        </period>
    </context>
    <context id="AsOf2019-04-25_custom_ConversionLabsPrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_custom_LegalSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">LFMD:LegalSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-01-22_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-03-312023-03-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-182022-01-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="From2022-01-182022-01-18_custom_FirstAndSecondAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LFMD:FirstAndSecondAnniversariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:StockPurchaseAgreeementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-04</startDate>
            <endDate>2023-02-04</endDate>
        </period>
    </context>
    <context id="From2023-02-042023-02-04_srt_MinimumMember_custom_StockPurchaseAgreeementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:StockPurchaseAgreeementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-04</startDate>
            <endDate>2023-02-04</endDate>
        </period>
    </context>
    <context id="From2023-02-062023-02-06_custom_FirstOfFiveQuarterlyInstallmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:FirstOfFiveQuarterlyInstallmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="From2023-04-172023-04-17_custom_SecondOfFiveQuarterlyInstallmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:SecondOfFiveQuarterlyInstallmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="From2023-07-172023-07-17_custom_ThirdOfFiveQuarterlyInstallmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ThirdOfFiveQuarterlyInstallmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="From2023-10-172023-10-17_custom_FourthOfFiveQuarterlyInstallmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:FourthOfFiveQuarterlyInstallmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-17</startDate>
            <endDate>2023-10-17</endDate>
        </period>
    </context>
    <context id="From2024-01-162024-01-16_custom_FifthQuarterlyInstallmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:FifthQuarterlyInstallmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-16</startDate>
            <endDate>2024-01-16</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-21_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="From2023-03-212023-03-21_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="From2023-09-262023-09-26_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AvenueFacilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AvenueFacilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-11_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="AsOf2023-12-12_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-12-112023-12-11_custom_MedifastPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:MedifastPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-11_custom_MedifastPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:MedifastPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="AsOf2024-06-07_custom_SharesAndSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:SharesAndSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-07</instant>
        </period>
    </context>
    <context id="From2024-06-072024-06-07_custom_ATMSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-07</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ATMSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwentyTwentyFourShelfMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwentyTwentyFourShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-07_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LifeMDPCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:LifeMDPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LifeMDPCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:LifeMDPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LifeMDPCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:LifeMDPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LifeMDPCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:LifeMDPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SoftwareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:SoftwareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SoftwareRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:SoftwareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MedifastIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TeleHealthInProcessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:TeleHealthInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TeleHealthInProcessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:TeleHealthInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkSimpliInProcessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:WorkSimpliInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkSimpliInProcessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:WorkSimpliInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TelehealthSubscriptionRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthSubscriptionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TelehealthSubscriptionRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthSubscriptionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MedifastCollaborationRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:MedifastCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MedifastCollaborationRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:MedifastCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LFMD:RestrictedStockUnitsAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LFMD:RestrictedStockUnitsAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertibleLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LFMD:ConvertibleLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LFMD:ConvertibleLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_ResumeBuildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">LFMD:ResumeBuildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_ResumeBuildMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">LFMD:ResumeBuildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ResumeBuildBrandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ResumeBuildBrandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ResumeBuildBrandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ResumeBuildBrandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerRelationshipAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:CustomerRelationshipAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerRelationshipAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:CustomerRelationshipAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClearedTradeNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ClearedTradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClearedTradeNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ClearedTradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClearedDevelopedTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ClearedDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ClearedDevelopedTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:ClearedDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PurchasedLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:PurchasedLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PurchasedLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:PurchasedLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WebsiteDomainNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:WebsiteDomainNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WebsiteDomainNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">LFMD:WebsiteDomainNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CRGFinancialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:CRGFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TenMonthFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TenMonthFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_custom_WorkingCapitalLoanMember_custom_AmazonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LFMD:WorkingCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AmazonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkingCapitalLoanMember_custom_AmazonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LFMD:WorkingCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AmazonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkingCapitalLoanMember_custom_AmazonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LFMD:WorkingCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AmazonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkingCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LFMD:WorkingCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkingCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LFMD:WorkingCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AvenueFacilityMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-11-15_custom_AvenueFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">LFMD:AvenueFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="From2023-11-152023-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ShelfAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ShelfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OctoberFifteenTwentyTwoAndTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:OctoberFifteenTwentyTwoAndTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OctoberFifteenTwentyThreeAndTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:OctoberFifteenTwentyThreeAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OctoberFifteenTwentyFourAndTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:OctoberFifteenTwentyFourAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OctoberFifteenTwentyFiveAndAfterFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:OctoberFifteenTwentyFiveAndAfterFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-27_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-27</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockPurchaseAgreeementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:StockPurchaseAgreeementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ATMSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_HarborsideMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:HarborsideMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-10_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="AsOf2023-08-14_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="From2023-07-102023-07-10_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="From2023-08-142023-08-14_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-12_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-12</instant>
        </period>
    </context>
    <context id="AsOf2023-08-15_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="From2023-03-202023-03-21_custom_AvenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AvenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-21_custom_AvenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AvenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="From2023-11-152023-11-15_custom_AvenueMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:AvenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="From2023-12-102023-12-11_custom_MedifastMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-11_custom_MedifastMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="From2023-12-102023-12-11_custom_MedifastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MedifastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-22_custom_ConversionLabsPRLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="From2021-01-202021-01-22_custom_ConversionLabsPRLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-22_custom_ConversionLabsPRLLCMember_custom_OperatingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OperatingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="AsOf2021-01-22_custom_ConversionLabsPRLLCMember_custom_OperatingAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OperatingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OptionAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OptionAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_OptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:ConversionLabsPRLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-11-15_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-15</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q2DividendsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">LFMD:S2023Q2DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="From2023-07-282023-07-28_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q3DividendsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">LFMD:S2023Q3DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-09-302023-09-30_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q4DividendsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">LFMD:S2023Q4DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2023-10-312023-10-31_custom_WorkSimpliSoftwareLlcMember_custom_O2023Q4DividendsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">LFMD:O2023Q4DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkSimpliSoftwareLlcMember_custom_S2024Q1DividendsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">LFMD:S2024Q1DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkSimpliSoftwareLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">LFMD:WorkSimpliSoftwareLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-08_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-08</instant>
        </period>
    </context>
    <context id="AsOf2021-01-02_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-02</instant>
        </period>
    </context>
    <context id="AsOf2021-06-24_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-24</instant>
        </period>
    </context>
    <context id="AsOf2022-06-16_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember18577125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantAndRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:WarrantAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantAndRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:WarrantAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LFMD:RestrictedStockUnitsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember18578218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_CO">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LancasterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">LFMD:LancasterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2016-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="From2016-01-012016-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PilarisLaboratoriesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:PilarisLaboratoriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_MALPHABETLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MALPHABETLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:CommonStockOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MALPHABETLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:CommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MALPHABETLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LFMD:CommonStockThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LFMD:MALPHABETLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-052023-09-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2023-09-05</startDate>
            <endDate>2023-09-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SoftwareDevelopmentServicesMember_custom_WorkSimpliSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:SoftwareDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:WorkSimpliSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SoftwareDevelopmentServicesMember_custom_WorkSimpliSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:SoftwareDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:WorkSimpliSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkSimpliSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:WorkSimpliSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkSimpliSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:WorkSimpliSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LegalServicesMember_custom_KingAndSpaldingLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:LegalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:KingAndSpaldingLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LegalServicesMember_custom_KingAndSpaldingLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LFMD:LegalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:KingAndSpaldingLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_KingAndSpaldingLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:KingAndSpaldingLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_KingAndSpaldingLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">LFMD:KingAndSpaldingLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-302023-05-30_custom_WillFebboMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:WillFebboMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WillFebboMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:WillFebboMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-06-142023-06-14_custom_RobertJindalMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:RobertJindalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-14</startDate>
            <endDate>2023-06-14</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RobertJindalMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:RobertJindalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-172024-07-17_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:NaveenBhatiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-17</startDate>
            <endDate>2024-07-17</endDate>
        </period>
    </context>
    <context id="From2024-06-142024-06-14_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:NaveenBhatiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LFMD:NaveenBhatiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LFMD:ConsultingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StaceyRobertsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LFMD:StaceyRobertsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StaceyRobertsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LFMD:StaceyRobertsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TelehealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:TelehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WorkSimpliMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LFMD:WorkSimpliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-02-012025-02-28_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="From2025-02-012025-02-28_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>LFMD:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0000948320</dei:EntityCentralIndexKey>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_TreasurySharesMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForLegalSettlement
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:NetPaymentsForMembershipInterestInWorksimpli
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0771"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:StockIssuedForDebtConversion
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:SeriesBPreferredStockConversion
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0810"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:NonCashWarrantsIssuedForDebtInstruments
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <LFMD:PurchasePricePayableOne
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="xdx2ixbrl1629"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="xdx2ixbrl1631"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="xdx2ixbrl1633"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="xdx2ixbrl1748"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1826"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1828"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1830"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1832"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1850"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1852"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1864"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl1866"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      id="xdx2ixbrl1951"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      id="xdx2ixbrl1995"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="xdx2ixbrl2007"
      unitRef="Shares"
      xsi:nil="true"/>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="xdx2ixbrl2009"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="xdx2ixbrl2021"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationDeductionsDividends
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      id="xdx2ixbrl2384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      id="xdx2ixbrl2432"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000017">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000019">001-39785</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000020">LIFEMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000022">76-0238453</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000023">236     Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000024">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000025">New     York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000026">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000028">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000029">351-5907</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue.01PerShareMember"
      id="Fact000030">Common     Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue.01PerShareMember"
      id="Fact000031">LFMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue.01PerShareMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember"
      id="Fact000033">8.875%     Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember"
      id="Fact000034">LFMDP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember"
      id="Fact000035">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000036">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000037">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000038">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000039">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000040">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000041">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000043">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="0"
      id="Fact000047"
      unitRef="USD">242784078</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-07"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">44583688</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000050">Portions
of the 2025 definitive proxy statement for the Registrant&#x2019;s Annual Meeting of Stockholders, to be filed within 120 days of our
fiscal year end (December 31, 2024) are incorporated by reference into Part III of this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000054">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of our business, we receive, process, use, store, and share digitally large amounts of data, including user data
as well as confidential, sensitive, proprietary, and personal information. Maintaining the integrity and availability of our information
technology systems and this information, as well as appropriate limitations on access and confidentiality of such information, is important
to our operations and business strategy. To this end, we have implemented a program designed to assess, identify, and manage risks from
potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality,
integrity, and availability of these systems and the data residing in them.&lt;/span&gt;The
program is managed and monitored by a dedicated security team, which is led by our Vice President of Information Security and includes
mechanisms, controls, technologies, systems, policies and other processes designed to prevent or mitigate data loss, theft, misuse, or
other security incidents or vulnerabilities affecting the systems and data residing in them. Cybersecurity incidents are escalated to
management when they meet pre-defined severity and impact criteria and to the Board of Directors for major events. Mitigation and remediation
are monitored by tracking progress, providing regular updates, and measuring key metrics. The Company continues to formalize its cybersecurity
policies and procedures.Our
Vice President of Information Security, who reports directly to the Chief Technology Officer and has over 20 years of experience working
in information technology and information security, including more than two years at the Company, together with our Compliance Team,
are responsible for assessing and managing cybersecurity risks.&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zRsrEdXaJWJ5"&gt; We consider cybersecurity, along with other significant risks that we
face, within our overall enterprise risk management framework. In the last fiscal year, we &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zqEFdY4vh3s7"&gt;have not identified&lt;/span&gt; any prior cybersecurity
incidents that have materially affected us or is reasonably likely to do so, but we face certain ongoing risks from cybersecurity threats
that, if realized, are reasonably likely to materially affect us. &lt;/span&gt;Additional information on cybersecurity risks we face is discussed
in Part I, Item 1A, &#x201c;Risk Factors,&#x201d; under the heading &#x201c;Risks Related to Our Business and Industry.&#x201d;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055"> We consider cybersecurity, along with other significant risks that we
face, within our overall enterprise risk management framework. In the last fiscal year, we &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zqEFdY4vh3s7"&gt;have not identified&lt;/span&gt; any prior cybersecurity
incidents that have materially affected us or is reasonably likely to do so, but we face certain ongoing risks from cybersecurity threats
that, if realized, are reasonably likely to materially affect us. </cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;The
Board of Directors has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage,
and mitigate those risks. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_ziT4f7Llgu8b"&gt;The Board of Directors receives regular updates on cybersecurity and information technology matters and related
risk exposures from members of the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_z67LDehNY49"&gt;senior leadership team&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">The Board of Directors receives regular updates on cybersecurity and information technology matters and related
risk exposures from members of the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_z67LDehNY49"&gt;senior leadership team&lt;/span&gt;.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000059">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <LFMD:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact000061">true</LFMD:NoInsiderTradingFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000063">688</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000064">We
have audited the accompanying consolidated balance sheets of LifeMD, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2024 and
2023, the related consolidated statements of operations, changes in stockholders&#x2019; (deficit) equity and cash flows for each of
the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;consolidated
financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of
the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United
States of America.</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000065">Marcum</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000066">Marlton, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">35004924</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">33146725</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">8217813</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">5277250</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">40763</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">485850</us-gaap:DepositsAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">2797358</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">2759932</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">2672231</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">934510</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">48733089</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">42604267</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">1479184</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">476303</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">6400596</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">594897</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">13816501</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">11795979</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">2030656</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">3009263</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">23726937</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">15876442</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">72460026</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">58480709</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">16009484</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">11084855</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">20811763</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">13937494</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">327597</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">508537</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">603180</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">8444444</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">14480917</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">8828598</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">60255145</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">34781724</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">9885057</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">17927727</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">6265192</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">73849</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">131250</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">76505394</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">52914550</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">5000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">5000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000188"
      unitRef="USDPShares">0</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000190"
      unitRef="USDPShares">0</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000200"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">1610000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">1610000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">1400000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">1400000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">1400000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">1400000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact000214"
      unitRef="USDPShares">25.55</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact000216"
      unitRef="USDPShares">25.55</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">140</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">140</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000221"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000223"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000225"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">42293907</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">38358641</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000233"
      unitRef="Shares">42190867</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000235"
      unitRef="Shares">38255601</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">422939</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">383586</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">230508339</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">217550583</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-236253218</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-214265236</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">103040</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">103040</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">163701</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">163701</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-5485501</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">3505372</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">1440133</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">2060787</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-4045368</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">5566159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">72460026</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">58480709</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_TelehealthRevenueMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">158438631</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_TelehealthRevenueMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">98152919</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliRevenueMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">54015207</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliRevenueMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">54394087</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">212453838</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">152547006</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_TelehealthRevenueMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">21440799</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_TelehealthRevenueMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">17480533</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliRevenueMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">2627680</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliRevenueMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">1419931</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">24068479</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000284"
      unitRef="USD">18900464</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">188385359</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">133646542</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">103020025</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000293"
      unitRef="USD">76451466</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">72662021</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">51694232</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">10217654</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">7632283</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:DevelopmentCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">9512308</us-gaap:DevelopmentCosts>
    <us-gaap:DevelopmentCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">6060513</us-gaap:DevelopmentCosts>
    <us-gaap:OtherGeneralExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">9118032</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">6297321</us-gaap:OtherGeneralExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">204530040</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">148135815</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-16144681</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-14489273</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">2181817</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">2596586</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-18326498</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-17411057</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">428000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">-18728498</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">-17839057</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">153234</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">2756935</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-18881732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-20595992</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">3106250</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">3106250</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">-21987982</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">-23702242</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000340"
      unitRef="USDPShares">-0.53</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000341"
      unitRef="USDPShares">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000343"
      unitRef="USDPShares">-0.53</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000344"
      unitRef="USDPShares">-0.70</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">41196292</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">33905155</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000352"
      unitRef="Shares">41196292</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000353"
      unitRef="Shares">33905155</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">1400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">140</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">31552775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">315528</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">179015250</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-190562994</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_custom_TreasurySharesMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-163701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-11395777</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-475548</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-11871325</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">978500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">9785</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">12479558</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">12489343</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">12489343</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptionsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000388"
      unitRef="Shares">74372</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptionsShares>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">744</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-744</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrantsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">79330</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrantsShares>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">793</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">-793</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">37500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">375</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">94125</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">94500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">94500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <LFMD:StockIssuedDuringPeriodSharesNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000421"
      unitRef="Shares">1068926</LFMD:StockIssuedDuringPeriodSharesNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">10689</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">2557311</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">2568000</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">2568000</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000432"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">531000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">532000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">532000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">873100</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">873100</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">873100</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <LFMD:SaleOfCommonStockUnderAtmNetShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000452"
      unitRef="Shares">1009907</LFMD:SaleOfCommonStockUnderAtmNetShares>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">10099</LFMD:SaleOfCommonStockUnderAtmNet>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">6192560</LFMD:SaleOfCommonStockUnderAtmNet>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">6202659</LFMD:SaleOfCommonStockUnderAtmNet>
    <LFMD:SaleOfCommonStockUnderAtmNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">6202659</LFMD:SaleOfCommonStockUnderAtmNet>
    <LFMD:StockIssuedForDebtInstrumentsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">672042</LFMD:StockIssuedForDebtInstrumentsShares>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">6720</LFMD:StockIssuedForDebtInstruments>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">993280</LFMD:StockIssuedForDebtInstruments>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1000000</LFMD:StockIssuedForDebtInstruments>
    <LFMD:StockIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">1000000</LFMD:StockIssuedForDebtInstruments>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">1224425</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">12244</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">9987756</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">10000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">10000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <LFMD:StockIssuedDuringPeriodSharesLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000485"
      unitRef="Shares">1560864</LFMD:StockIssuedDuringPeriodSharesLegalPreferredStockConversion>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-15609</LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">-5057205</LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">-5072814</LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion>
    <LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">-5072814</LFMD:StockIssuedDuringPeriodValueLegalPreferredStockConversion>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000490"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">144000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">144000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-229025</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">-229025</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-76600</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-305625</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">-20595992</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">-20595992</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">2756935</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-17839057</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000532"
      unitRef="Shares">1400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000523"
      unitRef="USD">140</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000534"
      unitRef="Shares">38358641</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">383586</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">217550583</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">-214265236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_custom_TreasurySharesMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-163701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">3505372</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">2060787</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">5566159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">1400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000536"
      unitRef="USD">140</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">38358641</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000537"
      unitRef="USD">383586</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">217550583</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-214265236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_custom_TreasurySharesMember"
      decimals="0"
      id="Fact000540"
      unitRef="USD">-163701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">3505372</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">2060787</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">5566159</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">1609960</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000550"
      unitRef="USD">16100</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000551"
      unitRef="USD">12218697</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000554"
      unitRef="USD">12234797</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000556"
      unitRef="USD">12234797</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <LFMD:StockIssuedDuringPeriodSharesNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">95821</LFMD:StockIssuedDuringPeriodSharesNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000561"
      unitRef="USD">958</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">641042</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000565"
      unitRef="USD">642000</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">642000</LFMD:StockIssuedDuringPeriodValueNoncontingentConsiderationPayment>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000580"
      unitRef="Shares">86250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">863</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000573"
      unitRef="USD">119449</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">120312</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">120312</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrantsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000591"
      unitRef="Shares">1630458</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrantsShares>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000583"
      unitRef="USD">16305</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000584"
      unitRef="USD">-16305</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockWarrants>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptionsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">512777</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptionsShares>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000594"
      unitRef="USD">5127</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000595"
      unitRef="USD">-5127</LFMD:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000609"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">3106250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000619"
      unitRef="USD">773888</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000620"
      unitRef="USD">773888</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000625"
      unitRef="USD">-18881732</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">-18881732</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">153234</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">-18728498</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000640"
      unitRef="Shares">1400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">140</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">42293907</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">422939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000633"
      unitRef="USD">230508339</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">-236253218</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_custom_TreasurySharesMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">-163701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">-5485501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000637"
      unitRef="USD">1440133</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">-4045368</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">1400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000644"
      unitRef="USD">140</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">42293907</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000645"
      unitRef="USD">422939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">230508339</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000647"
      unitRef="USD">-236253218</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_custom_TreasurySharesMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">-163701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000649"
      unitRef="USD">-5485501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000650"
      unitRef="USD">1440133</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-4045368</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">-18728498</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">-17839057</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000666"
      unitRef="USD">401775</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">333939</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">8021141</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">5424810</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">982405</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">971464</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionExpenseIncludingAssetRetirementObligations
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">13644</us-gaap:AccretionExpenseIncludingAssetRetirementObligations>
    <us-gaap:AccretionExpenseIncludingAssetRetirementObligations
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">167221</us-gaap:AccretionExpenseIncludingAssetRetirementObligations>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">487976</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000679"
      unitRef="USD">203952</us-gaap:Depreciation>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000681"
      unitRef="USD">675669</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">537685</us-gaap:InventoryWriteDown>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <LFMD:OperatingLeasePaymentsAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000687"
      unitRef="USD">776080</LFMD:OperatingLeasePaymentsAdjustments>
    <LFMD:OperatingLeasePaymentsAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">766280</LFMD:OperatingLeasePaymentsAdjustments>
    <LFMD:StockIssuedForLegalSettlement
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000691"
      unitRef="USD">532000</LFMD:StockIssuedForLegalSettlement>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">12234797</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">12489343</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000699"
      unitRef="USD">2940563</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">2442500</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">-445087</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000703"
      unitRef="USD">358585</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000705"
      unitRef="USD">713095</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">-405746</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000708"
      unitRef="USD">1737721</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000709"
      unitRef="USD">247488</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000711"
      unitRef="USD">-485079</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">-808368</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">5652319</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">3281092</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000717"
      unitRef="USD">4924629</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">978062</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000720"
      unitRef="USD">7502624</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">4678757</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">-579319</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">17513190</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">8820232</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireSoftware
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">10041663</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquireSoftware
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000733"
      unitRef="USD">8380602</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000735"
      unitRef="USD">1490857</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">203814</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">3798</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000739"
      unitRef="USD">148868</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-11536318</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">-8733284</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">19466887</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000751"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">2347691</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">6202659</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000759"
      unitRef="USD">327597</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">5142542</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">120312</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">94500</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDividends
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">3106250</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">3106250</us-gaap:PaymentsOfDividends>
    <LFMD:PaymentsToAcquireProductiveAsset
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">31250</LFMD:PaymentsToAcquireProductiveAsset>
    <LFMD:PaymentsToAcquireProductiveAsset
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000769"
      unitRef="USD">312500</LFMD:PaymentsToAcquireProductiveAsset>
    <LFMD:NetPaymentsForMembershipInterestInWorksimpli
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">-305625</LFMD:NetPaymentsForMembershipInterestInWorksimpli>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">773888</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000775"
      unitRef="USD">144000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000777"
      unitRef="USD">-4118673</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">29100820</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">1858199</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000781"
      unitRef="USD">29187768</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">33146725</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">3958957</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">35004924</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000787"
      unitRef="USD">33146725</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">2528042</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000793"
      unitRef="USD">2148454</us-gaap:InterestPaidNet>
    <LFMD:CashlessExerciseOfOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">5127</LFMD:CashlessExerciseOfOptions>
    <LFMD:CashlessExerciseOfOptions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">744</LFMD:CashlessExerciseOfOptions>
    <LFMD:CashlessExerciseOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000801"
      unitRef="USD">16305</LFMD:CashlessExerciseOfWarrants>
    <LFMD:CashlessExerciseOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">793</LFMD:CashlessExerciseOfWarrants>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">642000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">2568000</us-gaap:StockIssued1>
    <LFMD:StockIssuedForDebtConversion
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000808"
      unitRef="USD">1000000</LFMD:StockIssuedForDebtConversion>
    <LFMD:SeriesBPreferredStockConversion
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000811"
      unitRef="USD">5072814</LFMD:SeriesBPreferredStockConversion>
    <LFMD:NonCashWarrantsIssuedForDebtInstruments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000814"
      unitRef="USD">873100</LFMD:NonCashWarrantsIssuedForDebtInstruments>
    <LFMD:RightOfUseAsset
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000816"
      unitRef="USD">6581779</LFMD:RightOfUseAsset>
    <LFMD:RightOfUseAsset
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000817"
      unitRef="USD">155168</LFMD:RightOfUseAsset>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">6581779</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000820"
      unitRef="USD">155168</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-12-31" id="Fact000822">&lt;p id="xdx_80E_eus-gaap--NatureOfOperations_ze76XcHmY2Zh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_828_zjptyI5pUJO4"&gt;NATURE OF THE ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LifeMD,
Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc. The Company changed its name to Conversion
Labs, Inc. on June 22, 2018 and then subsequently, on February 22, 2021, it changed its name to LifeMD, Inc. Effective February 22, 2021,
the trading symbol for the Company&#x2019;s common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20210222_z4CImj7HxGub" title="Common stock per share"&gt;0.01&lt;/span&gt; per share on The Nasdaq Stock Market LLC changed from &#x201c;CVLB&#x201d;
to &#x201c;LFMD&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2016, the original operating agreement of Immudyne PR LLC (&#x201c;Immudyne PR&#x201d;), a joint venture to market the Company&#x2019;s
skincare products, was amended and restated and the Company increased its ownership and voting interest in Immudyne PR to &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20160401__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ImmudynePrLlcMember_zQPTC1Nfh56i" title="Equity method investment, ownership percentage"&gt;78.2&lt;/span&gt;%. Concurrent
with the name change of the parent company to Conversion Labs, Inc., Immudyne PR was renamed to Conversion Labs PR LLC (&#x201c;Conversion
Labs PR&#x201d;). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety to increase
the Company&#x2019;s ownership and voting interest in Conversion Labs PR to &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPrMember_zly51SMCp2U5" title="Equity method investment, ownership percentage"&gt;100&lt;/span&gt;%. On February 22, 2021, concurrent with the name of the
parent company to LifeMD, Inc., Conversion Labs PR was renamed to LifeMD PR, LLC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2018, the Company closed the strategic acquisition of &lt;span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180630__us-gaap--BusinessAcquisitionAxis__custom--LegalSimpliSoftwareLlcMember_zClhZGWqSuvg" title="Voting interests acquired"&gt;51&lt;/span&gt;% of LegalSimpli Software, LLC, which operates a software as a service application
for converting, editing, signing, and sharing PDF documents called PDFSimpli. In addition to LegalSimpli Software, LLC&#x2019;s growth
business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company. On July
15, 2021, LegalSimpli Software, LLC, changed its name to WorkSimpli Software LLC, (&#x201c;WorkSimpli&#x201d;). Effective January 22, 2021,
the Company consummated a transaction to restructure the ownership of WorkSimpli and concurrently increased its ownership interest in
WorkSimpli to &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zN3aEQHO9TQf"&gt;85.6&lt;/span&gt;%. Effective September 30, 2022, two option agreements were exercised which further restructured the ownership of WorkSimpli.
As a result, the Company&#x2019;s ownership interest in WorkSimpli decreased to &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zDmJ96GLz3n7"&gt;73.6&lt;/span&gt;%. Effective December 15, 2022, LifeMD PR, LLC merged
into WorkSimpli, with WorkSimpli being the surviving entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 31, 2023, the Company redeemed &lt;span id="xdx_909_ecustom--NumberOfMembershipInterestUnitsRedeemed_c20230331__20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zK5090a9kVaj" title="Number of membership interest units redeemed"&gt;500&lt;/span&gt; membership interest units in WorkSimpli and, as a result, the Company&#x2019;s ownership interest
in WorkSimpli increased to &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zoglit4CX2V9" title="Ownership Interest"&gt;74.1&lt;/span&gt;%. Effective June 30, 2023, an option agreement was exercised which further restructured the ownership
of WorkSimpli. As a result, the Company&#x2019;s ownership interest in WorkSimpli decreased to &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_z1AyhMz4GcJc" title="Ownership interest"&gt;73.3&lt;/span&gt;%. See Note 8 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 18, 2022, the Company acquired Cleared Technologies, PBC, a Delaware public benefit corporation (&#x201c;Cleared&#x201d;), a nationwide
allergy telehealth platform that provides personalized treatments for allergy, asthma, and immunology (See Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nature
of Business&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access
comprehensive, virtual and in-home healthcare. The Company believes the traditional model of visiting a doctor&#x2019;s office,
traveling to a retail pharmacy, and returning for follow-up care or prescription refills is complex, inefficient, and costly, which
discourages many individuals from seeking medical care. The Company is improving the delivery of the healthcare experience through
telehealth with our proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment
capabilities, and the unique ability to nurture patient relationships. Direct-to-patient telehealth technology companies, like the
Company, connect consumers to affiliated, licensed, healthcare professionals for care across numerous indications, including virtual
medical care, weight loss, sexual health, hormone replacement therapy, hair loss and other conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescription medications,
often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (&#x201c;OTC&#x201d;)
products. All products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments
of prescribed medications or products. This creates convenience and often discounted pricing opportunities for patients and recurring
revenue streams for the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair loss including
Food and Drug Administration (&#x201c;FDA&#x201d;) approved OTC minoxidil and an FDA-cleared medical device and a personalized
telehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a
full line of oral and topical prescription medications for hair loss. The Company&#x2019;s men&#x2019;s brand, RexMD, currently offers
access to virtual medical treatment for a variety of men&#x2019;s health needs, including erectile dysfunction, premature ejaculation and hair loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the first quarter of 2022, the Company launched our virtual primary care offering under the LifeMD brand, LifeMD Primary Care. This
offering provides patients with access to a affiliated high-quality providers for their urgent care and chronic
care needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April 2023, we launched our rapidly growing GLP-1 Weight Management
Program providing primary care, metabolic coaching, lab work, and prescription services (as appropriate) to patients seeking to access
a medically supported weight loss solution. In September 2024, we expanded our Weight Management Program with a personalized, non-GLP-1
treatment plan consisting of three oral medications &#x2013; metformin, bupropion, and topiramate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
and Subsidiary History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2018, the Company closed the strategic acquisition of &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20180630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zZw3dD9hmO4l"&gt;51&lt;/span&gt;% of WorkSimpli. As a result of various ownership restructurings, the Company&#x2019;s
ownership interest in WorkSimpli is &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zjuXGRvs7oKf"&gt;73.3&lt;/span&gt;% as of December 31, 2024. See Note 8 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 18, 2022, the Company acquired Cleared, a nationwide allergy telehealth platform that provides personalized treatments for allergy,
asthma, and immunology. Under the terms of the agreement, the Company acquired all outstanding shares of Cleared at closing in exchange
for a $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20220118__20220118_z0akz2kuIlhf" title="Payments to acquire businesses, net of cash acquired"&gt;460&lt;/span&gt; thousand upfront cash payment, and two non-contingent milestone payments for a total of $&lt;span id="xdx_903_ecustom--MileStonePayment_pn4n6_c20220118__20220118_zijXZ8CX3PVd" title="Milestone payments"&gt;3.46&lt;/span&gt; million ($&lt;span id="xdx_909_ecustom--MileStonePayment_pn4n6_c20220118__20220118__srt--StatementScenarioAxis__custom--FirstAndSecondAnniversariesMember_zEMztAl2Izpe" title="Milestone payments"&gt;1.73&lt;/span&gt; million each
on or before the first and second anniversaries of the closing date). The Company purchased a convertible note from a strategic pharmaceutical
investor for $&lt;span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_pn3n3_c20220118__20220118_zT0PznbPRgp4" title="Conversion of stock converted"&gt;507&lt;/span&gt; thousand which was converted upon closing of the Cleared acquisition. The Company also agreed to a performance-based
earnout based on Cleared&#x2019;s future net sales, payable in cash or shares at the Company&#x2019;s discretion. On February 4, 2023,
the Company entered into the First Amendment (the &#x201c;Cleared First Amendment&#x201d;) to the Stock Purchase Agreement, dated January
11, 2022, between the Company and the sellers of Cleared (the &#x201c;Cleared Stock Purchase Agreement&#x201d;). The Cleared Stock Purchase
Agreement was amended to, among other things: (i) reduce the total purchase price by $&lt;span id="xdx_900_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zsbpQWFXYACj" title="Payments to acquire businesses, net of cash acquired"&gt;250&lt;/span&gt; thousand to a total of $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn4n6_c20230204__20230204__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zADkTLvG5Uw8" title="Payments to acquire businesses, net of cash acquired"&gt;3.67&lt;/span&gt; million; (ii)
change the timing of the payment of the purchase price to $&lt;span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zVifIFxbTqN7" title="Payments to acquire businesses, gross"&gt;460&lt;/span&gt; thousand paid at closing (which has already been paid by the Company),
with the remaining amount to be paid in five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024;
(iii) remove all &#x201c;earn-out&#x201d; payments payable by the Company to the sellers; and (iv) remove certain representations and warranties
of the Company and sellers in connection with the transaction (See Note 3). The Company issued the following shares of common stock to
the sellers of Cleared under the Cleared First Amendment: (1) &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230206__20230206__us-gaap--AwardTypeAxis__custom--FirstOfFiveQuarterlyInstallmentMember_zgfAnwjoaFja" title="Stock issued during period shares new issues"&gt;337,895&lt;/span&gt; shares on February 6, 2023, (2) &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230417__20230417__us-gaap--AwardTypeAxis__custom--SecondOfFiveQuarterlyInstallmentMember_zZJqxS2sBvu" title="Stock issued during period shares new issues"&gt;455,319&lt;/span&gt; shares on April 17, 2023,
(3) &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230717__20230717__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyInstallmentMember_zbiXW1vmNxdd" title="Stock issued during period shares new issues"&gt;158,129&lt;/span&gt; shares on July 17, 2023, (4) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231017__20231017__us-gaap--AwardTypeAxis__custom--FourthOfFiveQuarterlyInstallmentMember_z38IYhj3Ze9d" title="Stock issued during period shares new issues"&gt;117,583&lt;/span&gt; shares on October 17, 2023 and (5) &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240116__20240116__us-gaap--AwardTypeAxis__custom--FifthQuarterlyInstallmentMember_zjsEGHWZ7a86" title="Stock issued during period shares new issues"&gt;95,821&lt;/span&gt; shares on January 16, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, WorkSimpli closed on an Asset Purchase Agreement (the &#x201c;ResumeBuild APA&#x201d;) with East Fusion FZCO, a Dubai, UAE
corporation (the &#x201c;Seller&#x201d;), whereby WorkSimpli acquired substantially all of the assets associated with the Seller&#x2019;s
business, offering subscription-based resume building software through software as a service online platforms (the &#x201c;Acquisition&#x201d;).
WorkSimpli paid $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zYxMy7T0nIYg" title="Consideration paid"&gt;4.0&lt;/span&gt; million to the Seller upon closing. The Seller is also entitled to a minimum of $&lt;span id="xdx_90B_ecustom--BusinessAcquisitionPeriodicPayments_pn3n3_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zyQLjxUAJge7" title="Business acquisition periodic payments"&gt;500&lt;/span&gt; thousand to be paid out in
quarterly payments equal to the greater of &lt;span id="xdx_90A_ecustom--PercentageOfPaymentAcquisition_pid_dp_uPure_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_ziBZEb8QjZqa" title="Percentage of payment acquisition"&gt;15&lt;/span&gt;% of net profits (as defined in the ResumeBuild APA) or approximately $&lt;span id="xdx_908_ecustom--AssetAcquisitionClosing_pn3n3_c20220201__20220228_zM9GpMDqQHm2" title="Asset acquisition closing"&gt;63&lt;/span&gt; thousand, for
a two-year period ending on the two-year anniversary of the closing of the Acquisition. As of December 31, 2024, WorkSimpli has paid
the Seller $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zsq5fbHll1b4" title="Consideration paid"&gt;500&lt;/span&gt; thousand in accordance with the ResumeBuild APA. WorkSimpli borrowed the purchase price from the Company pursuant to
a promissory note with the obligation secured by an equity purchase guarantee agreement and a stock option pledge agreement from Fitzpatrick
Consulting, LLC and its sole member Sean Fitzpatrick, who is Co-Founder and President of WorkSimpli (See Note 3). As of December 31,
2024, there is no remaining balance outstanding related to the promissory note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
otherwise indicated, the terms &#x201c;LifeMD,&#x201d; &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;
refer to LifeMD, Inc. (formerly known as Conversion Labs, Inc.), LifeMD Pharmacy Holdings LLC, an affiliated limited liability company,
(&#x201c;LifeMD Pharmacy&#x201d;) and our majority-owned subsidiary, WorkSimpli. The affiliated network of medical Professional Corporations
and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., (&#x201c;LifeMD PC&#x201d;) is
the Company&#x2019;s affiliated, variable interest entity in which we hold a controlling financial interest. Unless otherwise specified,
all dollar amounts are expressed in United States dollars.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
Evaluation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has an accumulated deficit approximating $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zcfUY0LDDZu9"&gt;236.3&lt;/span&gt; million and has experienced significant losses
from its operations. The Company is showing significant positive revenue trends and expects its burn rate of cash to continue to
improve and to maintain positive operating cash flows for the next 12 months following the date of this report. To date, the Company
has been funding operations primarily through the sales of its products, issuance of common and preferred stock, and through loans
and advances. The Company&#x2019;s continued operations are dependent upon obtaining an increase in its sale volumes or the issuance
of additional shares of common stock. There can be no assurances that we will be successful in increasing revenues and improving
operational efficiencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2023, the Company entered into and closed on a loan and security agreement (the &#x201c;Avenue Credit Agreement&#x201d;), and
a supplement to the Credit Agreement (the &#x201c;Avenue Supplement&#x201d;), with Avenue Venture Opportunities Fund II, L.P. and Avenue
Venture Opportunities Fund, L.P. (collectively, &#x201c;Avenue&#x201d;). The Avenue Credit Agreement provides for a convertible senior
secured credit facility of up to an aggregate amount of $&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zPRJ3aOid4Tg" title="Credit facility"&gt;40&lt;/span&gt; million, comprised of the following: (1) $&lt;span id="xdx_90E_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zvztD8VQ6xmj" title="Proceeds from line of credit"&gt;15&lt;/span&gt; million in term loans funded
at closing, (2) $&lt;span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230926__20230926__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zDd9LHpFpcef" title="Proceeds from line of credit"&gt;5&lt;/span&gt; million of additional committed term loans which the Company received on September 26, 2023 under the First Amendment
to the Avenue Credit Agreement (the &#x201c;Avenue First Amendment&#x201d;) and (3) $&lt;span id="xdx_909_ecustom--LinesOfCreditUncommittedTremLoan_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zD95LGVyJf2e" title="Uncommitted term loans"&gt;20&lt;/span&gt; million of additional uncommitted term loans, collectively
referred to as the &#x201c;Avenue Facility&#x201d;. The Company issued Avenue warrants to purchase $&lt;span id="xdx_90F_ecustom--WarrantToPurchaseStockValue_pn5n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zCkBmptp2Fo3" title="Warrants to purchase"&gt;1.2&lt;/span&gt; million of the Company&#x2019;s
common stock at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zhL9T5Nfasxc" title="Warrants exercise price"&gt;1.24&lt;/span&gt;, subject to adjustments (the &#x201c;Avenue Warrants&#x201d;). In addition, Avenue may convert
up to $&lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zzoZYbSPh2Ob" title="Debt conversion amount"&gt;2&lt;/span&gt; million of the $&lt;span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zrQgSQ8qdD78" title="Proceeds from line of credit"&gt;15&lt;/span&gt; million in term loans funded at closing into shares of the Company&#x2019;s common stock at any time while
the loans are outstanding, at a price per share equal to $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zDQWhiTpZQHf" title="Conversion price"&gt;1.49&lt;/span&gt;. Proceeds from the Avenue Facility were used to repay the Company&#x2019;s
outstanding notes payable balances with CRG Financial and are expected to be used for general corporate purposes. &lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityDescription_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zMjJgwuXKF8k" title="Line of credit, description"&gt;The Company is subject
to certain affirmative and negative covenants under the Avenue Facility, including the requirement, beginning on the closing date, to
maintain at least $5 million of unrestricted cash to be tested at the end of each month, and beginning on the period ended September
30, 2023, and at the end of each quarter thereafter, a trailing six-month cash flow, subject to certain adjustments as provided by the
Avenue Credit Agreement, of at least $2 million.&lt;/span&gt; As of December 31, 2024, there was $&lt;span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumMonthendOutstandingAmount_pn6n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_ztjYSmpmbg1h" title="Credit facility outstanding"&gt;19.0&lt;/span&gt; million outstanding under the Avenue Facility,
and the Company was in compliance with the Avenue Facility covenants. Loans under the Avenue Facility accrue interest at a variable rate
per annum equal to the greater of &lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateDescription_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zDOZkHHrBgD9" title="Credit facility interest rate description"&gt;(i) the sum of 4.75% plus the Prime Rate (as defined in the Avenue Supplement) and (ii) 12.50%. Payments
are interest only for up to 24 months and then fully amortized thereafter.&lt;/span&gt; The Avenue Facility matures on &lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z3MkZ5lU7TRb" title="Line of credit, expiration date"&gt;October 1, 2026&lt;/span&gt;. The Company
may prepay the loans, subject to a prepayment penalty of &lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember__srt--RangeAxis__srt--MinimumMember_zK5shUrlH999" title="Credit facility interest rate"&gt;1.00&lt;/span&gt;% to &lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember__srt--RangeAxis__srt--MaximumMember_zPIOExAl6Bwa" title="Credit facility interest rate"&gt;3.00&lt;/span&gt;% of the principal amount prepaid, depending on the timing of the
prepayment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 11, 2023, the Company entered into a collaboration with Medifast, Inc. through and with certain of its wholly-owned subsidiaries
(&#x201c;Medifast&#x201d;). Pursuant to certain agreements between the parties, Medifast has agreed to pay to the Company the amount of
$&lt;span id="xdx_907_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zBpmgoMG4NVk" title="Collaboration amount"&gt;10&lt;/span&gt; million to support the collaboration, funding enhancements to the Company platform, operations and supporting infrastructure, of
which $&lt;span id="xdx_90A_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231212__dei--LegalEntityAxis__custom--MedifastIncMember_zy6DRHGQklo2" title="Collaboration amount"&gt;5&lt;/span&gt; million was paid at the closing on December 12, 2023, $&lt;span id="xdx_90C_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240101__20240331__dei--LegalEntityAxis__custom--MedifastIncMember_z9eF3HbIsBag" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during the three months ended March 31, 2024, and
the remaining $&lt;span id="xdx_905_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240401__20240630__dei--LegalEntityAxis__custom--MedifastIncMember_zTf8mZP2RkJc" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during the three months ended June 30, 2024 (the &#x201c;Medifast Collaboration&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, in connection with the Medifast Collaboration, the Company entered into a stock purchase agreement and registration rights
agreement with Medifast&#x2019;s wholly-owned subsidiary, Jason Pharmaceuticals, Inc., whereby the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zIPhjzo8yVIk" title="Shares issued"&gt;1,224,425&lt;/span&gt; shares of
its common stock in a private placement (the &#x201c;Medifast Private Placement&#x201d;) at a purchase price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zvFflzIRh7El" title="Shares issued per share"&gt;8.1671&lt;/span&gt; per share, for
aggregate proceeds of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--MedifastPrivatePlacementMember_zpKaZfP5mfb5" title="Proceeds"&gt;10&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an At Market Issuance Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc. and
Cantor Fitzgerald &amp;amp; Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company
may, but is not obligated to, offer and sell, from time to time, shares of common stock, through or to the Agents, acting as agent or
principal. Sales of common stock, if any, will be made by any method permitted that is deemed an &#x201c;at the market offering&#x201d;
as defined in Rule 415 under the Securities Act. On June 7, 2024, the Company filed a shelf registration statement on Form S-3 under
the Securities Act, which was declared effective on July 18, 2024 (the &#x201c;2024 Shelf&#x201d;). Under the 2024 Shelf at the time of
effectiveness, the Company had the ability to raise up to $&lt;span id="xdx_906_eus-gaap--DebtSecurities_iI_pn5n6_c20240607__us-gaap--StatementEquityComponentsAxis__custom--SharesAndSecuritiesMember_zNEWjFemPaf7" title="Raise up funds"&gt;150.0&lt;/span&gt; million by selling common stock, preferred stock, debt securities, warrants,
and units including $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240607__20240607__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zEdOcVwr1IC9" title="Proceeds from issuance of common stock"&gt;53.3&lt;/span&gt; million of its common stock under the ATM Sales Agreement. As of December 31, 2024, the Company had $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zBWJ3nwmqvta" title="Proceeds from sale of securities"&gt;53.3&lt;/span&gt; million
available under the ATM Sales Agreement, which is part of the $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourShelfMember_zhpiUtZlW6s" title="Proceeds from sale of securities"&gt;150.0&lt;/span&gt; million available under the 2024 Shelf.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 7, 2025, the Company has a current cash balance of approximately $&lt;span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20250307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWAPurE1t6ei"&gt;27.2&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.
The Company reviewed its forecasted operating results and sources and uses of cash used in management&#x2019;s assessment, which
included the available financing and consideration of positive and negative evidence impacting management&#x2019;s forecasts, market,
and industry factors. Positive indicators that lead to the Company&#x2019;s expectation that it will have sufficient cash over the
next 12 months following the date of this report include: (1) the Company&#x2019;s continued strengthening of its revenues and
improvement of operational efficiencies across the business, (2) the expected improvement in its cash burn rate over the next 12
months and positive operating cash flows during the year ended December 31, 2024, (3) cash on hand of $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_znnl0jbumvie"&gt;35.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
as of December 31, 2024, (4) $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zaxCohefGXh1"&gt;53.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
available under the ATM Sales Agreement, which is part of the $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyFourShelfMember_z1DlUR8VLebd"&gt;150.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
available under the 2024 Shelf, (5) management&#x2019;s ability to curtail expenses, if necessary, and (6) the overall market value
of the telehealth industry, which the Company believes will continue to drive interest in the Company as already evidenced by the
Medifast Collaboration and Medifast Private Placement noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-02-22"
      decimals="INF"
      id="Fact000824"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2016-04-01_custom_ImmudynePrLlcMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.782</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-04-25_custom_ConversionLabsPrMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2018-06-30_custom_LegalSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000830"
      unitRef="Pure">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-22_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000831"
      unitRef="Pure">0.856</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-09-30_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Pure">0.736</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <LFMD:NumberOfMembershipInterestUnitsRedeemed
      contextRef="From2023-03-312023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">500</LFMD:NumberOfMembershipInterestUnitsRedeemed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000836"
      unitRef="Pure">0.741</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-06-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Pure">0.733</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2018-06-30_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Pure">0.733</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2022-01-182022-01-18"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">460000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <LFMD:MileStonePayment
      contextRef="From2022-01-182022-01-18"
      decimals="-4"
      id="Fact000844"
      unitRef="USD">3460000</LFMD:MileStonePayment>
    <LFMD:MileStonePayment
      contextRef="From2022-01-182022-01-18_custom_FirstAndSecondAnniversariesMember"
      decimals="-4"
      id="Fact000846"
      unitRef="USD">1730000</LFMD:MileStonePayment>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2022-01-182022-01-18"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">507000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact000850"
      unitRef="USD">250000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2023-02-042023-02-04_srt_MinimumMember_custom_StockPurchaseAgreeementMember"
      decimals="-4"
      id="Fact000852"
      unitRef="USD">3670000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">460000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-062023-02-06_custom_FirstOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">337895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-172023-04-17_custom_SecondOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">455319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-172023-07-17_custom_ThirdOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">158129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-172023-10-17_custom_FourthOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">117583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-162024-01-16_custom_FifthQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">95821</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember"
      decimals="-5"
      id="Fact000866"
      unitRef="USD">4000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <LFMD:BusinessAcquisitionPeriodicPayments
      contextRef="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember"
      decimals="-3"
      id="Fact000868"
      unitRef="USD">500000</LFMD:BusinessAcquisitionPeriodicPayments>
    <LFMD:PercentageOfPaymentAcquisition
      contextRef="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Pure">0.15</LFMD:PercentageOfPaymentAcquisition>
    <LFMD:AssetAcquisitionClosing
      contextRef="From2022-02-012022-02-28"
      decimals="-3"
      id="Fact000872"
      unitRef="USD">63000</LFMD:AssetAcquisitionClosing>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-01-012024-12-31_custom_AssetPurchaseAgreementMember"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000875"
      unitRef="USD">-236300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000877"
      unitRef="USD">40000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000879"
      unitRef="USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-09-262023-09-26_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000881"
      unitRef="USD">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <LFMD:LinesOfCreditUncommittedTremLoan
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000883"
      unitRef="USD">20000000</LFMD:LinesOfCreditUncommittedTremLoan>
    <LFMD:WarrantToPurchaseStockValue
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact000885"
      unitRef="USD">1200000</LFMD:WarrantToPurchaseStockValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact000887"
      unitRef="USDPShares">1.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000889"
      unitRef="USD">2000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000891"
      unitRef="USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact000893"
      unitRef="USDPShares">1.49</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:LineOfCreditFacilityDescription
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      id="Fact000895">The Company is subject
to certain affirmative and negative covenants under the Avenue Facility, including the requirement, beginning on the closing date, to
maintain at least $5 million of unrestricted cash to be tested at the end of each month, and beginning on the period ended September
30, 2023, and at the end of each quarter thereafter, a trailing six-month cash flow, subject to certain adjustments as provided by the
Avenue Credit Agreement, of at least $2 million.</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact000897"
      unitRef="USD">19000000.0</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
    <us-gaap:LineOfCreditFacilityInterestRateDescription
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      id="Fact000899">(i) the sum of 4.75% plus the Prime Rate (as defined in the Avenue Supplement) and (ii) 12.50%. Payments
are interest only for up to 24 months and then fully amortized thereafter.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      id="Fact000901">2026-10-01</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Pure">0.0100</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000905"
      unitRef="Pure">0.0300</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2023-12-11_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000907"
      unitRef="USD">10000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2023-12-12_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000909"
      unitRef="USD">5000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <LFMD:BusinessCombinationRemainingConsiderationTransferred
      contextRef="From2024-01-012024-03-31_custom_MedifastIncMember"
      decimals="-5"
      id="Fact000911"
      unitRef="USD">2500000</LFMD:BusinessCombinationRemainingConsiderationTransferred>
    <LFMD:BusinessCombinationRemainingConsiderationTransferred
      contextRef="From2024-04-012024-06-30_custom_MedifastIncMember"
      decimals="-5"
      id="Fact000913"
      unitRef="USD">2500000</LFMD:BusinessCombinationRemainingConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-12-112023-12-11_custom_MedifastPrivatePlacementMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">1224425</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-12-11_custom_MedifastPrivatePlacementMember"
      decimals="INF"
      id="Fact000917"
      unitRef="USDPShares">8.1671</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-12-112023-12-11_custom_MedifastPrivatePlacementMember"
      decimals="-6"
      id="Fact000919"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtSecurities
      contextRef="AsOf2024-06-07_custom_SharesAndSecuritiesMember"
      decimals="-5"
      id="Fact000921"
      unitRef="USD">150000000.0</us-gaap:DebtSecurities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-06-072024-06-07_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact000923"
      unitRef="USD">53300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact000925"
      unitRef="USD">53300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_TwentyTwentyFourShelfMember"
      decimals="-5"
      id="Fact000927"
      unitRef="USD">150000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:Cash
      contextRef="AsOf2025-03-07_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000928"
      unitRef="USD">27200000</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000929"
      unitRef="USD">35000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact000930"
      unitRef="USD">53300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_TwentyTwentyFourShelfMember"
      decimals="-5"
      id="Fact000931"
      unitRef="USD">150000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000933">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zye6T2ggnYjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_826_zH6UwVOAlOji"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zm97YFapuFt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the need to consolidate affiliates based on standards set forth in Accounting Standards Codification (&#x201c;ASC&#x201d;)
810, Consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company, LifeMD Pharmacy, its majority owned subsidiary, WorkSimpli, and
LifeMD PC, the Company&#x2019;s affiliated, variable interest entity in which we hold a controlling financial interest. Effective March
31, 2023, the Company redeemed &lt;span id="xdx_909_ecustom--NumberOfMembershipInterestUnitsRedeemed_c20230331__20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zGwRUW770Wi6" title="Number of membership interest units redeemed"&gt;500&lt;/span&gt; membership interest units in WorkSimpli and, as a result, the Company&#x2019;s ownership interest in
WorkSimpli increased to &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zCweAL7fodxb" title="Ownership Interest"&gt;74.1&lt;/span&gt;%. Effective June 30, 2023, an option agreement was exercised which further restructured the ownership of
WorkSimpli. As a result, the Company&#x2019;s ownership interest in WorkSimpli decreased to &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zFguHu11XHje" title="Ownership Interest"&gt;73.3&lt;/span&gt;%. See Note 8 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z73LwfLt7z9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains deposits in financial institutions that may, at times, exceed amounts guaranteed by the Federal Deposit Insurance
Corporation. &lt;span style="background-color: white"&gt;These
balances could be impacted if one or more of the financial institutions in which we deposit monies fails or is subject to other
adverse conditions in the financial or credit markets. &lt;/span&gt;We have never experienced any losses related to these
balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConsolidationVariableInterestEntityPolicy_zn7ukA5hcS8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Variable
Interest Entities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 810, Consolidation, the Company determines whether any legal entity in which the Company becomes involved is a variable
interest entity (a &#x201c;VIE&#x201d;) and subject to consolidation. This determination is based on whether an entity has sufficient equity
at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack
any of the characteristics of a controlling financial interest and whether the interest will absorb portions of a VIE&#x2019;s expected
losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with
changes in the fair value of the entity&#x2019;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate
it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest.
A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion
is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion
is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the LifeMD PC entity, the Company&#x2019;s affiliated network of medical Professional Corporations and medical
Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., is a VIE and subject to consolidation.
LifeMD PC and the Company do not have any stockholders in common. LifeMD PC is owned by licensed physicians, and the Company maintains
a managed service agreement with LifeMD PC whereby we provide all non-clinical services to LifeMD PC. The Company determined that it
is the primary beneficiary of LifeMD PC and must consolidate, as we have both the power to direct the activities of LifeMD PC that most
significantly impact the economic performance of the entity and we have the obligation to absorb the losses. As a result, the Company
presents the financial position, results of operations, and cash flows of LifeMD PC as part of the consolidated financial statements
of the Company. There is no non-controlling interest upon consolidation of LifeMD PC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Total net loss for LifeMD PC
was approximately $&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zFLYXPFpJ521"&gt;13.8
&lt;/span&gt;million and $&lt;span id="xdx_908_eus-gaap--NetIncomeLoss_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zt7QViA6WjOf"&gt;5.4&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively. Total assets and liabilities for the LifeMD
PC were approximately $&lt;span id="xdx_908_eus-gaap--Assets_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zru228JMgua7" title="Assets"&gt;6&lt;/span&gt; thousand and $&lt;span id="xdx_909_eus-gaap--Liabilities_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zujRp3stCrl3" title="Liabilities"&gt;378&lt;/span&gt; thousand, respectively, as of December 31, 2024 and $&lt;span id="xdx_909_eus-gaap--Assets_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zauqZHq0vip1" title="Assets"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Liabilities_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zQqXtZo9S2Vi" title="Liabilities"&gt;72&lt;/span&gt; thousand, respectively, as
of December 31, 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zradOVkaWn1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_z1vwtvSkULQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records revenue under the adoption of ASC 606, Revenue from Contracts with Customers, by analyzing exchanges with its customers
using a five-step analysis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    performance obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize
    revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the Company&#x2019;s product-based contracts with customers, the Company has determined that there is one performance obligation, which
is the delivery of the product; this performance obligation is transferred at a discrete point in time. The Company generally records
sales of finished products once the customer places and pays for the order, with the product being simultaneously shipped by a third-party
fulfillment service provider. In all cases, delivery is considered to have occurred when the customer obtains control, which is usually
commensurate upon shipment of the product. In the case where product is not simultaneously shipped when the customer places and pays
for the order, recognition of revenue is deferred until time of shipment. In the case of its product-based contracts, the Company provides
a subscription sensitive service based on the recurring shipment of products. The Company records the related revenue at the time it
fulfills the shipment obligation to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
its product-based contracts with customers, the Company records an estimate for provisions of discounts, returns, allowances, customer
rebates, and other adjustments for its product shipments and are reflected as contra revenues in arriving at reported net revenues. The
Company&#x2019;s discounts and customer rebates are known at the time of sale; correspondingly, the Company reduces gross product sales
for such discounts and customer rebates. The Company estimates customer returns and allowances based on information derived from historical
transaction detail and accounts for such provisions, as contra revenue, during the same period in which the related revenues are earned.
The Company has determined that the population of its product-based contracts with customers are homogenous, supporting the ability to
record estimates for returns and allowances to be applied to the entire product-based portfolio population.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
its telehealth contracts with customers, the Company offers one-time and subscription-based access to the Company&#x2019;s telehealth platform.
The Company offers monthly and multi-month subscriptions dependent upon the subscriber&#x2019;s enrollment selection. The Company has
determined that there is one performance obligation that is delivered over time, as the Company allows the subscriber to access the telehealth
platform for the time period of the subscription purchased. The majority of the Company&#x2019;s subscriptions are recognized over time
using the input method in which revenue is recognized on the basis of efforts or inputs toward satisfying a performance obligation relative
to the total expected inputs to satisfy the performance obligation. The Company uses time elapsed as the input. The measure used provides
a faithful depiction of the transfer of goods or services to the subscribers. The Company records the revenue over the customer&#x2019;s
subscription period for monthly and multi-month subscribers. The Company also offers bundled arrangements in which a subscriber receives
subscription-based access to the Company&#x2019;s telehealth platform as well as prescribed medication. The Company has determined that
there are two performance obligations related to these bundles: (i) one performance obligation for the subscription-based service that
is delivered over time and (ii) one performance obligation for the prescribed medication that is delivered as of a point in time. For
contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on a relative
stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products
and services. Revenue related to contracts with multiple performance obligations is not material for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
to fulfill its promise to customers for contracts that include the sale of prescription products, the Company maintains relationships
with certain third-party pharmacies, which are licensed mail order pharmacies providing prescription fulfillment to the Company&#x2019;s
customers. The third-party pharmacies fill prescription orders for customers who have received a prescription from a LifeMD PC provider.
The Company may account for prescription product revenue as the principal or agent in the arrangement with its customers depending on
the agreement with the related third-party pharmacy. The following factors are evaluated to determine if the Company acts as principal
or agent in the arrangement: (i) whether the Company has sole discretion in determining which pharmacy fills a customer&#x2019;s prescription;
(ii) whether the Company obtains control of the product; (iii) whether the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order; (iv) whether the Company is responsible for refunds of the prescription medication after
transfer of control to the customer; and (v) whether the Company sets all listed prices for the prescription products. Based on evaluation
of these factors, the Company accounts for prescription product revenue as the agent in the arrangement with its largest third-party
pharmacy provider.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
discounts, returns and rebates on telehealth revenues approximated $&lt;span id="xdx_905_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zR3FLC2R8wv2" title="Customer discounts and allowance"&gt;3.7&lt;/span&gt; million and $&lt;span id="xdx_900_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zALEBBxuzuj9" title="Customer discounts and allowance"&gt;2.1&lt;/span&gt; million, respectively, during the years ended
December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, through its majority-owned subsidiary WorkSimpli, offers a subscription-based service providing a suite of software applications
to its subscribers, principally on a monthly subscription basis. The software suite allows the subscriber/user to convert almost any
type of document to another electronic form of editable document, providing ease of editing. For these subscription-based contracts with
customers, the Company offers an initial 14-day trial period which is billed at $&lt;span id="xdx_901_ecustom--SubscriptionPricePerShare_iI_pid_c20241231_zlwqmQxy4Dth" title="Subscription price per share"&gt;1.95&lt;/span&gt;, followed by a monthly subscription, or a multi-month
subscription to the Company&#x2019;s software suite dependent on the subscriber&#x2019;s enrollment selection. The Company has determined
that there is one product and one performance obligation that is delivered over time, as the Company allows the subscriber to access
the suite of services for the time period of the subscription purchased. The Company allows the customer to cancel at any point during
the billing cycle, in which case the customer&#x2019;s subscription will not be renewed for the following month or year depending on the
original subscription. The Company records the revenue over the customer&#x2019;s subscription period for monthly and multi-month subscribers
or at the end of the initial 14-day service period for customers who purchased the initial subscription. The Company offers a discount
for the monthly or multi-month subscriptions being purchased, which is deducted at the time of payment at the initiation of the contract
term; therefore the contract price is fixed and determinable at the contract initiation. Monthly and multi-month subscriptions for the
service are recorded net of the Company&#x2019;s known discount rates. Customer discounts and allowances on WorkSimpli revenues approximated
$&lt;span id="xdx_908_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__custom--SoftwareRevenueMember_z8jQ3sEdysUh" title="Customer discounts and allowance"&gt;3.6&lt;/span&gt; million and $&lt;span id="xdx_90C_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__custom--SoftwareRevenueMember_z4hHAm6jcjH4" title="Customer discounts and allowance"&gt;3.3&lt;/span&gt; million, respectively, during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted above, on December 11, 2023, the Company entered into the Medifast Collaboration. Pursuant to certain agreements between the parties,
Medifast agreed to pay to the Company the amount of $&lt;span id="xdx_907_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zf6bgNfLH5E9" title="Collaboration amount"&gt;10&lt;/span&gt; million to support the collaboration, funding enhancements to the Company platform,
operations and supporting infrastructure, of which $&lt;span id="xdx_90A_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231212__dei--LegalEntityAxis__custom--MedifastIncMember_zlSOMaj7Ibvb" title="Collaboration amount"&gt;5&lt;/span&gt; million was paid at the closing on December 12, 2023, $&lt;span id="xdx_90B_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240101__20240331__dei--LegalEntityAxis__custom--MedifastIncMember_zrhtIZnRoVbd" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during
the three months ended March 31, 2024, and the remaining $&lt;span id="xdx_90A_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240401__20240630__dei--LegalEntityAxis__custom--MedifastIncMember_zU3XNGwHjNyg" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during the three months ended June 30, 2024. The Company
determined the transaction price totalled $&lt;span id="xdx_901_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20241231__dei--LegalEntityAxis__custom--MedifastIncMember_zCzRqWUsYnik" title="Transaction amount"&gt;10&lt;/span&gt; million, which was fully collected as of December 31, 2024. The Company has allocated the
total $&lt;span id="xdx_90E_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zZguWGy9xkef" title="Transaction amount"&gt;10&lt;/span&gt; million initial transaction price to three distinct performance obligations. As the Company completed its first performance
obligation related to this agreement, the $&lt;span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20230101__20231231__dei--LegalEntityAxis__custom--MedifastIncMember_zUuqzZip5ka8" title="Transaction amount collected"&gt;5&lt;/span&gt; million payment was fully recognized during the year ended December 31, 2023. The Company
recognized approximately $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20240101__20240331__dei--LegalEntityAxis__custom--MedifastIncMember_zfiHYAtiyqAh" title="Transaction amount collected"&gt;2&lt;/span&gt; million related to the second performance obligation during the three months ended March 31, 2024, and approximately
$&lt;span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20240401__20240630__dei--LegalEntityAxis__custom--MedifastIncMember_zZBoPsvsL8J8" title="Transaction amount collected"&gt;3&lt;/span&gt; million related to the second and third performance obligations during the three months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLzMGCujp3Kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company had the following disaggregated revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zbR3awranSOb" style="display: none"&gt;SCHEDULE OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Telehealth product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zKP7oIesetc3" style="width: 10%; text-align: right" title="Total net revenue"&gt;83,423,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcgEV2jtwSW4" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z8v06A4DTwoc" style="width: 10%; text-align: right" title="Total net revenue"&gt;88,886,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConcentrationRiskPercentage_dp_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zaldMQHZlj57" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Telehealth subscription revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zYURjZhiAv24" style="text-align: right" title="Total net revenue"&gt;70,015,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z0Q6jBGSMIuk" style="text-align: right" title="Total net revenue, percent"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zmxgVHHqlwI8" style="text-align: right" title="Total net revenue"&gt;4,266,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z97tmF8oQ2Nd" style="text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;WorkSimpli revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Oq3uaMWeZ9" style="text-align: right" title="Total net revenue"&gt;54,015,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zxHWFpuoKohi" style="text-align: right" title="Total net revenue, percent"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zVuMC9ZdLXp1" style="text-align: right" title="Total net revenue"&gt;54,394,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z6gtNaAp1oY6" style="text-align: right" title="Total net revenue, percent"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Medifast collaboration revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zfn9vH9cH9Xh" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zrH0ApqKH4Eg" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zgOrQfq83XZa" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zV00Ch5BtHT5" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_zbXHqsSFdX1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;212,453,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231_zaGqQ23BSbed" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zx5XX7FbPf85" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;152,547,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231_z1hfJoFVhnMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zXrEvWtQCxtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEfMRYJjxFFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records deferred revenues when cash payments are received or due in advance of its performance. As of December 31, 2024 and 2023,
the Company has accrued contract liabilities, as deferred revenue, of approximately $&lt;span id="xdx_908_eus-gaap--DeferredRevenue_iI_pn5n6_c20241231_zDHI6RjMYLU1" title="Deferred revenue"&gt;14.5&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_zfDXV1WZC5Hl" title="Deferred revenue"&gt;8.8&lt;/span&gt; million, respectively, which
represent the following: (1) $&lt;span id="xdx_906_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zPmrwKefRhM8" title="Accrued contract liabilities"&gt;10.1&lt;/span&gt; million and $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zdqUbz7uTUbc" title="Accrued contract liabilities"&gt;4.2&lt;/span&gt; million as of December 31, 2024 and 2023, respectively, related to obligations on
telehealth in-process monthly or yearly contracts with customers, (2) $&lt;span id="xdx_904_ecustom--ContractWithCustomerLiabilityNotYetObtained_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zSKVzvKuUI14" title="Accrued contract liabilities"&gt;1.9&lt;/span&gt; million and $&lt;span id="xdx_90A_ecustom--ContractWithCustomerLiabilityNotYetObtained_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zIFhQWuI4Tz7" title="Accrued contract liabilities"&gt;2.1&lt;/span&gt; million as of December 31, 2024 and 2023,
respectively, related to obligations for telehealth products which the customer has not yet obtained control due to non-shipment of the
product and (3) $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--WorkSimpliInProcessMember_zwxEhsk4jGZ4" title="Accrued contract liabilities"&gt;2.5&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--WorkSimpliInProcessMember_zXHwnQ1Inwh3" title="Accrued contract liabilities"&gt;2.5&lt;/span&gt; million as of December 31, 2024 and 2023, respectively, related to obligations on WorkSimpli in-process
monthly or multi-month contracts with customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
revenue increased by $&lt;span id="xdx_90E_ecustom--IncreaseInDeferredRevenue_iI_pn5n6_c20241231_zt65r6jg5p3h" title="Increase in deferred revenue"&gt;5.7&lt;/span&gt;
million to $&lt;span id="xdx_906_eus-gaap--DeferredRevenue_iI_pn5n6_c20241231_zpHbTNAY92z1" title="Deferred revenue"&gt;14.5&lt;/span&gt;
million as of December 31, 2024 compared to $&lt;span id="xdx_900_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_zTKz8KqzIr4f" title="Deferred revenue"&gt;8.8&lt;/span&gt;
million as of December 31, 2023. The increase is primarily due to the increase in telehealth monthly and multi-month subscription
revenue the year ended December 31, 2024 compared to the year ended December 31, 2023. The amount of revenue recognized during the
year ended December 31, 2024, that was included in the deferred revenue balance as of December 31, 2023, was $&lt;span id="xdx_900_ecustom--DeferredRevenueBalancesFromPreviousYear_pn5n6_c20240101__20241231_zJFrs1hmQCt4" title="Deferred revenue"&gt;7.6&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to recognize all of the deferred revenue related to future performance obligations that are unsatisfied or partially
unsatisfied as of December 31, 2024 as revenue by December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_ztbf26AdtpAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes deferred revenue activities for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B2_zFCjCcFwRqil" style="display: none"&gt;SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zYtyM4QsZUd9" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z2Z5ZrHWoiEc" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iS_zg31vyoMgiZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,547,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_z4UrHbqTFEg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214,304,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,319,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_z4HsaZPbzuta" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(208,652,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(55,038,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iE_zpPWjzXUPpJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;End of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,480,917&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG5LlLCLjh7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_znIilBkUAidb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets are included in
right-of-use assets on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included
in the current operating lease liabilities and noncurrent operating lease liabilities, respectively, on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over
the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate
based on the information available at the commencement date in determining the present value of future payments. Certain leases may include
options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease
term. Leases with an initial term of 12 months or less are not recorded in the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zmz19dswcxy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable principally consist of amounts due from third-party merchant processors, who process our subscription revenues; the merchant
accounts balance receivable represents the charges processed by the merchants that have not yet been deposited with the Company. The
unsettled merchant receivable amount normally represents processed sale transactions from the final one to three days of the month, with
collections being made by the Company within the first week of the following month. Management determines the need, if any, for an allowance
for future credits to be granted to customers, by regularly evaluating aggregate customer refund activity, coupled with the consideration
and current economic conditions in its evaluation of an allowance for future refunds and chargebacks. As of December 31, 2024 and 2023,
the reserve for sales returns and allowances was approximately $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20241231_z4j3lIxNMpig" title="Sales returns and allowances"&gt;894&lt;/span&gt; thousand and $&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20231231_zJLgZyEejnI5" title="Sales returns and allowances"&gt;528&lt;/span&gt; thousand, respectively. For all periods presented,
as noted above, the sales returns and allowances were recorded in accrued expenses on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zkqepLrc20wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounts receivable balances are as follows for each of the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zDTXJOILUkX2"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20240101__20241231_z8zc4k1tBhIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20230101__20231231_zl1nw7amA9si" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_iS_zYZ2hYqpXM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,834,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iE_zhNHrKIHc3e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;End of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,217,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zT8DFSCuDtqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_zibMULhB1mTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, inventory primarily consisted of finished goods, raw materials and packaging related to the Company&#x2019;s
OTC products included in the telehealth revenue section of the table above. Inventory is maintained at the Company&#x2019;s third-party
warehouse location in Wyoming and at various Amazon fulfillment centers. The Company also maintains inventory at a company owned warehouse
in Pennsylvania.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is valued at the lower of cost or net realizable value with cost determined on an average cost basis. Management compares the cost of
inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of December
31, 2024 and 2023, the Company recorded an inventory reserve of $&lt;span id="xdx_90B_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20241231_zAGeQ3U9EOd9" title="Inventory reserve"&gt;263&lt;/span&gt; thousand and $&lt;span id="xdx_905_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20231231_z4BMvYwH3Fx5" title="Inventory reserve"&gt;356&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLVbSGFfbLYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company&#x2019;s inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zdO2DJgyjb5g" style="display: none"&gt;SUMMARY OF INVENTORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zkOE2OciwrYl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zyGtoYvrF4V5" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maCze8N_zT5AbvCzFCe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,554,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,898,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryRawMaterials_iI_maCze8N_zZJCy3mPNVKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Raw materials and packaging components&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,506,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryValuationReserves_iNI_di_msCze8N_z3BPLT2Yt0dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Inventory reserve&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(263,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(355,685&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryNet_iTI_mtCze8N_z1SBcoDfxvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,797,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,759,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zCgB65mDvxE7" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--DepositContractsPolicy_z2z6QsndYNPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Product
Deposit&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Many
of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically range from
&lt;span id="xdx_90E_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDeposits_iI_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember_zLCzl46uCcMe" title="Percentage of interest-bearing domestic deposits"&gt;10&lt;/span&gt;% to &lt;span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDeposits_iI_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember_ztv82zpNLkr7" title="Percentage of interest-bearing domestic deposits"&gt;33&lt;/span&gt;% of the total purchased amount. Our vendors include a credit memo within their final invoice, recognizing the deposit amount
previously paid. As of December 31, 2024 and 2023, the Company has approximately $&lt;span id="xdx_90B_eus-gaap--DepositsAssetsCurrent_iI_pn3n3_c20241231_zPS4bSnJbaZ" title="Deposits assets, current"&gt;41&lt;/span&gt; thousand and $&lt;span id="xdx_902_eus-gaap--DepositsAssetsCurrent_iI_pn3n3_c20231231_z4gYR1nx8uBj" title="Deposits assets, current"&gt;486&lt;/span&gt; thousand, respectively, of product
deposits with multiple vendors for the purchase of raw materials or finished goods. The Company&#x2019;s history of product deposits with
its inventory vendors, creates an implicit purchase commitment equaling the total expected product acceptance cost in excess of the product
deposit. As of December 31, 2024, the Company approximates its implicit purchase commitments to be approximately $&lt;span id="xdx_902_eus-gaap--PurchaseObligation_iI_pn3n3_c20241231_zwf64zZJOHma" title="Purchase obligation"&gt;479&lt;/span&gt; thousand, of which
the vast majority are with two vendors that manufacture the Company&#x2019;s finished goods inventory for its RexMD product line.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--InProcessResearchAndDevelopmentPolicy_zADMO2jDITJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Capitalized
Software Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes certain internal payroll costs and third-party costs related to internally developed software and amortizes these
costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell
internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria
for capitalization, in accordance with ASC 350-40, Internal-Use Software, are expensed as incurred. As of December 31, 2024 and 2023,
the Company capitalized a net amount of $&lt;span id="xdx_90A_eus-gaap--CapitalizedComputerSoftwareNet_iI_pn5n6_c20241231_zPDvpMzKLp2d" title="Capitalized software costs"&gt;13.8&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--CapitalizedComputerSoftwareNet_iI_pn5n6_c20231231_znT9dwxoaNX1" title="Capitalized software costs"&gt;11.8&lt;/span&gt; million, respectively, related to internally developed software costs
which are amortized over the useful life and included in development costs on our consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zKbzQJRJ4cDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets are comprised of: (1) the ResumeBuild brand, (2) a customer relationship asset, (3) the Cleared trade name, (4) Cleared developed
technology, (5) a purchased license and (6) four purchased domain names. Intangible assets are amortized over their estimated lives using
the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over
the useful life of the asset which typically range from &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MinimumMember_zLpysWZaR0Vi" title="Intangible assets, term"&gt;one year&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zdUouEtN9m11" title="Intangible assets, term"&gt;ten years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zHogCpA2B41k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets include equipment and capitalized software. Long-lived assets are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. If such assets are considered to be impaired, an impairment is
recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of December 31,
2024 and 2023, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zaBvcT5MpXQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files corporate federal, state, and local tax returns. WorkSimpli files a tax return in Puerto Rico. The Company records current
and deferred taxes in accordance with ASC 740, Accounting for Income Taxes. This ASC requires recognition of deferred tax assets and
liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial
statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes
a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses
the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and management determines
the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement
recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit
from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that
the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company&#x2019;s
tax returns for all years since December 31, 2021, remain open to audit by all related taxing authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zQMiLxQVHfSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASC 718, Share-Based Payment. Under this guidance compensation cost generally is recognized at fair
value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of
grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based
upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected
volatility is based upon historical volatility of the Company&#x2019;s common shares using daily price observations over an observation
period that approximates the expected life of the options. The risk-free interest rate approximates the U.S. Treasury yield curve rate
in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the Company has
elected to account for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zd4MQAFivtFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per common share (&#x201c;EPS&#x201d;) is based on the weighted average number of shares outstanding during each period
presented. Shares of unissued vested restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are
included in our calculation of basic weighted average shares outstanding. Convertible securities, warrants and options to purchase common
stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings
per share when the effects would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed
issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated
using the &#x201c;treasury stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are
used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and preferred
stock is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted
at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the
entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zL9RY6OjmIhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from
the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price
could be less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zWaEu7j7H828" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zwnfAWrYHJRi" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zWvu7EMfTi99" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsAndRestrictedStockUnitMember_zZzWLuDdpBA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;RSUs and RSAs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,157,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,556,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zf1lmQSKfxP9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,288,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,336,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zf3aNkvm2RL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,743,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleLongTermDebtMember_zodfacqs0D6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zNLeBagnrNr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,860,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,294,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zJRT8naJGrZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5dQTvxwtqj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segment
Data&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
portfolio of brands are included within two operating segments: Telehealth and WorkSimpli. We believe our current segments and brands
within our segments complement one another and position us well for future growth. The Company&#x2019;s Chief Executive Officer is the
chief operating decision maker (&#x201c;CODM&#x201d;) and is responsible for reviewing segment operating results to make determinations
about resources to be allocated and to assess performance. Other factors, including type of business, revenue recognition and operating
results are reviewed in determining the Company&#x2019;s operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKQfI5DLM64k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in
an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement
are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement.
Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets
or liabilities, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability
    through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    or liabilities and that reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability
    at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In
those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input
that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued expenses,
and the face amount of notes payable and long-term debt approximate fair value for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zTCP7iO7Qpue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Concentrations
of Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times,
maintains balances in various operating accounts in excess of federally insured limits. We are dependent on certain third-party manufacturers
and pharmacies, although we believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our
current manufacturers or pharmacies cease to perform adequately. As of December 31, 2024, we utilized five (5) suppliers for fulfillment
services. As of December 31, 2023, we utilized three (3) suppliers for fulfillment services, nine (9) suppliers for manufacturing finished
goods, seven (7) suppliers for packaging, bottling, and labeling, and five (5) suppliers for prescription medications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDdHfjzUOXb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280). The amendments
in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 became effective for the Company&#x2019;s annual period beginning on January 1, 2024 and interim periods beginning after January
1, 2025. The Company adopted this guidance in the fourth quarter of 2024. Refer to Note 13 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--OtherRecentAccountingPronouncementsPolicyTextBlock_zIkP8SwUsNce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740):&lt;/i&gt; &lt;i&gt;Improvements to Income Tax Disclosures,&lt;/i&gt; to improve
its income tax disclosure requirements. Under ASU 2023-09, entities must annually: (1) disclose specific categories in the rate reconciliation
and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that ASU 2023-09 will have to its consolidated financial
statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40)&lt;/i&gt; to improve the disclosures about a public business entity&#x2019;s expenses and provide more detailed information
about the types of expenses included in certain expense captions in the consolidated financial statements. The amendments in this update
are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December
15, 2027. Early adoption is permitted and the amendments in this update should be applied either prospectively or retrospectively. The
Company is evaluating the impact this guidance will have on the disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are
not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_z0Jbq44JA3o5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000935">&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zm97YFapuFt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the need to consolidate affiliates based on standards set forth in Accounting Standards Codification (&#x201c;ASC&#x201d;)
810, Consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company, LifeMD Pharmacy, its majority owned subsidiary, WorkSimpli, and
LifeMD PC, the Company&#x2019;s affiliated, variable interest entity in which we hold a controlling financial interest. Effective March
31, 2023, the Company redeemed &lt;span id="xdx_909_ecustom--NumberOfMembershipInterestUnitsRedeemed_c20230331__20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zGwRUW770Wi6" title="Number of membership interest units redeemed"&gt;500&lt;/span&gt; membership interest units in WorkSimpli and, as a result, the Company&#x2019;s ownership interest in
WorkSimpli increased to &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zCweAL7fodxb" title="Ownership Interest"&gt;74.1&lt;/span&gt;%. Effective June 30, 2023, an option agreement was exercised which further restructured the ownership of
WorkSimpli. As a result, the Company&#x2019;s ownership interest in WorkSimpli decreased to &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zFguHu11XHje" title="Ownership Interest"&gt;73.3&lt;/span&gt;%. See Note 8 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <LFMD:NumberOfMembershipInterestUnitsRedeemed
      contextRef="From2023-03-312023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000937"
      unitRef="Shares">500</LFMD:NumberOfMembershipInterestUnitsRedeemed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Pure">0.741</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-06-30_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact000941"
      unitRef="Pure">0.733</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000943">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z73LwfLt7z9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains deposits in financial institutions that may, at times, exceed amounts guaranteed by the Federal Deposit Insurance
Corporation. &lt;span style="background-color: white"&gt;These
balances could be impacted if one or more of the financial institutions in which we deposit monies fails or is subject to other
adverse conditions in the financial or credit markets. &lt;/span&gt;We have never experienced any losses related to these
balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000945">&lt;p id="xdx_848_eus-gaap--ConsolidationVariableInterestEntityPolicy_zn7ukA5hcS8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Variable
Interest Entities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 810, Consolidation, the Company determines whether any legal entity in which the Company becomes involved is a variable
interest entity (a &#x201c;VIE&#x201d;) and subject to consolidation. This determination is based on whether an entity has sufficient equity
at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack
any of the characteristics of a controlling financial interest and whether the interest will absorb portions of a VIE&#x2019;s expected
losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with
changes in the fair value of the entity&#x2019;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate
it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest.
A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion
is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion
is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the LifeMD PC entity, the Company&#x2019;s affiliated network of medical Professional Corporations and medical
Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., is a VIE and subject to consolidation.
LifeMD PC and the Company do not have any stockholders in common. LifeMD PC is owned by licensed physicians, and the Company maintains
a managed service agreement with LifeMD PC whereby we provide all non-clinical services to LifeMD PC. The Company determined that it
is the primary beneficiary of LifeMD PC and must consolidate, as we have both the power to direct the activities of LifeMD PC that most
significantly impact the economic performance of the entity and we have the obligation to absorb the losses. As a result, the Company
presents the financial position, results of operations, and cash flows of LifeMD PC as part of the consolidated financial statements
of the Company. There is no non-controlling interest upon consolidation of LifeMD PC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Total net loss for LifeMD PC
was approximately $&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zFLYXPFpJ521"&gt;13.8
&lt;/span&gt;million and $&lt;span id="xdx_908_eus-gaap--NetIncomeLoss_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zt7QViA6WjOf"&gt;5.4&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively. Total assets and liabilities for the LifeMD
PC were approximately $&lt;span id="xdx_908_eus-gaap--Assets_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zru228JMgua7" title="Assets"&gt;6&lt;/span&gt; thousand and $&lt;span id="xdx_909_eus-gaap--Liabilities_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--LifeMDPCMember_zujRp3stCrl3" title="Liabilities"&gt;378&lt;/span&gt; thousand, respectively, as of December 31, 2024 and $&lt;span id="xdx_909_eus-gaap--Assets_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zauqZHq0vip1" title="Assets"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Liabilities_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--LifeMDPCMember_zQqXtZo9S2Vi" title="Liabilities"&gt;72&lt;/span&gt; thousand, respectively, as
of December 31, 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_LifeMDPCMember"
      decimals="-5"
      id="Fact000946"
      unitRef="USD">13800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_LifeMDPCMember"
      decimals="-5"
      id="Fact000947"
      unitRef="USD">5400000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_LifeMDPCMember"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">6000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31_custom_LifeMDPCMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">378000</us-gaap:Liabilities>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_LifeMDPCMember"
      decimals="-3"
      id="Fact000953"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31_custom_LifeMDPCMember"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">72000</us-gaap:Liabilities>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000957">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zradOVkaWn1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000959">&lt;p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_z1vwtvSkULQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records revenue under the adoption of ASC 606, Revenue from Contracts with Customers, by analyzing exchanges with its customers
using a five-step analysis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    performance obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate
    the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize
    revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the Company&#x2019;s product-based contracts with customers, the Company has determined that there is one performance obligation, which
is the delivery of the product; this performance obligation is transferred at a discrete point in time. The Company generally records
sales of finished products once the customer places and pays for the order, with the product being simultaneously shipped by a third-party
fulfillment service provider. In all cases, delivery is considered to have occurred when the customer obtains control, which is usually
commensurate upon shipment of the product. In the case where product is not simultaneously shipped when the customer places and pays
for the order, recognition of revenue is deferred until time of shipment. In the case of its product-based contracts, the Company provides
a subscription sensitive service based on the recurring shipment of products. The Company records the related revenue at the time it
fulfills the shipment obligation to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
its product-based contracts with customers, the Company records an estimate for provisions of discounts, returns, allowances, customer
rebates, and other adjustments for its product shipments and are reflected as contra revenues in arriving at reported net revenues. The
Company&#x2019;s discounts and customer rebates are known at the time of sale; correspondingly, the Company reduces gross product sales
for such discounts and customer rebates. The Company estimates customer returns and allowances based on information derived from historical
transaction detail and accounts for such provisions, as contra revenue, during the same period in which the related revenues are earned.
The Company has determined that the population of its product-based contracts with customers are homogenous, supporting the ability to
record estimates for returns and allowances to be applied to the entire product-based portfolio population.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
its telehealth contracts with customers, the Company offers one-time and subscription-based access to the Company&#x2019;s telehealth platform.
The Company offers monthly and multi-month subscriptions dependent upon the subscriber&#x2019;s enrollment selection. The Company has
determined that there is one performance obligation that is delivered over time, as the Company allows the subscriber to access the telehealth
platform for the time period of the subscription purchased. The majority of the Company&#x2019;s subscriptions are recognized over time
using the input method in which revenue is recognized on the basis of efforts or inputs toward satisfying a performance obligation relative
to the total expected inputs to satisfy the performance obligation. The Company uses time elapsed as the input. The measure used provides
a faithful depiction of the transfer of goods or services to the subscribers. The Company records the revenue over the customer&#x2019;s
subscription period for monthly and multi-month subscribers. The Company also offers bundled arrangements in which a subscriber receives
subscription-based access to the Company&#x2019;s telehealth platform as well as prescribed medication. The Company has determined that
there are two performance obligations related to these bundles: (i) one performance obligation for the subscription-based service that
is delivered over time and (ii) one performance obligation for the prescribed medication that is delivered as of a point in time. For
contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on a relative
stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products
and services. Revenue related to contracts with multiple performance obligations is not material for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
to fulfill its promise to customers for contracts that include the sale of prescription products, the Company maintains relationships
with certain third-party pharmacies, which are licensed mail order pharmacies providing prescription fulfillment to the Company&#x2019;s
customers. The third-party pharmacies fill prescription orders for customers who have received a prescription from a LifeMD PC provider.
The Company may account for prescription product revenue as the principal or agent in the arrangement with its customers depending on
the agreement with the related third-party pharmacy. The following factors are evaluated to determine if the Company acts as principal
or agent in the arrangement: (i) whether the Company has sole discretion in determining which pharmacy fills a customer&#x2019;s prescription;
(ii) whether the Company obtains control of the product; (iii) whether the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order; (iv) whether the Company is responsible for refunds of the prescription medication after
transfer of control to the customer; and (v) whether the Company sets all listed prices for the prescription products. Based on evaluation
of these factors, the Company accounts for prescription product revenue as the agent in the arrangement with its largest third-party
pharmacy provider.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
discounts, returns and rebates on telehealth revenues approximated $&lt;span id="xdx_905_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zR3FLC2R8wv2" title="Customer discounts and allowance"&gt;3.7&lt;/span&gt; million and $&lt;span id="xdx_900_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zALEBBxuzuj9" title="Customer discounts and allowance"&gt;2.1&lt;/span&gt; million, respectively, during the years ended
December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, through its majority-owned subsidiary WorkSimpli, offers a subscription-based service providing a suite of software applications
to its subscribers, principally on a monthly subscription basis. The software suite allows the subscriber/user to convert almost any
type of document to another electronic form of editable document, providing ease of editing. For these subscription-based contracts with
customers, the Company offers an initial 14-day trial period which is billed at $&lt;span id="xdx_901_ecustom--SubscriptionPricePerShare_iI_pid_c20241231_zlwqmQxy4Dth" title="Subscription price per share"&gt;1.95&lt;/span&gt;, followed by a monthly subscription, or a multi-month
subscription to the Company&#x2019;s software suite dependent on the subscriber&#x2019;s enrollment selection. The Company has determined
that there is one product and one performance obligation that is delivered over time, as the Company allows the subscriber to access
the suite of services for the time period of the subscription purchased. The Company allows the customer to cancel at any point during
the billing cycle, in which case the customer&#x2019;s subscription will not be renewed for the following month or year depending on the
original subscription. The Company records the revenue over the customer&#x2019;s subscription period for monthly and multi-month subscribers
or at the end of the initial 14-day service period for customers who purchased the initial subscription. The Company offers a discount
for the monthly or multi-month subscriptions being purchased, which is deducted at the time of payment at the initiation of the contract
term; therefore the contract price is fixed and determinable at the contract initiation. Monthly and multi-month subscriptions for the
service are recorded net of the Company&#x2019;s known discount rates. Customer discounts and allowances on WorkSimpli revenues approximated
$&lt;span id="xdx_908_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__custom--SoftwareRevenueMember_z8jQ3sEdysUh" title="Customer discounts and allowance"&gt;3.6&lt;/span&gt; million and $&lt;span id="xdx_90C_ecustom--CustomerDiscountsReturnsAndRebates_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__custom--SoftwareRevenueMember_z4hHAm6jcjH4" title="Customer discounts and allowance"&gt;3.3&lt;/span&gt; million, respectively, during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted above, on December 11, 2023, the Company entered into the Medifast Collaboration. Pursuant to certain agreements between the parties,
Medifast agreed to pay to the Company the amount of $&lt;span id="xdx_907_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zf6bgNfLH5E9" title="Collaboration amount"&gt;10&lt;/span&gt; million to support the collaboration, funding enhancements to the Company platform,
operations and supporting infrastructure, of which $&lt;span id="xdx_90A_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231212__dei--LegalEntityAxis__custom--MedifastIncMember_zlSOMaj7Ibvb" title="Collaboration amount"&gt;5&lt;/span&gt; million was paid at the closing on December 12, 2023, $&lt;span id="xdx_90B_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240101__20240331__dei--LegalEntityAxis__custom--MedifastIncMember_zrhtIZnRoVbd" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during
the three months ended March 31, 2024, and the remaining $&lt;span id="xdx_90A_ecustom--BusinessCombinationRemainingConsiderationTransferred_pn5n6_c20240401__20240630__dei--LegalEntityAxis__custom--MedifastIncMember_zU3XNGwHjNyg" title="Consideration to be transferred"&gt;2.5&lt;/span&gt; million was paid during the three months ended June 30, 2024. The Company
determined the transaction price totalled $&lt;span id="xdx_901_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20241231__dei--LegalEntityAxis__custom--MedifastIncMember_zCzRqWUsYnik" title="Transaction amount"&gt;10&lt;/span&gt; million, which was fully collected as of December 31, 2024. The Company has allocated the
total $&lt;span id="xdx_90E_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn6n6_c20231211__dei--LegalEntityAxis__custom--MedifastIncMember_zZguWGy9xkef" title="Transaction amount"&gt;10&lt;/span&gt; million initial transaction price to three distinct performance obligations. As the Company completed its first performance
obligation related to this agreement, the $&lt;span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20230101__20231231__dei--LegalEntityAxis__custom--MedifastIncMember_zUuqzZip5ka8" title="Transaction amount collected"&gt;5&lt;/span&gt; million payment was fully recognized during the year ended December 31, 2023. The Company
recognized approximately $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20240101__20240331__dei--LegalEntityAxis__custom--MedifastIncMember_zfiHYAtiyqAh" title="Transaction amount collected"&gt;2&lt;/span&gt; million related to the second performance obligation during the three months ended March 31, 2024, and approximately
$&lt;span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesGross_pn6n6_c20240401__20240630__dei--LegalEntityAxis__custom--MedifastIncMember_zZBoPsvsL8J8" title="Transaction amount collected"&gt;3&lt;/span&gt; million related to the second and third performance obligations during the three months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLzMGCujp3Kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company had the following disaggregated revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zbR3awranSOb" style="display: none"&gt;SCHEDULE OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Telehealth product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zKP7oIesetc3" style="width: 10%; text-align: right" title="Total net revenue"&gt;83,423,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcgEV2jtwSW4" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z8v06A4DTwoc" style="width: 10%; text-align: right" title="Total net revenue"&gt;88,886,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConcentrationRiskPercentage_dp_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zaldMQHZlj57" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Telehealth subscription revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zYURjZhiAv24" style="text-align: right" title="Total net revenue"&gt;70,015,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z0Q6jBGSMIuk" style="text-align: right" title="Total net revenue, percent"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zmxgVHHqlwI8" style="text-align: right" title="Total net revenue"&gt;4,266,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z97tmF8oQ2Nd" style="text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;WorkSimpli revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Oq3uaMWeZ9" style="text-align: right" title="Total net revenue"&gt;54,015,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zxHWFpuoKohi" style="text-align: right" title="Total net revenue, percent"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zVuMC9ZdLXp1" style="text-align: right" title="Total net revenue"&gt;54,394,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z6gtNaAp1oY6" style="text-align: right" title="Total net revenue, percent"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Medifast collaboration revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zfn9vH9cH9Xh" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zrH0ApqKH4Eg" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zgOrQfq83XZa" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zV00Ch5BtHT5" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_zbXHqsSFdX1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;212,453,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231_zaGqQ23BSbed" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zx5XX7FbPf85" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;152,547,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231_z1hfJoFVhnMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zXrEvWtQCxtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <LFMD:CustomerDiscountsReturnsAndRebates
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="-5"
      id="Fact000961"
      unitRef="USD">3700000</LFMD:CustomerDiscountsReturnsAndRebates>
    <LFMD:CustomerDiscountsReturnsAndRebates
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      decimals="-5"
      id="Fact000963"
      unitRef="USD">2100000</LFMD:CustomerDiscountsReturnsAndRebates>
    <LFMD:SubscriptionPricePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000965"
      unitRef="USDPShares">1.95</LFMD:SubscriptionPricePerShare>
    <LFMD:CustomerDiscountsReturnsAndRebates
      contextRef="From2024-01-012024-12-31_custom_SoftwareRevenueMember"
      decimals="-5"
      id="Fact000967"
      unitRef="USD">3600000</LFMD:CustomerDiscountsReturnsAndRebates>
    <LFMD:CustomerDiscountsReturnsAndRebates
      contextRef="From2023-01-012023-12-31_custom_SoftwareRevenueMember"
      decimals="-5"
      id="Fact000969"
      unitRef="USD">3300000</LFMD:CustomerDiscountsReturnsAndRebates>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2023-12-11_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000971"
      unitRef="USD">10000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2023-12-12_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000973"
      unitRef="USD">5000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <LFMD:BusinessCombinationRemainingConsiderationTransferred
      contextRef="From2024-01-012024-03-31_custom_MedifastIncMember"
      decimals="-5"
      id="Fact000975"
      unitRef="USD">2500000</LFMD:BusinessCombinationRemainingConsiderationTransferred>
    <LFMD:BusinessCombinationRemainingConsiderationTransferred
      contextRef="From2024-04-012024-06-30_custom_MedifastIncMember"
      decimals="-5"
      id="Fact000977"
      unitRef="USD">2500000</LFMD:BusinessCombinationRemainingConsiderationTransferred>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2024-12-31_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000979"
      unitRef="USD">10000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2023-12-11_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000981"
      unitRef="USD">10000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-01-012023-12-31_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000983"
      unitRef="USD">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2024-01-012024-03-31_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000985"
      unitRef="USD">2000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2024-04-012024-06-30_custom_MedifastIncMember"
      decimals="-6"
      id="Fact000987"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000989">&lt;p id="xdx_89C_eus-gaap--DisaggregationOfRevenueTableTextBlock_zLzMGCujp3Kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company had the following disaggregated revenue:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zbR3awranSOb" style="display: none"&gt;SCHEDULE OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Telehealth product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zKP7oIesetc3" style="width: 10%; text-align: right" title="Total net revenue"&gt;83,423,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcgEV2jtwSW4" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z8v06A4DTwoc" style="width: 10%; text-align: right" title="Total net revenue"&gt;88,886,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConcentrationRiskPercentage_dp_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zaldMQHZlj57" style="width: 10%; text-align: right" title="Total net revenue, percent"&gt;58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Telehealth subscription revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zYURjZhiAv24" style="text-align: right" title="Total net revenue"&gt;70,015,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z0Q6jBGSMIuk" style="text-align: right" title="Total net revenue, percent"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_zmxgVHHqlwI8" style="text-align: right" title="Total net revenue"&gt;4,266,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthSubscriptionRevenueMember_z97tmF8oQ2Nd" style="text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;WorkSimpli revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Oq3uaMWeZ9" style="text-align: right" title="Total net revenue"&gt;54,015,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zxHWFpuoKohi" style="text-align: right" title="Total net revenue, percent"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zVuMC9ZdLXp1" style="text-align: right" title="Total net revenue"&gt;54,394,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z6gtNaAp1oY6" style="text-align: right" title="Total net revenue, percent"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Medifast collaboration revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zfn9vH9cH9Xh" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zrH0ApqKH4Eg" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zgOrQfq83XZa" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue"&gt;5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedifastCollaborationRevenueMember_zV00Ch5BtHT5" style="border-bottom: Black 1pt solid; text-align: right" title="Total net revenue, percent"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_zbXHqsSFdX1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;212,453,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConcentrationRiskPercentage_dp_uPure_c20240101__20241231_zaGqQ23BSbed" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zx5XX7FbPf85" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue"&gt;152,547,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConcentrationRiskPercentage_dp_uPure_c20230101__20231231_z1hfJoFVhnMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total net revenue, percent"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_TelehealthMember"
      decimals="0"
      id="Fact000991"
      unitRef="USD">83423428</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2024-01-012024-12-31_custom_TelehealthMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Pure">0.40</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_TelehealthMember"
      decimals="0"
      id="Fact000995"
      unitRef="USD">88886664</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2023-01-012023-12-31_custom_TelehealthMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">0.58</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_TelehealthSubscriptionRevenueMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">70015203</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2024-01-012024-12-31_custom_TelehealthSubscriptionRevenueMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Pure">0.33</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_TelehealthSubscriptionRevenueMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">4266255</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2023-01-012023-12-31_custom_TelehealthSubscriptionRevenueMember"
      decimals="INF"
      id="Fact001005"
      unitRef="Pure">0.03</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">54015207</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliMember"
      decimals="INF"
      id="Fact001009"
      unitRef="Pure">0.25</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">54394087</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliMember"
      decimals="INF"
      id="Fact001013"
      unitRef="Pure">0.36</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_MedifastCollaborationRevenueMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2024-01-012024-12-31_custom_MedifastCollaborationRevenueMember"
      decimals="INF"
      id="Fact001017"
      unitRef="Pure">0.02</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_MedifastCollaborationRevenueMember"
      decimals="0"
      id="Fact001019"
      unitRef="USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2023-01-012023-12-31_custom_MedifastCollaborationRevenueMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Pure">0.03</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001023"
      unitRef="USD">212453838</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001025"
      unitRef="Pure">1</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001027"
      unitRef="USD">152547006</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <LFMD:ConcentrationRiskPercentage
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001029"
      unitRef="Pure">1</LFMD:ConcentrationRiskPercentage>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001031">&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEfMRYJjxFFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records deferred revenues when cash payments are received or due in advance of its performance. As of December 31, 2024 and 2023,
the Company has accrued contract liabilities, as deferred revenue, of approximately $&lt;span id="xdx_908_eus-gaap--DeferredRevenue_iI_pn5n6_c20241231_zDHI6RjMYLU1" title="Deferred revenue"&gt;14.5&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_zfDXV1WZC5Hl" title="Deferred revenue"&gt;8.8&lt;/span&gt; million, respectively, which
represent the following: (1) $&lt;span id="xdx_906_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zPmrwKefRhM8" title="Accrued contract liabilities"&gt;10.1&lt;/span&gt; million and $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zdqUbz7uTUbc" title="Accrued contract liabilities"&gt;4.2&lt;/span&gt; million as of December 31, 2024 and 2023, respectively, related to obligations on
telehealth in-process monthly or yearly contracts with customers, (2) $&lt;span id="xdx_904_ecustom--ContractWithCustomerLiabilityNotYetObtained_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zSKVzvKuUI14" title="Accrued contract liabilities"&gt;1.9&lt;/span&gt; million and $&lt;span id="xdx_90A_ecustom--ContractWithCustomerLiabilityNotYetObtained_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--TeleHealthInProcessMember_zIFhQWuI4Tz7" title="Accrued contract liabilities"&gt;2.1&lt;/span&gt; million as of December 31, 2024 and 2023,
respectively, related to obligations for telehealth products which the customer has not yet obtained control due to non-shipment of the
product and (3) $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--WorkSimpliInProcessMember_zwxEhsk4jGZ4" title="Accrued contract liabilities"&gt;2.5&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20231231__srt--ProductOrServiceAxis__custom--WorkSimpliInProcessMember_zXHwnQ1Inwh3" title="Accrued contract liabilities"&gt;2.5&lt;/span&gt; million as of December 31, 2024 and 2023, respectively, related to obligations on WorkSimpli in-process
monthly or multi-month contracts with customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
revenue increased by $&lt;span id="xdx_90E_ecustom--IncreaseInDeferredRevenue_iI_pn5n6_c20241231_zt65r6jg5p3h" title="Increase in deferred revenue"&gt;5.7&lt;/span&gt;
million to $&lt;span id="xdx_906_eus-gaap--DeferredRevenue_iI_pn5n6_c20241231_zpHbTNAY92z1" title="Deferred revenue"&gt;14.5&lt;/span&gt;
million as of December 31, 2024 compared to $&lt;span id="xdx_900_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_zTKz8KqzIr4f" title="Deferred revenue"&gt;8.8&lt;/span&gt;
million as of December 31, 2023. The increase is primarily due to the increase in telehealth monthly and multi-month subscription
revenue the year ended December 31, 2024 compared to the year ended December 31, 2023. The amount of revenue recognized during the
year ended December 31, 2024, that was included in the deferred revenue balance as of December 31, 2023, was $&lt;span id="xdx_900_ecustom--DeferredRevenueBalancesFromPreviousYear_pn5n6_c20240101__20241231_zJFrs1hmQCt4" title="Deferred revenue"&gt;7.6&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to recognize all of the deferred revenue related to future performance obligations that are unsatisfied or partially
unsatisfied as of December 31, 2024 as revenue by December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_ztbf26AdtpAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes deferred revenue activities for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B2_zFCjCcFwRqil" style="display: none"&gt;SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zYtyM4QsZUd9" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z2Z5ZrHWoiEc" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iS_zg31vyoMgiZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,547,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_z4UrHbqTFEg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214,304,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,319,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_z4HsaZPbzuta" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(208,652,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(55,038,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iE_zpPWjzXUPpJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;End of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,480,917&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG5LlLCLjh7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001033"
      unitRef="USD">14500000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001035"
      unitRef="USD">8800000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2024-12-31_custom_TeleHealthInProcessMember"
      decimals="-5"
      id="Fact001037"
      unitRef="USD">10100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_TeleHealthInProcessMember"
      decimals="-5"
      id="Fact001039"
      unitRef="USD">4200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <LFMD:ContractWithCustomerLiabilityNotYetObtained
      contextRef="AsOf2024-12-31_custom_TeleHealthInProcessMember"
      decimals="-5"
      id="Fact001041"
      unitRef="USD">1900000</LFMD:ContractWithCustomerLiabilityNotYetObtained>
    <LFMD:ContractWithCustomerLiabilityNotYetObtained
      contextRef="AsOf2023-12-31_custom_TeleHealthInProcessMember"
      decimals="-5"
      id="Fact001043"
      unitRef="USD">2100000</LFMD:ContractWithCustomerLiabilityNotYetObtained>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2024-12-31_custom_WorkSimpliInProcessMember"
      decimals="-5"
      id="Fact001045"
      unitRef="USD">2500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_WorkSimpliInProcessMember"
      decimals="-5"
      id="Fact001047"
      unitRef="USD">2500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <LFMD:IncreaseInDeferredRevenue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001049"
      unitRef="USD">5700000</LFMD:IncreaseInDeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001051"
      unitRef="USD">14500000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001053"
      unitRef="USD">8800000</us-gaap:DeferredRevenue>
    <LFMD:DeferredRevenueBalancesFromPreviousYear
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001055"
      unitRef="USD">7600000</LFMD:DeferredRevenueBalancesFromPreviousYear>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001057">&lt;p id="xdx_89C_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_ztbf26AdtpAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes deferred revenue activities for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B2_zFCjCcFwRqil" style="display: none"&gt;SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zYtyM4QsZUd9" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z2Z5ZrHWoiEc" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iS_zg31vyoMgiZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,547,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_z4UrHbqTFEg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214,304,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,319,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_z4HsaZPbzuta" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(208,652,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(55,038,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredRevenueCurrent_iE_zpPWjzXUPpJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;End of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,480,917&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,828,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001059"
      unitRef="USD">8828598</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001060"
      unitRef="USD">5547506</us-gaap:DeferredRevenueCurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">214304407</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001063"
      unitRef="USD">58319435</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001065"
      unitRef="USD">208652088</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">55038343</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">14480917</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">8828598</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001071">&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_znIilBkUAidb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets are included in
right-of-use assets on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included
in the current operating lease liabilities and noncurrent operating lease liabilities, respectively, on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over
the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate
based on the information available at the commencement date in determining the present value of future payments. Certain leases may include
options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease
term. Leases with an initial term of 12 months or less are not recorded in the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-01to2024-12-31" id="Fact001073">&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zmz19dswcxy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounts
Receivable, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable principally consist of amounts due from third-party merchant processors, who process our subscription revenues; the merchant
accounts balance receivable represents the charges processed by the merchants that have not yet been deposited with the Company. The
unsettled merchant receivable amount normally represents processed sale transactions from the final one to three days of the month, with
collections being made by the Company within the first week of the following month. Management determines the need, if any, for an allowance
for future credits to be granted to customers, by regularly evaluating aggregate customer refund activity, coupled with the consideration
and current economic conditions in its evaluation of an allowance for future refunds and chargebacks. As of December 31, 2024 and 2023,
the reserve for sales returns and allowances was approximately $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20241231_z4j3lIxNMpig" title="Sales returns and allowances"&gt;894&lt;/span&gt; thousand and $&lt;span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20231231_zJLgZyEejnI5" title="Sales returns and allowances"&gt;528&lt;/span&gt; thousand, respectively. For all periods presented,
as noted above, the sales returns and allowances were recorded in accrued expenses on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zkqepLrc20wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounts receivable balances are as follows for each of the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zDTXJOILUkX2"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20240101__20241231_z8zc4k1tBhIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20230101__20231231_zl1nw7amA9si" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_iS_zYZ2hYqpXM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,834,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iE_zhNHrKIHc3e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;End of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,217,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zT8DFSCuDtqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">894000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">528000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001079">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zkqepLrc20wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounts receivable balances are as follows for each of the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zDTXJOILUkX2"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20240101__20241231_z8zc4k1tBhIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20230101__20231231_zl1nw7amA9si" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_iS_zYZ2hYqpXM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,834,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iE_zhNHrKIHc3e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;End of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,217,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,277,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001081"
      unitRef="USD">5277250</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001082"
      unitRef="USD">2834750</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001084"
      unitRef="USD">8217813</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001085"
      unitRef="USD">5277250</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001087">&lt;p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_zibMULhB1mTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, inventory primarily consisted of finished goods, raw materials and packaging related to the Company&#x2019;s
OTC products included in the telehealth revenue section of the table above. Inventory is maintained at the Company&#x2019;s third-party
warehouse location in Wyoming and at various Amazon fulfillment centers. The Company also maintains inventory at a company owned warehouse
in Pennsylvania.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is valued at the lower of cost or net realizable value with cost determined on an average cost basis. Management compares the cost of
inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of December
31, 2024 and 2023, the Company recorded an inventory reserve of $&lt;span id="xdx_90B_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20241231_zAGeQ3U9EOd9" title="Inventory reserve"&gt;263&lt;/span&gt; thousand and $&lt;span id="xdx_905_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20231231_z4BMvYwH3Fx5" title="Inventory reserve"&gt;356&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLVbSGFfbLYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company&#x2019;s inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zdO2DJgyjb5g" style="display: none"&gt;SUMMARY OF INVENTORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zkOE2OciwrYl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zyGtoYvrF4V5" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maCze8N_zT5AbvCzFCe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,554,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,898,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryRawMaterials_iI_maCze8N_zZJCy3mPNVKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Raw materials and packaging components&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,506,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryValuationReserves_iNI_di_msCze8N_z3BPLT2Yt0dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Inventory reserve&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(263,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(355,685&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryNet_iTI_mtCze8N_z1SBcoDfxvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,797,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,759,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zCgB65mDvxE7" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001089"
      unitRef="USD">263000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001091"
      unitRef="USD">356000</us-gaap:InventoryValuationReserves>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001093">&lt;p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLVbSGFfbLYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company&#x2019;s inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zdO2DJgyjb5g" style="display: none"&gt;SUMMARY OF INVENTORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zkOE2OciwrYl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zyGtoYvrF4V5" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maCze8N_zT5AbvCzFCe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,554,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,898,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryRawMaterials_iI_maCze8N_zZJCy3mPNVKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Raw materials and packaging components&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,506,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryValuationReserves_iNI_di_msCze8N_z3BPLT2Yt0dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Inventory reserve&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(263,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(355,685&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryNet_iTI_mtCze8N_z1SBcoDfxvk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,797,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,759,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">1554600</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">1898784</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001098"
      unitRef="USD">1506078</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001099"
      unitRef="USD">1216833</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">263320</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001102"
      unitRef="USD">355685</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001104"
      unitRef="USD">2797358</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001105"
      unitRef="USD">2759932</us-gaap:InventoryNet>
    <us-gaap:DepositContractsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact001107">&lt;p id="xdx_848_eus-gaap--DepositContractsPolicy_z2z6QsndYNPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Product
Deposit&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Many
of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically range from
&lt;span id="xdx_90E_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDeposits_iI_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember_zLCzl46uCcMe" title="Percentage of interest-bearing domestic deposits"&gt;10&lt;/span&gt;% to &lt;span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDeposits_iI_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember_ztv82zpNLkr7" title="Percentage of interest-bearing domestic deposits"&gt;33&lt;/span&gt;% of the total purchased amount. Our vendors include a credit memo within their final invoice, recognizing the deposit amount
previously paid. As of December 31, 2024 and 2023, the Company has approximately $&lt;span id="xdx_90B_eus-gaap--DepositsAssetsCurrent_iI_pn3n3_c20241231_zPS4bSnJbaZ" title="Deposits assets, current"&gt;41&lt;/span&gt; thousand and $&lt;span id="xdx_902_eus-gaap--DepositsAssetsCurrent_iI_pn3n3_c20231231_z4gYR1nx8uBj" title="Deposits assets, current"&gt;486&lt;/span&gt; thousand, respectively, of product
deposits with multiple vendors for the purchase of raw materials or finished goods. The Company&#x2019;s history of product deposits with
its inventory vendors, creates an implicit purchase commitment equaling the total expected product acceptance cost in excess of the product
deposit. As of December 31, 2024, the Company approximates its implicit purchase commitments to be approximately $&lt;span id="xdx_902_eus-gaap--PurchaseObligation_iI_pn3n3_c20241231_zwf64zZJOHma" title="Purchase obligation"&gt;479&lt;/span&gt; thousand, of which
the vast majority are with two vendors that manufacture the Company&#x2019;s finished goods inventory for its RexMD product line.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DepositContractsPolicy>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDeposits
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001109"
      unitRef="Pure">0.10</us-gaap:PercentageOfInterestBearingDomesticDepositsToDeposits>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDeposits
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Pure">0.33</us-gaap:PercentageOfInterestBearingDomesticDepositsToDeposits>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001113"
      unitRef="USD">41000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">486000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001117"
      unitRef="USD">479000</us-gaap:PurchaseObligation>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2024-01-01to2024-12-31" id="Fact001119">&lt;p id="xdx_843_eus-gaap--InProcessResearchAndDevelopmentPolicy_zADMO2jDITJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Capitalized
Software Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes certain internal payroll costs and third-party costs related to internally developed software and amortizes these
costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell
internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria
for capitalization, in accordance with ASC 350-40, Internal-Use Software, are expensed as incurred. As of December 31, 2024 and 2023,
the Company capitalized a net amount of $&lt;span id="xdx_90A_eus-gaap--CapitalizedComputerSoftwareNet_iI_pn5n6_c20241231_zPDvpMzKLp2d" title="Capitalized software costs"&gt;13.8&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--CapitalizedComputerSoftwareNet_iI_pn5n6_c20231231_znT9dwxoaNX1" title="Capitalized software costs"&gt;11.8&lt;/span&gt; million, respectively, related to internally developed software costs
which are amortized over the useful life and included in development costs on our consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001121"
      unitRef="USD">13800000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001123"
      unitRef="USD">11800000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact001125">&lt;p id="xdx_849_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zKbzQJRJ4cDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets are comprised of: (1) the ResumeBuild brand, (2) a customer relationship asset, (3) the Cleared trade name, (4) Cleared developed
technology, (5) a purchased license and (6) four purchased domain names. Intangible assets are amortized over their estimated lives using
the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over
the useful life of the asset which typically range from &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MinimumMember_zLpysWZaR0Vi" title="Intangible assets, term"&gt;one year&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zdUouEtN9m11" title="Intangible assets, term"&gt;ten years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="Fact001127">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact001129">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001131">&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zHogCpA2B41k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets include equipment and capitalized software. Long-lived assets are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. If such assets are considered to be impaired, an impairment is
recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of December 31,
2024 and 2023, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001133">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zaBvcT5MpXQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files corporate federal, state, and local tax returns. WorkSimpli files a tax return in Puerto Rico. The Company records current
and deferred taxes in accordance with ASC 740, Accounting for Income Taxes. This ASC requires recognition of deferred tax assets and
liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial
statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes
a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses
the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and management determines
the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement
recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit
from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that
the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company&#x2019;s
tax returns for all years since December 31, 2021, remain open to audit by all related taxing authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001135">&lt;p id="xdx_847_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zQMiLxQVHfSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASC 718, Share-Based Payment. Under this guidance compensation cost generally is recognized at fair
value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of
grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based
upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected
volatility is based upon historical volatility of the Company&#x2019;s common shares using daily price observations over an observation
period that approximates the expected life of the options. The risk-free interest rate approximates the U.S. Treasury yield curve rate
in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the Company has
elected to account for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001137">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zd4MQAFivtFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per common share (&#x201c;EPS&#x201d;) is based on the weighted average number of shares outstanding during each period
presented. Shares of unissued vested restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are
included in our calculation of basic weighted average shares outstanding. Convertible securities, warrants and options to purchase common
stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings
per share when the effects would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed
issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated
using the &#x201c;treasury stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are
used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and preferred
stock is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted
at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the
entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zL9RY6OjmIhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from
the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price
could be less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zWaEu7j7H828" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zwnfAWrYHJRi" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zWvu7EMfTi99" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsAndRestrictedStockUnitMember_zZzWLuDdpBA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;RSUs and RSAs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,157,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,556,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zf1lmQSKfxP9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,288,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,336,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zf3aNkvm2RL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,743,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleLongTermDebtMember_zodfacqs0D6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zNLeBagnrNr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,860,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,294,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zJRT8naJGrZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001139">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zL9RY6OjmIhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from
the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price
could be less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zWaEu7j7H828" style="display: none"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zwnfAWrYHJRi" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zWvu7EMfTi99" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsAndRestrictedStockUnitMember_zZzWLuDdpBA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;RSUs and RSAs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,157,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,556,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zf1lmQSKfxP9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,288,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,336,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zf3aNkvm2RL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,743,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleLongTermDebtMember_zodfacqs0D6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zNLeBagnrNr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,860,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,294,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockUnitMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">3157706</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockUnitMember"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">3556375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001144"
      unitRef="Shares">1288000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">2336222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001147"
      unitRef="Shares">1743730</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001148"
      unitRef="Shares">4730607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_ConvertibleLongTermDebtMember"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">671141</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertibleLongTermDebtMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Shares">671141</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001153"
      unitRef="Shares">6860577</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">11294345</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001156">&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5dQTvxwtqj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segment
Data&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
portfolio of brands are included within two operating segments: Telehealth and WorkSimpli. We believe our current segments and brands
within our segments complement one another and position us well for future growth. The Company&#x2019;s Chief Executive Officer is the
chief operating decision maker (&#x201c;CODM&#x201d;) and is responsible for reviewing segment operating results to make determinations
about resources to be allocated and to assess performance. Other factors, including type of business, revenue recognition and operating
results are reviewed in determining the Company&#x2019;s operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact001158">&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKQfI5DLM64k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in
an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement
are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement.
Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets
or liabilities, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability
    through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    or liabilities and that reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability
    at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In
those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input
that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the Company&#x2019;s financial instruments, including cash, accounts receivable, accounts payable, accrued expenses,
and the face amount of notes payable and long-term debt approximate fair value for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact001160">&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zTCP7iO7Qpue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Concentrations
of Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times,
maintains balances in various operating accounts in excess of federally insured limits. We are dependent on certain third-party manufacturers
and pharmacies, although we believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our
current manufacturers or pharmacies cease to perform adequately. As of December 31, 2024, we utilized five (5) suppliers for fulfillment
services. As of December 31, 2023, we utilized three (3) suppliers for fulfillment services, nine (9) suppliers for manufacturing finished
goods, seven (7) suppliers for packaging, bottling, and labeling, and five (5) suppliers for prescription medications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001162">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDdHfjzUOXb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280). The amendments
in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 became effective for the Company&#x2019;s annual period beginning on January 1, 2024 and interim periods beginning after January
1, 2025. The Company adopted this guidance in the fourth quarter of 2024. Refer to Note 13 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <LFMD:OtherRecentAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001164">&lt;p id="xdx_84D_ecustom--OtherRecentAccountingPronouncementsPolicyTextBlock_zIkP8SwUsNce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740):&lt;/i&gt; &lt;i&gt;Improvements to Income Tax Disclosures,&lt;/i&gt; to improve
its income tax disclosure requirements. Under ASU 2023-09, entities must annually: (1) disclose specific categories in the rate reconciliation
and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that ASU 2023-09 will have to its consolidated financial
statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40)&lt;/i&gt; to improve the disclosures about a public business entity&#x2019;s expenses and provide more detailed information
about the types of expenses included in certain expense captions in the consolidated financial statements. The amendments in this update
are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December
15, 2027. Early adoption is permitted and the amendments in this update should be applied either prospectively or retrospectively. The
Company is evaluating the impact this guidance will have on the disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are
not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;

</LFMD:OtherRecentAccountingPronouncementsPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001166">&lt;p id="xdx_807_eus-gaap--AssetAcquisitionTextBlock_zanSnG7pHAfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_829_znB1FcweEh"&gt;ACQUISITIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 18, 2022, the Company completed the acquisition of Cleared. The Company accounted for the transaction using the acquisition method
in accordance with ASC 805, &lt;i&gt;Business Combinations&lt;/i&gt;, with the purchase price being allocated to tangible and identifiable intangible
assets acquired and liabilities assumed based on their respective estimated fair values on the acquisition date. Fair values were determined
using income approaches. The results of Cleared are included within the consolidated financial statements commencing on the acquisition
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 60pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2023, the Company entered into the Cleared First Amendment. The Cleared Stock Purchase Agreement was amended to, among other
things: (i) reduce the total purchase price by $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zkecdHarGQ08" title="Payments to acquire businesses, net of cash acquired"&gt;250&lt;/span&gt; thousand to a total of $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn4n6_c20230204__20230204__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zyecBa77RDCf" title="Payments to acquire businesses, net of cash acquired"&gt;3.67&lt;/span&gt; million; (ii) change the timing of the payment of the
purchase price to $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zul0DSzN3Sw5" title="Payments to acquire businesses, gross"&gt;460&lt;/span&gt; thousand paid at closing (which has already been paid by the Company), with the remaining amount to be paid in
five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024; (iii) remove all &#x201c;earn-out&#x201d;
payments payable by the Company to the sellers; and (iv) remove certain representations and warranties of the Company and sellers in
connection with the transaction. The Company issued the following shares of common stock to the sellers of Cleared under the Cleared
First Amendment: (1) &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230206__20230206__us-gaap--AwardTypeAxis__custom--FirstOfFiveQuarterlyInstallmentMember_z1CXTsQRVj0h" title="Stock issued during period shares new issues"&gt;337,895&lt;/span&gt; shares on February 6, 2023, (2) &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230417__20230417__us-gaap--AwardTypeAxis__custom--SecondOfFiveQuarterlyInstallmentMember_zluXQpLAtb96" title="Stock issued during period shares new issues"&gt;455,319&lt;/span&gt; shares on April 17, 2023, (3) &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230717__20230717__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyInstallmentMember_zAR3d1AnKq0f" title="Stock issued during period shares new issues"&gt;158,129&lt;/span&gt; shares on July 17, 2023, (4)
&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231017__20231017__us-gaap--AwardTypeAxis__custom--FourthOfFiveQuarterlyInstallmentMember_z3tH38DKYeUg" title="Stock issued during period shares new issues"&gt;117,583&lt;/span&gt; shares on October 17, 2023 and (5) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240116__20240116__us-gaap--AwardTypeAxis__custom--FifthQuarterlyInstallmentMember_zBETS8lJsQGl" title="Stock issued during period shares new issues"&gt;95,821&lt;/span&gt; shares on January 16, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, WorkSimpli closed on the ResumeBuild APA to purchase the related intangible assets associated with the ResumeBuild brand,
a subscription-based resume building software. The acquisition further adds to the capabilities of the WorkSimpli software as a service
application. The purchase price was $&lt;span id="xdx_90B_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn5n6_c20220201__20220228__us-gaap--AssetAcquisitionAxis__custom--ResumeBuildMember_zBTpPn7ev683" title="Asset acquisition, price of acquisition, expected"&gt;4.5&lt;/span&gt; million, including cash paid upfront of $&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zbgtYy45hQx4" title="Consideration paid"&gt;4.0&lt;/span&gt; million and contingent consideration of $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_pn3n3_c20220228__us-gaap--BusinessAcquisitionAxis__custom--ResumeBuildMember_zrVXlxzBMXRb" title="Business combination, contingent consideration, asset"&gt;500&lt;/span&gt; thousand.
In accordance with ASC 805, Business Combinations, the Company accounted for the ResumeBuild APA as an acquisition of assets as substantially
all the fair value of the gross assets acquired is concentrated in a group of similar assets. The Company has elected to group the complementary
intangible assets acquired as a single brand intangible asset. Additionally, the Seller is entitled to quarterly payments equal to the
greater of &lt;span id="xdx_907_ecustom--PercentageOfPaymentAcquisition_pid_dp_uPure_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z4xysGYMreq2" title="Payment acquisition"&gt;15&lt;/span&gt;% of net profits (as defined in the ResumeBuild APA) or approximately $&lt;span id="xdx_907_ecustom--AssetAcquisitionClosing_pn3n3_c20220201__20220228_zUaq7QKETrMi" title="Acquisition closing"&gt;63&lt;/span&gt; thousand, for a two-year period ending on the
two-year anniversary of the closing of the Acquisition. As of December 31, 2024, WorkSimpli has paid the Seller $&lt;span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zNE1Ka9iAnAd" title="Consideration paid"&gt;500&lt;/span&gt; thousand in accordance
with the ResumeBuild APA. The Company estimated the fair value of the contingent consideration using the income approach.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact001168"
      unitRef="USD">250000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2023-02-042023-02-04_srt_MinimumMember_custom_StockPurchaseAgreeementMember"
      decimals="-4"
      id="Fact001170"
      unitRef="USD">3670000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact001172"
      unitRef="USD">460000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-062023-02-06_custom_FirstOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">337895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-172023-04-17_custom_SecondOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001176"
      unitRef="Shares">455319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-172023-07-17_custom_ThirdOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">158129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-172023-10-17_custom_FourthOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001180"
      unitRef="Shares">117583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-162024-01-16_custom_FifthQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001182"
      unitRef="Shares">95821</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="From2022-02-012022-02-28_custom_ResumeBuildMember"
      decimals="-5"
      id="Fact001184"
      unitRef="USD">4500000</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember"
      decimals="-6"
      id="Fact001186"
      unitRef="USD">4000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationAsset
      contextRef="AsOf2022-02-28_custom_ResumeBuildMember"
      decimals="-3"
      id="Fact001188"
      unitRef="USD">500000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <LFMD:PercentageOfPaymentAcquisition
      contextRef="From2022-02-012022-02-28_custom_AssetPurchaseAgreementMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Pure">0.15</LFMD:PercentageOfPaymentAcquisition>
    <LFMD:AssetAcquisitionClosing
      contextRef="From2022-02-012022-02-28"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">63000</LFMD:AssetAcquisitionClosing>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2024-01-012024-12-31_custom_AssetPurchaseAgreementMember"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001196">&lt;p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zGBwQdv5elP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013;&lt;span id="xdx_82A_zurCwRUfIpMl"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zmfBbIUhjLcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company has the following amounts related to amortizable intangible assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B4_zDVYq06Wmxu1" style="display: none"&gt;SCHEDULE
OF  INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; padding-left: 0.125in; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zRUGWO2DOI27" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zbqziQZkNvyf" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;Amortizable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: left"&gt;&lt;b&gt;Amortizable Intangible Assets:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ResumeBuildBrandMember_zzgrTpUX4yx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 47%; text-align: left"&gt;ResumeBuild brand&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ResumeBuildBrandMember_z7pdMM0Aw7uk" title="Amortizable Life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipAssetMember_zeOckw0Mi50l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Customer relationship asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipAssetMember_zVydFAAFbaD1" title="Amortizable Life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedTradeNameMember_zKNR8MHtDQX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cleared trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedTradeNameMember_zyHsMAiANGof" title="Amortizable Life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedDevelopedTechnologyMember_z08ekceLoBh7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cleared developed technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedDevelopedTechnologyMember_ztSSjdpGYkxg" title="Amortizable Life"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedLicensesMember_zq1QHuzrgrgd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Purchased licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedLicensesMember_zRnZEy3LG1U3" title="Amortizable Life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zlFcYEvqNno" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Website domain names&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zeNhV6V24S46" title="Amortizable Life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zFoSsXTTjIA3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Amortizable
    intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_z2V0F4hWIOpl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,997,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,015,435&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zsx3CkceOvv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total net amortizable intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,030,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,009,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zf6BqwlUDbii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate amortization expense of the Company&#x2019;s intangible assets was $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zvCFI2EGl84g" title="Amortization expense"&gt;982&lt;/span&gt; thousand and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zo3pPKG4Pamg" title="Amortization expense"&gt;971&lt;/span&gt; thousand for the years ended December
31, 2024 and 2023, respectively. Total amortization expense for 2025 is $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20241231_zR8nskMojc72" title="2025"&gt;978&lt;/span&gt; thousand, $&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_c20241231_zFXdjbRimGab" title="2026"&gt;940&lt;/span&gt; thousand for 2026, and approximately $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_c20241231_zHOngaTXW0qf" title="2027"&gt;113&lt;/span&gt;
thousand for 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001198">&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zmfBbIUhjLcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company has the following amounts related to amortizable intangible assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B4_zDVYq06Wmxu1" style="display: none"&gt;SCHEDULE
OF  INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; padding-left: 0.125in; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zRUGWO2DOI27" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zbqziQZkNvyf" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;Amortizable&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: left"&gt;&lt;b&gt;Amortizable Intangible Assets:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ResumeBuildBrandMember_zzgrTpUX4yx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 47%; text-align: left"&gt;ResumeBuild brand&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ResumeBuildBrandMember_z7pdMM0Aw7uk" title="Amortizable Life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipAssetMember_zeOckw0Mi50l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Customer relationship asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipAssetMember_zVydFAAFbaD1" title="Amortizable Life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedTradeNameMember_zKNR8MHtDQX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cleared trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedTradeNameMember_zyHsMAiANGof" title="Amortizable Life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedDevelopedTechnologyMember_z08ekceLoBh7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cleared developed technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ClearedDevelopedTechnologyMember_ztSSjdpGYkxg" title="Amortizable Life"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedLicensesMember_zq1QHuzrgrgd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Purchased licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PurchasedLicensesMember_zRnZEy3LG1U3" title="Amortizable Life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zlFcYEvqNno" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Website domain names&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zeNhV6V24S46" title="Amortizable Life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteDomainNameMember_zFoSsXTTjIA3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Amortizable
    intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_z2V0F4hWIOpl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,997,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,015,435&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zsx3CkceOvv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total net amortizable intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,030,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,009,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_ResumeBuildBrandMember"
      decimals="0"
      id="Fact001200"
      unitRef="USD">4500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_ResumeBuildBrandMember"
      decimals="0"
      id="Fact001201"
      unitRef="USD">4500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_ResumeBuildBrandMember"
      id="Fact001203">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_CustomerRelationshipAssetMember"
      decimals="0"
      id="Fact001205"
      unitRef="USD">1006840</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_CustomerRelationshipAssetMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">1006840</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_CustomerRelationshipAssetMember"
      id="Fact001208">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_ClearedTradeNameMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">133339</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_ClearedTradeNameMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">133339</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_ClearedTradeNameMember"
      id="Fact001213">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_ClearedDevelopedTechnologyMember"
      decimals="0"
      id="Fact001215"
      unitRef="USD">12920</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_ClearedDevelopedTechnologyMember"
      decimals="0"
      id="Fact001216"
      unitRef="USD">12920</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_ClearedDevelopedTechnologyMember"
      id="Fact001218">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_PurchasedLicensesMember"
      decimals="0"
      id="Fact001220"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_PurchasedLicensesMember"
      decimals="0"
      id="Fact001221"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_PurchasedLicensesMember"
      id="Fact001223">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_WebsiteDomainNameMember"
      decimals="0"
      id="Fact001225"
      unitRef="USD">175397</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_WebsiteDomainNameMember"
      decimals="0"
      id="Fact001226"
      unitRef="USD">171599</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_WebsiteDomainNameMember"
      id="Fact001228">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_WebsiteDomainNameMember"
      decimals="0"
      id="Fact001230"
      unitRef="USD">175397</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_WebsiteDomainNameMember"
      decimals="0"
      id="Fact001231"
      unitRef="USD">171599</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">3997840</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001234"
      unitRef="USD">3015435</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">2030656</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001237"
      unitRef="USD">3009263</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001239"
      unitRef="USD">982000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001241"
      unitRef="USD">971000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001243"
      unitRef="USD">978000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001245"
      unitRef="USD">940000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001247"
      unitRef="USD">113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001249">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zZAf21ox9ste" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_821_zrdqkyrYqUe5"&gt;ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFA0V4sF4oyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company has the following amounts related to accrued expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_ztu473SwUnw5" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zA7w131LFHqd" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zZIMDO6Xcgx1" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedMarketingCostsCurrent_iI_maALCzLi3_zqNj9PPeXPp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued selling and marketing expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,149,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,198,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzLi3_zm7sOVfH84re" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,106,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzLi3_zQL6PCHxdor4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,267,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_maALCzLi3_zgj5oAflJnx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued dividends payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PurchasePricePayableOne_iI_maALCzLi3_zA0Gqun93huk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Purchase price payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzLi3_zKQN8b8x3rE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,510,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,817,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzLi3_zWPbizRXLi1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,811,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,937,494&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zIMWgVDJX5X4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001251">&lt;p id="xdx_892_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFA0V4sF4oyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company has the following amounts related to accrued expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_ztu473SwUnw5" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zA7w131LFHqd" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zZIMDO6Xcgx1" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedMarketingCostsCurrent_iI_maALCzLi3_zqNj9PPeXPp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued selling and marketing expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,149,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,198,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzLi3_zm7sOVfH84re" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,106,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,003,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzLi3_zQL6PCHxdor4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,267,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_maALCzLi3_zgj5oAflJnx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued dividends payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PurchasePricePayableOne_iI_maALCzLi3_zA0Gqun93huk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Purchase price payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzLi3_zKQN8b8x3rE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,510,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,817,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzLi3_zWPbizRXLi1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,811,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,937,494&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001253"
      unitRef="USD">9149967</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001254"
      unitRef="USD">5198123</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">5106989</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001257"
      unitRef="USD">3003007</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">2267447</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001260"
      unitRef="USD">2501035</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001262"
      unitRef="USD">776563</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001263"
      unitRef="USD">776563</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <LFMD:PurchasePricePayableOne
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001266"
      unitRef="USD">641042</LFMD:PurchasePricePayableOne>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001268"
      unitRef="USD">3510797</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001269"
      unitRef="USD">1817724</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">20811763</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001272"
      unitRef="USD">13937494</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001274">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zKcaIwvpB5Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_823_zicDvcELVpR1"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Working
Capital Loans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company financed a $&lt;span id="xdx_907_eus-gaap--PrepaidInsurance_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--CRGFinancialMember_zC7vTEGQiikl" title="Prepaid insurance policy"&gt;348&lt;/span&gt; thousand prepaid insurance policy under a 10-month financing agreement
with Arthur J. Gallagher Risk Management Services, LLC. The terms of the agreement include finance fees in the amount of $&lt;span id="xdx_908_eus-gaap--AmortizationOfDeferredLoanOriginationFeesNet_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--TenMonthFinancingAgreementMember_zu1CFiYDnkAg" title="Loan origination fees"&gt;13&lt;/span&gt; thousand.
As of December 31, 2024 and December 31, 2023, the outstanding balance was $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_pn3n3_c20241231_zs4j4N0k73Pj" title="Notes payable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_pn3n3_c20231231_zPpJIno3PCUf" title="Notes payable"&gt;217&lt;/span&gt; thousand, respectively, and is included in notes
payable, net, on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2022, the Company received proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_pn3n3_c20221001__20221031__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__dei--LegalEntityAxis__custom--AmazonMember_zYZ2yHh61BD6" title="Proceeds from short term loan"&gt;976&lt;/span&gt; thousand under a 12-month working capital loan with Amazon. The terms of the loan
include interest in the amount of $&lt;span id="xdx_900_eus-gaap--InterestExpense_pn3n3_c20221001__20221031__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__dei--LegalEntityAxis__custom--AmazonMember_zt3Fe8m2sq9d" title="Interest expense"&gt;62&lt;/span&gt; thousand. As of December 31, 2024 and 2023, the outstanding balance was $&lt;span id="xdx_90B_eus-gaap--NotesPayable_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__dei--LegalEntityAxis__custom--AmazonMember_za5P3RUy6iI1" title="Notes payable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__dei--LegalEntityAxis__custom--AmazonMember_zPuAYMgamW52" title="Notes payable"&gt;111&lt;/span&gt; thousand, respectively,
and is included in notes payable, net, on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
interest expense on notes payable amounted to $&lt;span id="xdx_907_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember_zbQKvxW3sP0c" title="Interest expense"&gt;7&lt;/span&gt; thousand and $&lt;span id="xdx_908_eus-gaap--InterestExpense_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember_zUdLiRCh0B24" title="Interest expense"&gt;256&lt;/span&gt; thousand for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31_custom_CRGFinancialMember"
      decimals="-3"
      id="Fact001276"
      unitRef="USD">348000</us-gaap:PrepaidInsurance>
    <us-gaap:AmortizationOfDeferredLoanOriginationFeesNet
      contextRef="From2023-01-012023-12-31_custom_TenMonthFinancingAgreementMember"
      decimals="-3"
      id="Fact001278"
      unitRef="USD">13000</us-gaap:AmortizationOfDeferredLoanOriginationFeesNet>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001280"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001282"
      unitRef="USD">217000</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2022-10-012022-10-31_custom_WorkingCapitalLoanMember_custom_AmazonMember"
      decimals="-3"
      id="Fact001284"
      unitRef="USD">976000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:InterestExpense
      contextRef="From2022-10-012022-10-31_custom_WorkingCapitalLoanMember_custom_AmazonMember"
      decimals="-3"
      id="Fact001286"
      unitRef="USD">62000</us-gaap:InterestExpense>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_WorkingCapitalLoanMember_custom_AmazonMember"
      decimals="-3"
      id="Fact001288"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_WorkingCapitalLoanMember_custom_AmazonMember"
      decimals="-3"
      id="Fact001290"
      unitRef="USD">111000</us-gaap:NotesPayable>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_WorkingCapitalLoanMember"
      decimals="-3"
      id="Fact001292"
      unitRef="USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_WorkingCapitalLoanMember"
      decimals="-3"
      id="Fact001294"
      unitRef="USD">256000</us-gaap:InterestExpense>
    <us-gaap:LongTermDebtTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001296">&lt;p id="xdx_800_eus-gaap--LongTermDebtTextBlock_zHs1LYjxPvhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82D_z3CgtuSB8Exd"&gt;LONG-TERM DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Avenue
Capital Credit Facility&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted in Note 1 above, on March 21, 2023, the Company entered into the Avenue Credit Agreement and the Avenue Supplement. The Avenue
Credit Agreement provides for a convertible senior secured credit facility of up to an aggregate amount of $&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zAOmFcRyIfac" title="Line of credit amount"&gt;40&lt;/span&gt;
million, comprised of the following: (1) $&lt;span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zgJWY2UqrNDl" title="Line of credit"&gt;15&lt;/span&gt;
million in term loans funded at closing, (2) $&lt;span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230926__20230926__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zp6GZeGiowP4" title="Line of credit"&gt;5&lt;/span&gt;
million of additional committed term loans received on September 26, 2023 in conjunction with the Avenue First Amendment and (3)
$&lt;span id="xdx_909_ecustom--LinesOfCreditUncommittedTremLoan_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z5Kn5CqBDzk9" title="Line of credit"&gt;20&lt;/span&gt;
million of additional uncommitted term loans, collectively referred to as the &#x201c;Avenue Facility&#x201d;. The Company issued
Avenue Warrants to purchase $&lt;span id="xdx_90E_ecustom--WarrantToPurchaseStockValue_pn5n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_ze4INbUpBlOk" title="Warrant to purchase stock"&gt;1.2&lt;/span&gt;
million of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zC5jR3bDR2q4" title="Exercise price"&gt;1.24&lt;/span&gt;,
subject to adjustments. The Avenue Warrants have a term of five years. The relative fair value of the Avenue Warrants upon closing
was $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zb9CUU95PIq4" title="Fair value of warrants"&gt;873&lt;/span&gt;
thousand. In addition, Avenue may convert up to $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z1YcVbwA5IK7" title="Debt conversion amount"&gt;2&lt;/span&gt;
million of the $&lt;span id="xdx_900_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_z226MZtFahOe" title="Line of credit"&gt;15&lt;/span&gt;
million in term loans funded at closing into shares of the Company&#x2019;s common stock at any time while the loans are outstanding,
at a price per share equal to $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zSx6yve4GFlk" title="Conversion price per share"&gt;1.49&lt;/span&gt;.
As of December 31, 2024, there is $&lt;span id="xdx_902_ecustom--DebtTermLoansRemainingToBeConverted_pn6n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zWWU5W3hyWP5" title="Term loans remaining"&gt;1&lt;/span&gt;
million in term loans remaining to be converted. The relative fair value of the Avenue Warrants was recorded to debt discount and is
included as a reduction to long-term debt on the consolidated balance sheet as of December 31, 2024. &lt;span id="xdx_907_eus-gaap--DebtInstrumentDescription_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zu5ZgocgFkf5" title="Debt instrument description"&gt;The
Company incurred other fees associated with the Avenue Facility including: (1) a $300 thousand financing fee, (2) a $200 thousand
upfront commitment fee of 1% of the total $20 million in committed capital and (3) $27 thousand in legal fees. The total debt
discount recorded of $1.4 million will be amortized over a forty-two-month period.&lt;/span&gt; Total amortization of debt discount was
$&lt;span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zNPd9nQf8cn9" title="Amortization of debt discount premium"&gt;402&lt;/span&gt;
thousand and $&lt;span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zgIP7odNqwQ5" title="Amortization of debt discount premium"&gt;334&lt;/span&gt;
thousand for the years ended December 31, 2024 and 2023, respectively. The balance of debt discount was approximately $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_ztSnyn0womO4" title="Debt discount"&gt;670&lt;/span&gt; thousand
as of December 31, 2024. The Company received gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zRP9Dkf0MHFa"&gt;15.0&lt;/span&gt;
million at closing (net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zRpISdNvt877" title="Proceeds from issuance costs"&gt;12.3&lt;/span&gt;
million after repayment of the $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfLongTermDebt_pn6n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zdI1cLZ8Ne3"&gt;2&lt;/span&gt;
million outstanding CRG loan balance and various fees).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Avenue Facility matures on &lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zGpchrsyUE55"&gt;October 1, 2026&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateTerms_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zZfxw8dkkLfh"&gt;interest is based on the greater of: (1) the Prime Rate (as defined in the Supplement)
plus 4.75% and (2) 12.5%. As of December 31, 2024, the interest rate was 12.5%. Interest only payments were extended until May 2025.
&lt;/span&gt;The Company may prepay the loans, subject to a prepayment penalty of &lt;span id="xdx_90D_ecustom--PrepaymentPenaltyPercentage_pid_dp_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zdeV4IM7ECh" title="Prepayment penalty percentage"&gt;1.00&lt;/span&gt;% to &lt;span id="xdx_905_ecustom--PrepaymentPenaltyPercentage_pid_dp_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z76YgBiR4Lql" title="Prepayment penalty percentage"&gt;3.00&lt;/span&gt;% of the principal amount prepaid, depending on the
timing of the prepayment. Proceeds from the Avenue Facility were used to repay the Company&#x2019;s outstanding notes payable balances
with CRG Financial and are expected to be utilized for general corporate purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company will pay $&lt;span id="xdx_907_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_pn5n6_c20241231_z2RMnwYCl3l5" title="Principal payment to be paid in 2025"&gt;8.4&lt;/span&gt; million in 2025 and $&lt;span id="xdx_901_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_pn5n6_c20241231_zXkPhBkW0Kll" title="Principal payment to be paid in 2026"&gt;10.6&lt;/span&gt; million in 2026 in principal payments under the Avenue Facility.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company is subject to certain affirmative and negative covenants under the Avenue Facility, including the requirement, beginning on the
closing date, to maintain at least $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn6n6_c20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHg5ZCJQHiVb" title="Liquidation value"&gt;5&lt;/span&gt; million of unrestricted cash to be tested at the end of each month, and beginning on the period
ended September 30, 2023, and at the end of each quarter thereafter, a trailing six-month cash flow, subject to certain adjustments as
provided by the Avenue Credit Agreement, of at least $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zPyXxKAkRx12" title="Credit facility"&gt;2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 15, 2023, Avenue converted $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20231115__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zFPrqmobTfVc" title="Principal amount"&gt;1&lt;/span&gt; million of the principal amount of the outstanding term loans into shares of the Company&#x2019;s
common stock. This resulted in &lt;span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20231115__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zFA2VGV7z3Xk" title="Common stock issued"&gt;672,042&lt;/span&gt; shares of common stock issued to Avenue. Additionally on November 15, 2023, Avenue exercised &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231115__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zKTMSNN7giH7" title="Exercise of warrants"&gt;96,773&lt;/span&gt;
of the Avenue Warrants on a cashless basis resulting in &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231115__20231115_zLfVJFj3h9o8" title="Issuance of shares"&gt;79,330&lt;/span&gt; shares of the Company&#x2019;s common stock issued. &lt;span style="background-color: white"&gt;As
of December 31, 2024, there was $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zMoz0Da9maae" title="Debt instrument, face amount"&gt;19.0&lt;/span&gt; million outstanding under the Avenue Facility and the Company was in compliance with the Avenue
Facility covenants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
interest expense on long-term debt, inclusive of amortization of debt discounts, amounted to $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zRkR5POTsAS3" title="Interest expense, debt"&gt;2.7&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_pn5n6_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zn5EcATJJU2a" title="Interest expense, debt"&gt;2.0&lt;/span&gt; million for the years
ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001298"
      unitRef="USD">40000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001300"
      unitRef="USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-09-262023-09-26_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001302"
      unitRef="USD">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <LFMD:LinesOfCreditUncommittedTremLoan
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001304"
      unitRef="USD">20000000</LFMD:LinesOfCreditUncommittedTremLoan>
    <LFMD:WarrantToPurchaseStockValue
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001306"
      unitRef="USD">1200000</LFMD:WarrantToPurchaseStockValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact001308"
      unitRef="USDPShares">1.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-3"
      id="Fact001310"
      unitRef="USD">873000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001312"
      unitRef="USD">2000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001314"
      unitRef="USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-03-21_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact001316"
      unitRef="USDPShares">1.49</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <LFMD:DebtTermLoansRemainingToBeConverted
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001318"
      unitRef="USD">1000000</LFMD:DebtTermLoansRemainingToBeConverted>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      id="Fact001320">The
Company incurred other fees associated with the Avenue Facility including: (1) a $300 thousand financing fee, (2) a $200 thousand
upfront commitment fee of 1% of the total $20 million in committed capital and (3) $27 thousand in legal fees. The total debt
discount recorded of $1.4 million will be amortized over a forty-two-month period.</us-gaap:DebtInstrumentDescription>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-3"
      id="Fact001322"
      unitRef="USD">402000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31_custom_AvenueFacilityMember"
      decimals="-3"
      id="Fact001324"
      unitRef="USD">334000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-12-31_custom_AvenueFacilityMember"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">670000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001327"
      unitRef="USD">15000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001329"
      unitRef="USD">12300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001330"
      unitRef="USD">2000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      id="Fact001331">2026-10-01</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      id="Fact001332">interest is based on the greater of: (1) the Prime Rate (as defined in the Supplement)
plus 4.75% and (2) 12.5%. As of December 31, 2024, the interest rate was 12.5%. Interest only payments were extended until May 2025.</us-gaap:DebtInstrumentInterestRateTerms>
    <LFMD:PrepaymentPenaltyPercentage
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001334"
      unitRef="Pure">0.0100</LFMD:PrepaymentPenaltyPercentage>
    <LFMD:PrepaymentPenaltyPercentage
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001336"
      unitRef="Pure">0.0300</LFMD:PrepaymentPenaltyPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001338"
      unitRef="USD">8400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001340"
      unitRef="USD">10600000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2023-12-31_custom_AvenueFacilityMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-6"
      id="Fact001342"
      unitRef="USD">5000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-12-31_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001344"
      unitRef="USD">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-15_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001346"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-11-15_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">672042</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-11-15_custom_AvenueFacilityMember"
      decimals="INF"
      id="Fact001350"
      unitRef="Shares">96773</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-11-152023-11-15"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">79330</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001354"
      unitRef="USD">19000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001356"
      unitRef="USD">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_AvenueFacilityMember"
      decimals="-5"
      id="Fact001358"
      unitRef="USD">2000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001360">&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoAnFdfXVCEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_82E_zvKefsXjKka2"&gt;STOCKHOLDERS&#x2019; (DEFICIT) EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has authorized the issuance of up to &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zMZB0wjW35o8" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of common stock, $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zlTqSK7aUdF1" title="Common stock, par value"&gt;0.01&lt;/span&gt; par value, and &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z1S9PHQXiu0c" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares of preferred stock,
$&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zoML3aD0LVcc" title="Preferred stock, at par value"&gt;0.0001&lt;/span&gt; par value, of which &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z4JQwI7DeEFc" title="Preferred stock, shares authorized"&gt;5,000&lt;/span&gt; shares are designated as Series B Convertible Preferred Stock, &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziofRmimQ8xe" title="Preferred stock, shares authorized"&gt;1,610,000&lt;/span&gt; are designated as Series A
Preferred Stock and &lt;span id="xdx_904_ecustom--UndesignatedPreferredStock_iI_c20241231_zVt1htIOBuU7" title="Undesignated preferred stock"&gt;3,385,000&lt;/span&gt; shares of preferred stock remain undesignated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock. On June
7, 2024, the Company filed the 2024 Shelf. Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up
to $&lt;span id="xdx_90C_eus-gaap--DebtSecurities_iI_pn5n6_c20240607__us-gaap--StatementEquityComponentsAxis__custom--SharesAndSecuritiesMember_z9AY08CourUh" title="Raise up funds"&gt;150.0&lt;/span&gt; million by selling common stock, preferred stock, debt securities, warrants, and units including $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240607__20240607__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zvLpJHdCwIii" title="Offering price"&gt;53.3&lt;/span&gt; million of its common
stock under the ATM Sales Agreement. As of December 31, 2024, the Company had $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zyyRZ1vAJYxh" title="Offering price"&gt;53.3&lt;/span&gt; million available under the ATM Sales Agreement,
which is part of the $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ShelfAgreementMember_zMRBAZqw1w2g" title="Proceeds from sale of securities"&gt;150.0&lt;/span&gt; million available under the 2024 Shelf.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2021, the Company entered into the Preferred Underwriting Agreement with B.Riley. Pursuant to the Preferred Underwriting Agreement,
the Company agreed to sell &lt;span id="xdx_90D_ecustom--PurchaseOfUnderwritingShares_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zs0vb4ZZOaa8" title="Purchase of underwriting shares"&gt;1,400,000&lt;/span&gt; shares of its Series A Preferred Stock under the Preferred Stock Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock ranks senior to the Company&#x2019;s common stock with respect to the payment of dividends and liquidation rights.
The Company will pay cumulative distributions on the Series A Preferred Stock, from the date of original issuance, in the amount of $&lt;span id="xdx_907_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20240101__20241231_zjqId4Utxqob" title="Cumulative Distributions on Preferred Stock"&gt;2.21875&lt;/span&gt;
per share each year, which is equivalent to &lt;span id="xdx_90F_ecustom--PercentageOfPreferredStockLiquidationPreference_pid_dp_uPure_c20240101__20241231_zXuZlNhTL52g" title="Percentage of preferred stock liquidation preference"&gt;8.875&lt;/span&gt;% of the $&lt;span id="xdx_906_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20241231_zidCeDiFAh04" title="Preferred stock liquidation preference"&gt;25.00&lt;/span&gt; liquidation preference per share. Dividends on the Series A Preferred
Stock will be payable quarterly in arrears, on or about the 15th day of January, April, July and October of each year. The first dividend
on the Series A Preferred Stock sold in this offering was declared on December 23, 2021 to holders of record as of January 4, 2022 and
was paid on January 14, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
declared and paid on the Series A Preferred Stock during the year ended December 31, 2024 are as follows: (1) quarterly dividend declared
on March 26, 2024 to holders of record as of April 5, 2024, which was paid on April 15, 2024, (2) quarterly dividend declared on June
25, 2024 to holders of record as of July 5, 2024 which was paid on July 15, 2024, (3) quarterly dividend declared on September 24, 2024
to holders of record as of October 4, 2024 which was paid on October 15, 2024, and (4) quarterly dividend declared on December 24, 2024
to holders of record as of January 3, 2025 and was paid on January 15, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
declared and paid on the Series A Preferred Stock during the year ended December 31, 2023 are as follows: (1) quarterly dividend declared
on March 28, 2023 to holders of record as of April 7, 2023 and was paid on April 17, 2023, (2) quarterly dividend declared on June 27,
2023 to holders of record as of July 7, 2023 and was paid on July 17, 2023, (3) quarterly dividend declared on September 26, 2023 to
holders of record as of October 6, 2023 and was paid on October 16, 2023 and (4) quarterly dividend declared on December 26, 2023 to
holders of record as of January 5, 2024 and was paid on January 15, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of the Series A Preferred Stock have no voting rights except in the case of certain dividend nonpayments. If dividends on the Series
A Preferred Stock are in arrears, whether or not declared, for six or more quarterly periods, whether or not these quarterly periods
are consecutive, holders of Series A Preferred Stock and holders of all other classes or series of parity preferred stock with which
the holders of Series A Preferred Stock are entitled to vote together as a single class will be entitled to vote, at a special meeting
called by the holders of record of at least &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvestorsMember_zdOxiGmTodql" title="Ownership percentage"&gt;10&lt;/span&gt;% of any series of preferred stock as to which dividends are so in arrears or at the next
annual meeting of stockholders, for the election of two additional directors to serve on our Board until all dividend arrearages have
been paid. If and when all accumulated dividends on the Series A Preferred Stock for all past dividend periods shall have been paid in
full, holders of shares of Series A Preferred Stock shall be divested of the voting rights set forth above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20241231_zhDafTPIsha5" title="Equity description"&gt;The
Series A Preferred Stock is perpetual and has no maturity date. No outstanding shares of Series A Preferred Stock have been redeemed.
However, the Series A Preferred Stock will be redeemable at our option, in whole or in part, at the following redemption prices, plus
any accrued and unpaid dividends up to, but not including, the date of redemption: 1) on and after October 15, 2022 and prior to October
15, 2023, at a redemption price equal to $&lt;span id="xdx_903_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--OctoberFifteenTwentyTwoAndTwentyThreeMember_z5pSI73DiaOb" title="Redemption price"&gt;25.75&lt;/span&gt; per share, 2) on and after October 15, 2023 and prior to October 15, 2024, at a redemption
price equal to $&lt;span id="xdx_90E_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--OctoberFifteenTwentyThreeAndTwentyFourMember_zj0dZyRO3B4c"&gt;25.50&lt;/span&gt; per share, 3) on and after October 15, 2024 and prior to and prior to October 15, 2025 at a redemption price equal
to $&lt;span id="xdx_908_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--OctoberFifteenTwentyFourAndTwentyFiveMember_zMa638hUjdic"&gt;25.25&lt;/span&gt; per share and 4) on and after October 15, 2025 at a redemption price equal to $&lt;span id="xdx_901_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--OctoberFifteenTwentyFiveAndAfterFiveMember_zvjfnj6oPeCf"&gt;25.00&lt;/span&gt; per share. In addition, upon the occurrence
of a delisting event or change of control, we may, subject to certain conditions, at our option, redeem the Series A Preferred Stock,
in whole or in part within 90 days after the first date on which such delisting event occurred or within 120 days after the first date
on which such change of control occurred, as applicable, by paying $&lt;span id="xdx_90B_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20241231_zM4w3aWkn60c" title="Accumulated and unpaid dividends"&gt;25.00&lt;/span&gt; per share, plus any accumulated and unpaid dividends up to,
but not including, the redemption date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the occurrence of a delisting event or a change of control, each holder of Series A Preferred Stock will have the right unless we have
provided or provide notice of our election to redeem the Series A Preferred Stock, to convert some or all of the shares of Series A Preferred
Stock held by such holder into a number of shares of our common stock (or equivalent value of alternative consideration) per share of
Series A Preferred Stock, or the &#x201c;Common Stock Conversion Consideration&#x201d;. In the case of a delisting event or change of control,
pursuant to which shares of common stock shall be converted into cash, securities or other property or assets (the &#x201c;Alternative
Form Consideration&#x201d;), a holder of shares of Series A Preferred Stock shall receive upon conversion of such shares of Series A Preferred
Stock the kind and amount of Alternative Form Consideration which such holder would have owned or been entitled to receive upon the delisting
event or change of control, had such holder held a number of shares of common stock equal to the Common Stock Conversion Consideration
immediately prior to the effective time of the delisting event or change of control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 27, 2020, the Secretary of State of the State of Delaware delivered confirmation of the effective filing of the Company&#x2019;s
Certificate of Designations of the Series B Convertible Preferred Stock, which established &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20200827__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBf9VJTXtgo7" title="Preferred stock, shares authorized"&gt;5,000&lt;/span&gt; shares of the Company&#x2019;s Series
B Preferred Stock, having such designations, rights and preferences as set forth therein (the &#x201c;Series B Designations&#x201d;). The
holders of Series B Preferred Stock rank senior to the Common Stock with respect to payment of dividends and rights upon liquidation
and will vote together with the holders of the Common Stock on an as-converted basis, subject to beneficial ownership limitations, on
each matter submitted to a vote of holders of Common Stock (whether at a meeting of stockholders or by written consent). In addition,
as further described in the Series B Designations, if at least 30% of the number of shares of Series B Preferred Stock are outstanding,
the Company will not take certain corporate actions without the affirmative vote at a meeting (or the written consent with or without
a meeting) of the purchasers holding a majority of the shares of Series B Preferred Stock then outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Options
and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;year ended December 31, &lt;span style="background-color: white"&gt;2024,
the Company issued an aggregate of &lt;span id="xdx_905_ecustom--CashlessExerciseOfOptionsShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbgMYhaYCXC5" title="Cashless exercise of options shares"&gt;512,777&lt;/span&gt; shares of common stock related to the cashless exercise of options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;year ended December 31, &lt;span style="background-color: white"&gt;2024,
the Company issued an aggregate of &lt;span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesCashLessWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoiwaI2wYbQ2" title="Number of cash less warrants exercised"&gt;1,630,458&lt;/span&gt; shares of common stock related to the cashless exercise of warrants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;year ended December 31, &lt;span style="background-color: white"&gt;2024,
the Company issued an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqOoXWQil0O8" title="Number of stock issued for option exercise"&gt;86,250&lt;/span&gt; shares of common stock related to the exercise of options for total proceeds of approximately
$&lt;span id="xdx_90E_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8rTVjn8Lhj9" title="Cash proceeds"&gt;120&lt;/span&gt; thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued an aggregate of &lt;span id="xdx_90E_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdYql0Qi4sbb" title="Cashless exercise of options shares"&gt;74,372&lt;/span&gt; shares of common stock related to the cashless exercise of
options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcE5157DGGR9" title="Number of stock issued for option exercise"&gt;37,500&lt;/span&gt; shares of common stock related to the exercise of options
for total proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhKZagA1Xqfe" title="Cash proceeds"&gt;94,500&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued an aggregate of &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCashLessWarrantsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwvL9tBL5x5f" title="Number of cash less warrants exercised"&gt;79,330&lt;/span&gt; shares of common stock related to the cashless exercise of
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Transactions During the Year Ended December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the year ended December 31, 2024, the Company issued an aggregate of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEMW6XrvnVk2" title="Common stock share service"&gt;1,609,960&lt;/span&gt; shares of common stock for service, including vested restricted
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2023, the Company entered into the Cleared First Amendment between the Company and the sellers of Cleared. The Cleared Stock
Purchase Agreement was amended to, among other things change the timing of the payment of the purchase price to $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zxsOMS8tLRr8" title="Payments to acquire businesses, gross"&gt;460&lt;/span&gt; thousand paid at
closing (which has already been paid by the Company), with the remaining amount to be paid in five quarterly installments beginning on
or before February 6, 2023 and ending January 15, 2024. The Company issued the following shares of common stock to the sellers of Cleared
under the Cleared First Amendment: (1) &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230206__20230206__us-gaap--AwardTypeAxis__custom--FirstOfFiveQuarterlyInstallmentMember_zqAhOYFeXBxj" title="Number of shares issued"&gt;337,895&lt;/span&gt; shares on February 6, 2023, (2) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230417__20230417__us-gaap--AwardTypeAxis__custom--SecondOfFiveQuarterlyInstallmentMember_zaR4zOvqgUO6" title="Number of shares issued"&gt;455,319&lt;/span&gt; shares on April 17, 2023, (3) &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230717__20230717__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyInstallmentMember_zgUiku4IrSba" title="Number of shares issued"&gt;158,129&lt;/span&gt; shares on
July 17, 2023, (4) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231017__20231017__us-gaap--AwardTypeAxis__custom--FourthOfFiveQuarterlyInstallmentMember_zQRG7evN8U1b" title="Number of shares issued"&gt;117,583&lt;/span&gt; shares on October 17, 2023 and (5) &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240116__20240116__us-gaap--AwardTypeAxis__custom--FifthQuarterlyInstallmentMember_zMqeaxzyURZh" title="Number of shares issued"&gt;95,821&lt;/span&gt; shares on January 16, 2024. The fair value of the stock issuance
under the Cleared First Amendment during the year ended December 31, 2024 was $&lt;span id="xdx_903_eus-gaap--StockIssued1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_zJzTM04OtVz5" title="Fair value of stock issued"&gt;642&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Transactions During the Year Ended December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zm3xE2zl1Hhh" title="Common stock share service"&gt;978,500&lt;/span&gt; shares of common stock for service, including vested restricted
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2023, the Company entered into the Cleared First Amendment between the Company and the sellers of Cleared. The Cleared Stock
Purchase Agreement was amended to, among other things change the timing of the payment of the purchase price to $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreeementMember_z4KhmKIarbY2" title="Payments to acquire businesses, gross"&gt;460&lt;/span&gt; thousand paid at
closing (which has already been paid by the Company), with the remaining amount to be paid in five quarterly installments beginning on
or before February 6, 2023 and ending January 15, 2024. The Company issued the following shares of common stock to the sellers of Cleared
under the Cleared First Amendment during the year ended December 31, 2023: (1) &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230206__20230206__us-gaap--AwardTypeAxis__custom--FirstOfFiveQuarterlyInstallmentMember_zxnk07MUbv5g" title="Number of shares issued"&gt;337,895&lt;/span&gt; shares on February 6, 2023, (2) &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230417__20230417__us-gaap--AwardTypeAxis__custom--SecondOfFiveQuarterlyInstallmentMember_zz1KMp176jvi" title="Number of shares issued"&gt;455,319&lt;/span&gt; shares
on April 17, 2023, (3) &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230717__20230717__us-gaap--AwardTypeAxis__custom--ThirdOfFiveQuarterlyInstallmentMember_zijjEWzBoyE7" title="Number of shares issued"&gt;158,129&lt;/span&gt; shares on July 17, 2023 and (4) &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231017__20231017__us-gaap--AwardTypeAxis__custom--FourthOfFiveQuarterlyInstallmentMember_zhgPY4vygHg3" title="Number of shares issued"&gt;117,583&lt;/span&gt; shares on October 17, 2023. The fair value of the stock issuances
under the Cleared First Amendment during the year ended December 31, 2023 was $&lt;span id="xdx_90E_eus-gaap--StockIssued1_pn5n6_c20230101__20231231_zYbb3SsEIet6" title="Fair value of stock issued"&gt;2.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zj9w6IuffuA5" title="Number of common stock shares sold"&gt;1,009,907&lt;/span&gt; shares of common stock under the ATM Sales Agreement and net proceeds received
were $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_ztdhoUQy3Ewk" title="Proceeds from issuance of sale of equity"&gt;6.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--HarborsideMember_zUF6mBpnxOGd" title="Common stock share services"&gt;100,000&lt;/span&gt; shares of common stock related to the settlement of the &lt;i&gt;Harborside Advisors
LLC v. LifeMD, Inc.,&lt;/i&gt; Case No. 21-cv-10593, and the &lt;i&gt;Specialty Medical Drugstore, LLC D/B/A GoGoMeds v. LifeMD, Inc.,&lt;/i&gt; Case No.
21-cv-10599, matters. The shares issued were valued based on the closing price of the Company&#x2019;s stock, or $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231_zYLOw4OpJmn3" title="Shares issued price per share"&gt;5.32&lt;/span&gt;, on the date of
settlement, July 10, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2023, and August 14, 2023, PA001 Holdings, the holder of the Company&#x2019;s Series B Preferred Stock, elected to convert &lt;span id="xdx_908_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20230710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUhAG4cKwX61" title="Preferred Stock Conversion"&gt;2,275&lt;/span&gt;
and &lt;span id="xdx_909_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zK4Y1t8bIKCf" title="Preferred Stock Conversion"&gt;1,225&lt;/span&gt; shares, respectively, of the Company&#x2019;s Series B Preferred Stock into common stock, at a price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20230710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYmYW15dKqi8" title="Share issue price per share"&gt;&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkjZEJcXBOW6" title="Share issue price per share"&gt;3.25&lt;/span&gt;&lt;/span&gt; per share of Series
B Preferred Stock, pursuant to the terms of the PA001 Securities Purchase Agreement. The conversion was calculated based on the original
issuance price of the Series B Preferred Stock plus all accrued dividends to date or approximately $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn5n6_c20230710__20230710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zepok49paBa2" title="Conversion of stock value"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn5n6_c20230814__20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUonZTZat1U2" title="Conversion of stock value"&gt;5.1&lt;/span&gt;&lt;/span&gt; million. The conversion resulted
in &lt;span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230712__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPvNnnLPWnBf" title="Preferred Stock Conversion"&gt;1,010,170&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2RQupQed1V6" title="Preferred Stock Conversion"&gt;550,694&lt;/span&gt; shares of the Company&#x2019;s common stock issued to PA001 Holdings, on July 12, 2023 and August 15, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2023, in connection with the Company&#x2019;s closing of the Avenue Credit Agreement, the Company issued Avenue Warrants to
purchase $&lt;span id="xdx_905_ecustom--WarrantToPurchaseStockValue_pn5n6_c20230320__20230321__dei--LegalEntityAxis__custom--AvenueMember_zKk2dZonY0hc" title="Warrant to purchase stock"&gt;1.2&lt;/span&gt; million of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230321__dei--LegalEntityAxis__custom--AvenueMember_zJNOuwho9iZe" title="Exercise price"&gt;1.24&lt;/span&gt;, subject to adjustments. In addition, Avenue
may convert up to $&lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20230320__20230321__dei--LegalEntityAxis__custom--AvenueMember_zua9OCze8SGi" title="Debt conversion amount"&gt;2&lt;/span&gt; million of the $&lt;span id="xdx_900_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20230321__20230321__us-gaap--CreditFacilityAxis__custom--AvenueFacilityMember_zjVjy4LPaTvc" title="Line of credit"&gt;15&lt;/span&gt; million in term loans funded at closing into shares of the Company&#x2019;s common stock at any
time while the loans are outstanding, at a price per share equal to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230321__dei--LegalEntityAxis__custom--AvenueMember_zDvm7ePDkJR1" title="Conversion price per share"&gt;1.49&lt;/span&gt;. On November 15, 2023, Avenue converted $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn6n6_c20231115__20231115__dei--LegalEntityAxis__custom--AvenueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcgIkp1oRvKg" title="Conversion of stock value"&gt;1&lt;/span&gt; million of the principal
amount of the outstanding term loans into shares of the Company&#x2019;s common stock. This resulted in &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20231115__20231115__dei--LegalEntityAxis__custom--AvenueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqfnOY3G2fVh" title="Conversion of stock, shares"&gt;672,042&lt;/span&gt; shares of common stock
issued to Avenue. Additionally on November 15, 2023, Avenue exercised &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20231115__20231115__dei--LegalEntityAxis__custom--AvenueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqc4fMxP8FP6" title="Number of warrants exercised"&gt;96,773&lt;/span&gt; of the Avenue Warrants on a cashless basis, resulting in
&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231115__20231115__dei--LegalEntityAxis__custom--AvenueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYAX4pawhlK5" title="Issuance of common stock, shares"&gt;79,330&lt;/span&gt; shares of the Company&#x2019;s common stock issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 11, 2023, in connection with the Medifast Collaboration, the Company entered into a stock purchase agreement with Medifast&#x2019;s
wholly-owned subsidiary, Jason Pharmaceuticals, Inc., whereby the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231210__20231211__dei--LegalEntityAxis__custom--MedifastMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3JGSuHFhKvc" title="Issuance of common stock, shares"&gt;1,224,425&lt;/span&gt; shares of its common stock, in a private placement
at a purchase price of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20231211__dei--LegalEntityAxis__custom--MedifastMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoFFffsQNxGe" title="Purchase price of common stock"&gt;8.1671&lt;/span&gt; per share, for aggregate proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20231210__20231211__dei--LegalEntityAxis__custom--MedifastMember_zmmfRTSFkg59" title="Proceeds from common stock"&gt;10&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;WorkSimpli
Software Restructuring Transaction (&#x201c;WSS Restructuring&#x201d;)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 22, 2021 (the &#x201c;WSS Effective Date&#x201d;), the Company consummated the WSS Restructuring. To effect the WSS Restructuring,
the Company&#x2019;s wholly-owned subsidiary at the time, Conversion Labs PR (or subsequently &#x201c;LifeMD PR&#x201d;), entered into a
series of membership interest exchange agreements, pursuant to which, Conversion Labs PR exchanged a promissory note, dated May 8, 2019
with an outstanding balance of $&lt;span id="xdx_903_eus-gaap--NotesPayable_iI_pn3n3_c20210122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConversionLabsPRLLCMember_zVc05MyKbV84" title="Notes payable"&gt;376&lt;/span&gt; thousand (the &#x201c;CVLB PR Note&#x201d;), issued by WSS in favor of Conversion Labs PR, for &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210120__20210122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConversionLabsPRLLCMember_z1BJV5WXc0l8" title="Debt conversion shares issued"&gt;37,531&lt;/span&gt;
newly issued membership interests of WSS (the &#x201c;Exchange&#x201d;). Upon consummation of the Exchange the CVLB PR Note was extinguished.
Concurrently, in furtherance of the WSS Restructuring, Conversion Labs PR entered into certain Membership Interest Purchase Agreements
whereby Conversion Labs PR purchased membership interests of WSS. Following the consummation of the WSS Restructuring, Conversion Labs
PR increased its ownership of WSS from &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_uPure_c20210122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OperatingAgreementMember_zyXf6IFRFaRd" title="Operating agreement amendment"&gt;51&lt;/span&gt;% to approximately &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_uPure_c20210122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OperatingAgreementMember__srt--RangeAxis__srt--MaximumMember_zZ6JERf1Hvz9" title="Operating agreement amendment"&gt;85.58&lt;/span&gt;% on a fully diluted basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
Conversion Labs PR entered into option agreements with Sean Fitzpatrick (the &#x201c;Fitzpatrick Option Agreement&#x201d;) and Varun Pathak
(the &#x201c;Pathak Option Agreement&#x201d; together with Fitzpatrick Option Agreement the &#x201c;Option Agreements&#x201d;), pursuant
to which Conversion Labs PR granted options to purchase membership interest units of WSS. On September 30, 2022, Sean Fitzpatrick and
Varun Pathak exercised their options to purchase &lt;span id="xdx_905_ecustom--TrancheeSharesMembershipInterest_iI_pid_c20220930__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember__srt--RangeAxis__srt--MinimumMember_zfMQX2Yns3wa" title="Tranchee shares membership interest"&gt;10,300&lt;/span&gt; and &lt;span id="xdx_908_ecustom--TrancheeSharesMembershipInterest_iI_pid_c20220930__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zS5ER8QEPPdg" title="Tranchee shares membership interest"&gt;2,100&lt;/span&gt; membership interest units, respectively, of WorkSimpli for an exercise
price of $&lt;span id="xdx_908_ecustom--PurchasePricePerMembershipInterest_iI_pid_c20220930__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_znnd8QSJ1hZ3" title="Purchase price per membership interest"&gt;1.00&lt;/span&gt; per membership interest unit under the Option Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;WorkSimpli
Software Capitalization Update&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 31, 2023, the Company redeemed &lt;span id="xdx_904_ecustom--NumberOfMembershipInterestUnitsRedeemed_c20230331__20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zXMHyPPhOxKl" title="Number of membership interest units redeemed"&gt;500&lt;/span&gt; membership interest units in WorkSimpli. Following the retirement, the Company&#x2019;s ownership
interest in WorkSimpli increased to &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z4aGrfrPBqs3" title="Ownership Interest"&gt;74.1&lt;/span&gt;%. On June 30, 2023, WorkSimpli&#x2019;s Chief Operating Officer, exercised her option agreement
(the &#x201c;WorkSimpli COO Option Agreement&#x201d;) to purchase &lt;span id="xdx_901_ecustom--TrancheeSharesMembershipInterest_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zTKiZlp6ZEfc" title="Tranchee shares membership interest"&gt;889&lt;/span&gt; membership interest units of WorkSimpli for an exercise price of
$&lt;span id="xdx_90A_ecustom--PurchasePricePerMembershipInterest_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember_zdffuvOvcxbg" title="Purchase price per membership interest"&gt;1.00&lt;/span&gt; per membership interest unit. Following the exercise of the WorkSimpli COO Option Agreement, the Company decreased its ownership
interest in WorkSimpli from &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember__srt--RangeAxis__srt--MinimumMember_z6TjBcefCvNa" title="Re-purchase of additional stock options reduced"&gt;74.1&lt;/span&gt;% to &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPRLLCMember__us-gaap--TypeOfArrangementAxis__custom--OptionAgreementMember__srt--RangeAxis__srt--MaximumMember_zGUh0KxnpJml" title="Re-purchase of additional stock options reduced"&gt;73.3&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Non-controlling
Interest&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
income attributed to non-controlling interest amounted to $&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231_zG4L2Gafxul7" title="Net income attributed to the non-controlling interest"&gt;153&lt;/span&gt; thousand and $&lt;span id="xdx_90B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn5n6_c20230101__20231231_z8YY4P0olWMi" title="Net income attributed to the non-controlling interest"&gt;2.8&lt;/span&gt; million for the years ended December 31, 2024 and 2023,
respectively. During the years ended December 31, 2024 and 2023, the Company paid distributions to non-controlling shareholders of $&lt;span id="xdx_909_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_pn3n3_c20240101__20241231_zLjnyUP7PMB2" title="Distribution to non-controlling shareholders"&gt;774&lt;/span&gt;
thousand and $&lt;span id="xdx_90D_eus-gaap--MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_pn3n3_c20230101__20231231_z0WUnntsU0k7" title="Distribution to non-controlling shareholders"&gt;144&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 31, 2024, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_90E_ecustom--CashDividend_iI_pid_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z7T0OHhPwaqh" title="Dividend payable"&gt;11.20&lt;/span&gt; per membership interest unit to all unit holders of record
as of March 31, 2024 and was paid on April 10, 2024. On July 1, 2024, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_907_ecustom--CashDividend_iI_pid_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zlPWlfZ22gL8" title="Dividend payable"&gt;9.05&lt;/span&gt;
per membership interest unit to all unit holders of record as of June 30, 2024 and was paid on July 1, 2024. On November 15, 2024, WorkSimpli
declared a cash distribution in the amount of $&lt;span id="xdx_90C_ecustom--CashDividend_iI_pid_c20241115__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z2J2r5xDkc3" title="Dividend payable"&gt;5.66&lt;/span&gt; per membership interest unit to all unit holders of record as of November 1, 2024
and was paid on November 18, 2024. The total of these distributions was $&lt;span id="xdx_900_eus-gaap--OtherInterestAndDividendIncome_pn3n3_c20240101__20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zfVPUrcqDGNd" title="Dividend declared to noncontrolling interest"&gt;630&lt;/span&gt; thousand and is included in distributions to non-controlling
interest within the statement of stockholders&#x2019; deficit for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2023, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_907_ecustom--CashDividend_iI_pid_c20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zg5sx58KrPLi" title="Dividend payable"&gt;22.40&lt;/span&gt; per membership interest unit to all unit holders of record
as of June 30, 2023 and was paid on &lt;span id="xdx_902_eus-gaap--DividendPayableDateToBePaidDayMonthAndYear_dd_c20230101__20230630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember__us-gaap--DividendsAxis__custom--S2023Q2DividendsMember_zCaSDMGTkVa7" title="Dividend payable date"&gt;July 3, 2023&lt;/span&gt;. On July 31, 2023, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_903_ecustom--CashDividend_iI_pid_c20230731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_znlFwp89ooCf" title="Dividend payable"&gt;11.20&lt;/span&gt; per
membership interest unit to all unit holders of record as of July 28, 2023 and was paid on &lt;span id="xdx_90C_eus-gaap--DividendPayableDateToBePaidDayMonthAndYear_dd_c20230728__20230728__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember__us-gaap--DividendsAxis__custom--S2023Q3DividendsMember_zxtsBPzYvF88" title="Dividend payable date"&gt;August 1, 2023&lt;/span&gt;. On August 31, 2023, WorkSimpli
declared a cash distribution in the amount of $&lt;span id="xdx_904_ecustom--CashDividend_iI_pid_c20230831__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zQbb0lXDpva8" title="Dividend payable"&gt;16.80&lt;/span&gt; per membership interest unit to all unit holders of record as of August 30, 2023
and was paid on September 1, 2023. On September 30, 2023, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_90B_ecustom--CashDividend_iI_pid_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z8V5n2ttCMH2" title="Dividend payable"&gt;14.00&lt;/span&gt; per membership
interest unit to all unit holders of record as of September 30, 2023 and was paid on &lt;span id="xdx_904_eus-gaap--DividendPayableDateToBePaidDayMonthAndYear_dd_c20230930__20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember__us-gaap--DividendsAxis__custom--S2023Q4DividendsMember_zbyYQdc5mvV8" title="Dividend payable date"&gt;October 5, 2023&lt;/span&gt;. On October 31, 2023, WorkSimpli
declared a cash distribution in the amount of $&lt;span id="xdx_908_ecustom--CashDividend_iI_pid_c20231031__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zw8S2lxjv7i8" title="Dividend payable"&gt;11.20&lt;/span&gt; per membership interest unit to all unit holders of record as of October 31, 2023
and was paid on &lt;span id="xdx_903_eus-gaap--DividendPayableDateToBePaidDayMonthAndYear_dd_c20231031__20231031__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember__us-gaap--DividendsAxis__custom--O2023Q4DividendsMember_zvjFqDkTasz2" title="Dividend payable date"&gt;November 8, 2023&lt;/span&gt;. On December 31, 2023, WorkSimpli declared a cash distribution in the amount of $&lt;span id="xdx_906_ecustom--CashDividend_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_z7ZQiAv4nEt9" title="Dividend payable"&gt;13.44&lt;/span&gt; per membership
interest unit to all unit holders of record as of January 5, 2024 and was paid on &lt;span id="xdx_906_eus-gaap--DividendPayableDateToBePaidDayMonthAndYear_dd_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember__us-gaap--DividendsAxis__custom--S2024Q1DividendsMember_zcpCXUTuAQT5" title="Dividend payable date"&gt;January 5, 2024&lt;/span&gt;. The total of these distributions was
$&lt;span id="xdx_900_eus-gaap--OtherInterestAndDividendIncome_pn5n6_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WorkSimpliSoftwareLlcMember_zvxqTVq7ghP8" title="Dividend declared to noncontrolling interest"&gt;2.1&lt;/span&gt; million and is included in within general and administrative expenses for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020
Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2021, the Company approved the Company&#x2019;s 2020 Equity and Incentive Plan (the &#x201c;2020 Plan&#x201d;). Approval of the
2020 Plan was included as Proposal 1 in the Company&#x2019;s definitive proxy statement for its Special Meeting of Stockholders filed
with the Securities and Exchange Commission on December 7, 2020. The 2020 Plan is administered by the Compensation Committee of the Board
of Directors (the &#x201c;Board&#x201d;) and initially provided for the issuance of up to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210108__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zVgNZB4h5ixd" title="Issuance of share based compensation"&gt;1,500,000&lt;/span&gt; shares of Common Stock. The number
of shares of Common Stock available for issuance under the 2020 Plan automatically increases by &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z5Xhu7lw793h" title="Number of shares available for issuance"&gt;150,000&lt;/span&gt; shares of Common Stock on January
1st of each year, for a period of not more than ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030.
Awards under the 2020 Plan can be granted in the form of stock options, non-qualified and incentive options, stock appreciation rights,
restricted stock, and restricted stock units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 24, 2021, at the Annual Meeting of Stockholders, the stockholders of the Company approved the amendment to the 2020 Plan to increase
the maximum number of shares of the Company&#x2019;s common stock available for issuance under the 2020 Plan by &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210624__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zQ3lvTDkSA35" title="Number of shares available for issuance"&gt;1,500,000&lt;/span&gt; shares. On June
16, 2022, at the Annual Meeting of Stockholders, the stockholders of the Company approved the second amendment and restatement of the
2020 Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company&#x2019;s common stock available for issuance
under the 2020 Plan by &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220616__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zDRF2RYrnWlh" title="Number of shares available for issuance"&gt;1,500,000&lt;/span&gt; shares. On June 14, 2024, at the Annual Meeting of Stockholders, the stockholders of the Company approved
the third amendment and restatement to the 2020 Plan (the &#x201c;Amended 2020 Plan&#x201d;), which further amended the 2020 Plan by increasing
the maximum number of shares of the Company&#x2019;s common stock available for issuance under the Amended 2020 Plan by &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240614__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zd2GJa2V0tJ4" title="Number of shares available for issuance"&gt;3,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Amended 2020 Plan provided for the issuance of up to &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zRnjrcHHIbvg" title="Issuance of share based compensation"&gt;8,100,000&lt;/span&gt; shares of Common Stock. Remaining authorization
under the Amended 2020 Plan was &lt;span id="xdx_907_ecustom--RemainingAuthorizationOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zjIxYhyDkat8" title="Remaining authorization of shares"&gt;1,940,844&lt;/span&gt; shares as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
forms of award agreements to be used in connection with awards made under the Amended 2020 Plan to the Company&#x2019;s executive officers
and non-employee directors are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Form
    of Non-Qualified Option Agreement (Non-Employee Director Awards)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Form
    of Non-Qualified Option Agreement (Employee Awards); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Form
    of Restricted Stock Award Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zQQ5BnNCapAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
the Company had granted service-based stock options and performance-based stock options separate from the Amended 2020 plan. The following
is a summary of outstanding options activity under our Amended 2020 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zC2F6OV3x14j" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zqO3MtJvK82b" style="width: 12%; text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,784,587&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zfDnjKnudgGk" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;2.30&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zkLDJRk8ghx5" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;21.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zZnm1tYjPMXf" title="Weighted Average Remaining Contractual Life, Granted"&gt;6.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zLTuCiUzb6ec" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Ending balance"&gt;9.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z6bq3dFZN4d" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;109,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zbXkYCvi4iVl" title="Exercise Price per Share, Granted"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zLgz6dZLKs5l" title="Exercise Price per Share, Granted"&gt;7.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zvQGqmLbctRh" title="Weighted Average Remaining Contractual Life, Granted"&gt;3.86&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zM4OlkBISvcc" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;3.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zX5r1rBsCmR5" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(37,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zXAuSzsD03Sj" title="Exercise Price per Share, Exercised"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zep960Ip4Vh2" title="Weighted Average Remaining Contractual Life, Exercised"&gt;2.70&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z4bMvYtgIrFe" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zbcwMHZu2GJd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled/Forfeited/Expired"&gt;(1,129,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zDQPd0lacIih" title="Share based compensation exercise price per share forfeited"&gt;2.30&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z6MP2tLWT305" title="Share based compensation exercise price per share forfeited"&gt;21.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z21iP99BQ2Wc" title="Options Outstanding Weighted Average Remaining Contractual Life, Cancelled/Forfeited/Expired"&gt;6.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zslltuXOfuS9" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;10.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zdUR8tJ6n679" style="text-align: right" title="Outstanding number of shares, beginning balance"&gt;726,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zzrIIbvvCzG4" title="Exercise Price per Share, Beginning balance"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zAGCbUuvrxo5" title="Exercise Price per Share, Beginning balance"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zPztwQVHd929" title="Weighted Average Remaining Contractual Life"&gt;4.93&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zEosLek7N0Ki" style="text-align: right" title="Weighted Average Exercise Price per Share, Beginning balance"&gt;8.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z2QE1AFtL7u2" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zKE4IBY6EM84" title="Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1631"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zDyC2osU0ai2" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zv6eparNMngf" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(172,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zV2I2fPbHmkh" title="Exercise Price per Share, Exercised"&gt;6.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_znz8S2sv0xGi" title="Exercise Price per Share, Exercised"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zm95rNGEq7Yh" title="Weighted Average Remaining Contractual Life, Exercised"&gt;5.86&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z2tqk15h4S85" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;6.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zPJFI1wGo3dk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled/Forfeited/Expired"&gt;(39,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zyoVXp7xlYF6" title="Share based compensation exercise price per share forfeited"&gt;7.44&lt;/span&gt; &#x2013; &lt;span id="xdx_900_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zGMd6MjbjK5j" title="Share based compensation exercise price per share forfeited"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z9uyLqCmwwWe" title="Options Outstanding Weighted Average Remaining Contractual Life, Cancelled/Forfeited/Expired"&gt;5.74&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zsSCIILv8gz2" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;12.77&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zdgVqzG6ZTse" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding number of shares, ending balance"&gt;515,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zTbD6iDznlZ1" title="Exercise Price per Share, Ending balance"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zKWrvIgBOQyj" title="Exercise Price per Share, Ending balance"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z1fB7fphExO9" title="Weighted Average Remaining Contractual Life, Ending"&gt;4.81&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zRJGRWcV0wmf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price per Share, Ending balance"&gt;8.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zgnm4QN0fpJe" style="text-align: right" title="Number of Options, Exercisable, Ending"&gt;604,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zhpShk4hmf6h" title="Number of Options, Exercise price, Ending"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zKNP1x6zmIra" title="Number of Options, Exercise price, Ending"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zqZnQg4rbwQc" title="Weighted Average Remaining Contractual Life, Exercisable, Ending"&gt;6.23&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_ztJQ3WGI4UL7" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercisable, Ending"&gt;8.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zO7IANYQ2G1" style="text-align: right" title="Number of Options, Exercisable, Ending"&gt;504,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zaXQjnsaQOHd" title="Number of Options, Exercise price, Ending"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_znXRWIxYcqk6" title="Number of Options, Exercise price, Ending"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_za2zrEXL0OTc" title="Weighted Average Remaining Contractual Life, Exercisable, Ending"&gt;4.84&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zT95aEK8dsr2" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercisable, Ending"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zWifhynuI4U7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
compensation expense under the Amended 2020 Plan options above was $&lt;span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn5n6_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zxghyEWVYKuk" title="Fair value of options granted"&gt;1.2&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn5n6_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zTXHiTgxZMD9" title="Fair value of options granted"&gt;4.5&lt;/span&gt; million for the years ended December 31, 2024
and 2023, respectively, with unamortized expense remaining of $&lt;span id="xdx_901_ecustom--UnamortizedExpense_iI_pn3n3_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zMVAv076oCt3"&gt;30&lt;/span&gt; thousand as of December 31, 2024. During the year ended December 31,
2024, &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zzwPhx8ZQ6wa" title="Number of share based compensation option exercised for cashless"&gt;172,222&lt;/span&gt; options were exercised on a cashless basis, which resulted in &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zown1nGOlam7" title="Number of shares issued"&gt;62,781&lt;/span&gt; shares issued. As of December 31, 2024, the aggregate
intrinsic value of vested service-based options outstanding was $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zglt53nhdMP7" title="Options outstanding intrinsic value"&gt;200&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKmXcnZJtPQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding service-based options activity (prior to the establishment of the Amended 2020 Plan above):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_z13y98xqNvu8" style="display: none"&gt;SCHEDULE
                                            OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zklUBk6nwTtg" style="width: 12%; text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,439,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zF82gtGAoBVd" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z5ZohH8K7Pkd" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;19.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zQTHhxaz5itj" title="Options Outstanding Weighted Average Remaining Contractual Life, Beginning"&gt;5.63&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zOVEVxXXiV0i" style="width: 12%; text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Beginning"&gt;6.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zDTtKRzLugDj" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zrjn3q0TDzRl" title="Options Outstanding Exercise Price Per Share, Granted"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z2Rp1awaShz2" title="Options Outstanding Exercise Price Per Share, Granted"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zDItSrVITUZc" title="Weighted Average Remaining Contractual Life, Granted"&gt;1.94&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zwP6VYxBZjec" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Granted"&gt;1.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKqQNCPaGOHl" style="text-align: right" title="Options Outstanding Number of Shares, Exercised"&gt;(120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_znkksBUd8rp4" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zCikqjW5CL7b" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zcATZyPFhB9b" title="Weighted Average Remaining Contractual Life, Exercised"&gt;4.34&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zpzRM2NEOsDg" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Exercised"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z3xKSFmR0bef" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding Number of Shares, Cancelled/Forfeited/Expired"&gt;(335,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zHg1q57unAIe" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;1.25&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zlTLrg3WLVZe" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;19.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKr8okVmhAuc" title="Weighted Average Remaining Contractual Life, Granted"&gt;3.90&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zI7t73t7qUIk" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;14.09&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zpEP31AjUGW7" style="text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,124,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_ztnJ12sWyx4e" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zTFYhBB5paVi" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zqX0GmppfPJ8" title="Options Outstanding Weighted Average Remaining Contractual Life, Beginning"&gt;4.60&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zsmr8g7VGAcf" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Beginning"&gt;3.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKUI13pxWr6d" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1748"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zaJvzNXzWMEj" style="text-align: right" title="Options Outstanding Number of Shares, Exercised"&gt;(232,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zMlFzofNJCP3" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZuIk03s1Wc" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zYmdMMf5kDOe" title="Weighted Average Remaining Contractual Life, Exercised"&gt;2.55&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zAkNmU5Di2S1" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Exercised"&gt;2.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zuJG6pRD0jwh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding Number of Shares, Cancelled/Forfeited/Expired"&gt;(210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zKKVZpEQOGKa" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zvU2x29kLuxb" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zBhE0niZEOOc" title="Weighted Average Remaining Contractual Life, Granted"&gt;2.78&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zuH2YYYN5yWd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;2.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zha9ZIW4Faf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Number of Shares, Ending"&gt;682,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zRi1QVF2uFP5" title="Options Outstanding Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zuPTo1RRrU1j" title="Options Outstanding Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zEODPd1P73Nc" title="Options Outstanding Weighted Average Remaining Contractual Life, Ending"&gt;4.24&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zGonLNVpITm1" style="padding-bottom: 2.5pt; text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Ending"&gt;4.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zvmdmceCGrje" style="text-align: right" title="Options Exercisable Number of Shares, Ending"&gt;1,090,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zAac8lFt9mR6" title="Options Exercisable Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z8tvUnBmGYv2" title="Options Exercisable Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z8MrCV5Wt0t7" title="Options Exercisable Weighted Average Remaining Contractual Life, Ending"&gt;4.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zvM7oyHRmfSd" style="text-align: right" title="Options Exercisable Weighted Average Exercise Price Per Share, Ending"&gt;3.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zsv72LGDnFD9" style="text-align: right" title="Options Exercisable Number of Shares, Ending"&gt;682,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zSKOkj6YDoGi" title="Options Exercisable Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zujGxwDZGoxf" title="Options Exercisable Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zxDQtMtTcaE7" title="Options Exercisable Weighted Average Remaining Contractual Life, Ending"&gt;4.24&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zQCwPz2vX9Mi" style="text-align: right" title="Options Exercisable Weighted Average Exercise Price Per Share, Ending"&gt;4.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z8qHjGNcrE7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
compensation expense under the above service-based option plan was $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zrJFGkCgveF7" title="Compensation expense"&gt;291&lt;/span&gt; thousand and $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zfGGNy0FhKGc" title="Compensation expense"&gt;1.7&lt;/span&gt; million for the years ended December 31, 2024
and 2023, respectively, with &lt;span id="xdx_907_ecustom--UnamortizedExpense_iI_do_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z8YVj2Rx1ogh" title="Unamortized expense"&gt;no&lt;/span&gt; unamortized expense remaining as of December 31, 2024. Of the total service-based options exercised during
the year ended December 31, 2024, &lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zvia9Yve7I1e" title="Number of share based compensation option exercised for cashless"&gt;170,750&lt;/span&gt; options were exercised on a cashless basis, which resulted in &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z6dZsLn8wZN3" title="Number of shares issued"&gt;134,302&lt;/span&gt; shares issued and &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zNVqSkMuy5dk" title="Number of share based compensation option exercised for cash"&gt;61,250&lt;/span&gt;
options were exercised for cash. As of December 31, 2024, aggregate intrinsic value of vested service-based options outstanding was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z5ovU1hA6qxk" title="Options outstanding intrinsic value"&gt;1.1&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5leMymNwflh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding performance-based options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zNliMHVsguQe" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;br/&gt;

    Outstanding&lt;br/&gt;
    Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
    Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zAnMPEecsjCh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options Outstanding Number of Shares Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;535,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zAo949EWBlWl" title="Exercise Price per Share Beginning"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zU4eXJ94btfi" title="Exercise Price per Share Beginning"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zR60IFbcIzka" title="Weighted Average Remaining Contractual Life Beginning"&gt;4.59&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ziJEaAwmjVD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price per Share Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeJ8pQFzMHbd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBxXtAhTlmFl" title="Exercise Price per Share Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpKhe4ZbHBXk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z1bE3h1U2Ftk" title="Exercise Price per Share Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;-&lt;/span&gt;&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFkLeIqigoGl" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNT1XrmKPXw9" title="Exercise Price per Share Cancelled/Forfeited/Expired"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcq5XnplRkc6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpWSvpFvEva9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;485,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zNN75ORo0iC8" title="Exercise Price per Share Beginning"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zQh9j393Y9bh" title="Exercise Price per Share Beginning"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2O4NC6qsfRk" title="Weighted Average Remaining Contractual Life Beginning"&gt;4.13&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOmi743eT0s4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znLPPtDrr3w" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfJm8T5RvbBc" title="Exercise Price per Share Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHKW7Dyg6Im2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(395,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zr80O1d1xb7b" title="Exercise Price per Share Exercised"&gt;1.50&lt;/span&gt;
    &#x2013; &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zDwOaWDkwxvf" title="Exercise Price per Share Exercised"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsInExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztV7q6HyCJV2" title="Weighted Average Remaining Contractual Life Exercised"&gt;3.31&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbntfmOV4Qj2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.53&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFbD6xJcZE4h" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1864"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z610ImwuU8wb" title="Exercise Price per Share Cancelled/Forfeited/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zainNrYcviGb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zauv1kPclcgb" title="Exercise Price per Share Ending"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zjwunWVAf6z6" title="Exercise Price per Share Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZigezOKXz36" title="Weighted Average Remaining Contractual Life"&gt;2.30&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzXkzCtSA6He" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmqCuB5hxtYf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;420,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zq5A9tYKbecg" title="Exercise Price per Share Exercisable Ending"&gt;1.50&lt;/span&gt;
    &#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_z9vgqHD3C6Sa" title="Exercise Price per Share Exercisable Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZ9RxMXMt41" title="Weighted Average Remaining Contractual Life Ending"&gt;4.20&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zP6VVynjFzy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLB8A4BIPGs2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zBFbIdoadmD5" title="Exercise Price per Share Exercisable Ending"&gt;1.75&lt;/span&gt;
    &#x2013; &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zRrLK59srKM8" title="Exercise Price per Share Exercisable Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsYGLZUmR1yd" title="Weighted Average Remaining Contractual Life Ending"&gt;1.40&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfJdXhguTDbc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_z41OWl99XPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
compensation expense was recognized on the performance-based options above for the years ended December 31, 2024 and 2023. As of December
31, 2024, aggregate intrinsic value of vested performance options outstanding was $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgGrmlLakP2k"&gt;73&lt;/span&gt; thousand. Of the total performance-based options
exercised during the year ended December 31, 2024, &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zxSdl49maYdf" title="Number of share based compensation option exercised for cashless"&gt;370,000&lt;/span&gt; options were exercised on a cashless basis, which resulted in &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zVkOC2D8XRzj" title="Number of shares issued"&gt;315,694&lt;/span&gt; shares
issued and &lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zIbf4rcq3qQ2" title="Number of share based compensation option exercised for cash"&gt;25,000&lt;/span&gt; options were exercised for cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;RSUs
and RSAs (under our Amended 2020 Plan)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zevMYGJZdx15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding RSUs and RSAs activity under our Amended 2020 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zN7J3Qd2JGKk" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;RSUs and RSAs Outstanding&lt;br/&gt; Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z2OeT7DJNzqb" style="width: 16%; text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;1,028,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z79UtHLteEm3" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;3,625,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zZU6Na0mhjT1" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(674,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z7DBcCPfdgIb" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(785,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zoz7KmTS1Ahd" style="text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;3,194,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zHVKMVzlAIcd" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;1,759,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zjBbO1OW02tj" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(1,454,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zbuOMjvNwY57" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(450,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zSKzuMzGYKQ" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU Outstanding Number of Shares, Ending"&gt;3,049,944&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z4jQlZNnuZH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total fair value of the &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zrPRjhRyh4Ga" title="Fair value"&gt;1,759,767&lt;/span&gt; RSUs and RSAs granted was $&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOfValue_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zeo86YeFsjp" title="Grants value"&gt;12.3&lt;/span&gt; million which was determined using the fair value of the quoted market
price on the date of grant. Total compensation expense under the above Amended 2020 Plan RSUs and RSAs was $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zKEPNhgxuCd8" title="Share based compensation"&gt;9.9&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zQUatIiQ3R1c" title="Share based compensation"&gt;5.4&lt;/span&gt; million
for the years ended December 31, 2024 and 2023, respectively, with unamortized expense remaining of $&lt;span id="xdx_902_ecustom--UnamortizedExpense_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z7utnlrTnqVg" title="Unamortized expense"&gt;7.1&lt;/span&gt; million as of December 31, 2024.
During the year ended December 31, 2024, &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zs5hlzJLmX84" title="Shares vested"&gt;1,454,198&lt;/span&gt; RSUs and RSAs vested, of which &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zPXhtnMPwVQb" title="Shares vested, issued"&gt;1,359,960&lt;/span&gt; RSUs and RSAs were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;RSUs
and RSAs (outside of our Amended 2020 Plan)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQoNVShTyuZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding RSUs and RSAs activity (outside of our Amended 2020 Plan):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zQ55D4XKLRo8" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;RSUs and RSAs&lt;/b&gt;&lt;b&gt; Outstanding&lt;br/&gt; Number
    of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zbajta5hjzS6" style="width: 16%; text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;715,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_ziX7oTXffBxl" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;725,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zv3TfGBkXpTd" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(390,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zA3y39gFYFT3" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zRa0KIrcIlv4" style="text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zspmYLI54pR3" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1951"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_z6lbIxQvGina" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zaxNZMrda2v7" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU Outstanding Number of Shares, Ending"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z2l1X77ZYWR" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
compensation expense for RSUs and RSAs outside of the Amended 2020 Plan was $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zYuuxGduFPgb" title="Share based compensation"&gt;809&lt;/span&gt; thousand and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zyUbgfNJS4k2" title="Share based compensation"&gt;885&lt;/span&gt; thousand for the years ended December
31, 2024 and 2023, respectively, with &lt;span id="xdx_90B_ecustom--UnamortizedExpense_iI_do_c20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_ztUs94xsNdLl" title="Unamortized expense"&gt;no&lt;/span&gt; unamortized expense remaining as of December 31, 2024. During the year ended December 31, 2024,
&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zhB6SJAcnzPk" title="Shares vested"&gt;250,000&lt;/span&gt; RSUs and RSAs vested, of which &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zcWOeoOoYmfb" title="Shares issued"&gt;250,000&lt;/span&gt; RSUs and RSAs were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z4Nclr5xRYKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding and exercisable warrant activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BF_ziuq1gnvjXI7" style="display: none"&gt;SCHEDULE
OF WARRANT OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNXihH1Hg11l" style="width: 12%; text-align: right" title="Outstanding number of shares, beginning balance"&gt;3,859,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z7kOKgmboPsd" title="Exercise price per share"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIkR2mczTX0f" title="Exercise price per share"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDPU0R5iPucl" title="Weighted average remaining contractual life beginning"&gt;4.89&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5bgGQbaOuJl" style="width: 12%; text-align: right" title="Weighted average exercise price per share beginning"&gt;5.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuSEj5TbRQ76" style="text-align: right" title="Outstanding number of shares, granted"&gt;967,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQBOInZWOyx9" title="Exercise price per share, exercised"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedNonOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv1iUFOZz6Vc" title="Weighted average remaining contractual life, granted"&gt;4.22&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zexynFCqryX6" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIKbmQ7yAZQ7" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(96,773&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXxEi2eZ0fd1" title="Exercise price per share, exercised"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrvuH4RRieN7" title="Weighted average remaining contractual life, exercised"&gt;4.22&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGAfMHOtgZzk" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDOPxZ84zH8" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding number of shares, cancelled/forfeited/expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1995"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBHbpjT1eze" style="text-align: right" title="Outstanding number of shares, beginning balance"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zKl3ikP2xR34" title="Exercise price per share, ending balance"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z1surV1LHS8h" title="Exercise price per share, ending balance"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AJg04gYGB7" title="Weighted average remaining contractual life beginning"&gt;3.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfaLejhUqOjg" style="text-align: right" title="Weighted average exercise price per share beginning"&gt;4.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPbIno2o9gq6" style="text-align: right" title="Outstanding number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlaJ4ioSGff5" title="Exercise price per share, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2009"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSygIpTtKh05" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(2,986,877&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_znDc83Fv0sA3" title="Exercise price per share, exercised"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvlOfk67VGg7" title="Exercise price per share, exercised"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sfZfp1dLz2" title="Weighted average remaining contractual life, exercised"&gt;3.13&lt;/span&gt; years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfBTvmVu0JWl" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;4.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEnvPl9NnAIh" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding number of shares, cancelled/forfeited/expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqD1sIIHjV4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding number of shares, ending balance"&gt;1,743,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWItD5jFS3Mk" title="Exercise price per share"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zFWrlBQM4pT9" title="Exercise price per share"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwusgWON7j0f" title="Weighted average remaining contractual life ending"&gt;2.66&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP3KjbixeFag" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price per share beginning"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIZePJy6oSB7" style="text-align: right" title="Outstanding number of shares, exercisable, ending"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zp09eoB3dkD" title="Exercise price per share, exercisable, ending"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYzFJx5zCYec" title="Exercise price per share, exercisable, ending"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0osIOvb4w7h" title="Weighted average remaining contractual life, exercisable"&gt;3.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbyt0BsCcUC2" style="text-align: right" title="Weighted average exercise price per share exercisable ending"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zocojXGXzXj8" style="text-align: right" title="Outstanding number of shares, exercisable, ending"&gt;1,743,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zgRUc5KKk0Di" title="Exercise price per share, exercisable, ending"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9xWJcFhRAZk" title="Exercise price per share, exercisable, ending"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zb8zq3VLV3Hk" title="Weighted average remaining contractual life, exercisable"&gt;2.66&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMOTMnD3uCe" style="text-align: right" title="Weighted average exercise price per share exercisable ending"&gt;4.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zcMswTEkWxkl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
compensation expense for warrants granted prior to the year ended December 31, 2023 was $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zlQgAdZh4444" title="Share based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zSj7atGrNtca" title="Share based compensation"&gt;18&lt;/span&gt; thousand for the years ended December
31, 2024 and 2023, respectively, with no unamortized expense remaining as of December 31, 2024. No stock-based compensation expense on
the warrants granted during the year ended December 31, 2023 was recorded as the warrants are amortized through debt discount (see Note
7). During the year ended December 31, 2024, &lt;span id="xdx_909_ecustom--AvenueExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg0k8FYuLJBf" title="Avenue exercised"&gt;2,986,877&lt;/span&gt; warrants were exercised on a cashless basis, which resulted in &lt;span id="xdx_904_ecustom--AvenueWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTsfx4CvuoM8" title="Avenue warrants"&gt;1,630,458&lt;/span&gt; shares
issued. As of December 31, 2024, aggregate intrinsic value of vested warrants outstanding was $&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWr85S8pFoIf" title="Warrants outstanding"&gt;4.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based compensation expense related to common stock issued for services, service-based stock options, performance-based stock
options, warrants and RSUs, and RSAs amounted to $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantAndRestrictedStockUnitsRSUMember_zv4NHI6vCqw2" title="Share based compensation"&gt;12.2&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantAndRestrictedStockUnitsRSUMember_zRvFN4v64BUj" title="Share based compensation"&gt;12.5&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively.
Such amounts are included in general and administrative expenses in the consolidated statements of operations. Unamortized expense remaining
related to service-based stock options, performance-based stock options, warrants, RSUs, and RSAs was $&lt;span id="xdx_90D_ecustom--UnamortizedExpenses_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantAndRestrictedStockUnitsRSUMember_zhWo0i3hsdL3" title="Unamortized expenses"&gt;7.1&lt;/span&gt; million as of December 31,
2024, which is expected to be recognized through 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001366"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001368"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001372"
      unitRef="Shares">1610000</us-gaap:PreferredStockSharesAuthorized>
    <LFMD:UndesignatedPreferredStock
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001374"
      unitRef="Shares">3385000</LFMD:UndesignatedPreferredStock>
    <us-gaap:DebtSecurities
      contextRef="AsOf2024-06-07_custom_SharesAndSecuritiesMember"
      decimals="-5"
      id="Fact001376"
      unitRef="USD">150000000.0</us-gaap:DebtSecurities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-06-072024-06-07_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact001378"
      unitRef="USD">53300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact001380"
      unitRef="USD">53300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-12-31_custom_ShelfAgreementMember"
      decimals="-5"
      id="Fact001382"
      unitRef="USD">150000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <LFMD:PurchaseOfUnderwritingShares
      contextRef="AsOf2021-09-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001384"
      unitRef="Shares">1400000</LFMD:PurchaseOfUnderwritingShares>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001386"
      unitRef="USDPShares">2.21875</us-gaap:PreferredStockDividendsPerShareDeclared>
    <LFMD:PercentageOfPreferredStockLiquidationPreference
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001388"
      unitRef="Pure">0.08875</LFMD:PercentageOfPreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001390"
      unitRef="USDPShares">25.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_InvestorsMember"
      decimals="INF"
      id="Fact001392"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2024-01-01to2024-12-31" id="Fact001394">The
Series A Preferred Stock is perpetual and has no maturity date. No outstanding shares of Series A Preferred Stock have been redeemed.
However, the Series A Preferred Stock will be redeemable at our option, in whole or in part, at the following redemption prices, plus
any accrued and unpaid dividends up to, but not including, the date of redemption: 1) on and after October 15, 2022 and prior to October
15, 2023, at a redemption price equal to $25.75 per share, 2) on and after October 15, 2023 and prior to October 15, 2024, at a redemption
price equal to $25.50 per share, 3) on and after October 15, 2024 and prior to and prior to October 15, 2025 at a redemption price equal
to $25.25 per share and 4) on and after October 15, 2025 at a redemption price equal to $25.00 per share. In addition, upon the occurrence
of a delisting event or change of control, we may, subject to certain conditions, at our option, redeem the Series A Preferred Stock,
in whole or in part within 90 days after the first date on which such delisting event occurred or within 120 days after the first date
on which such change of control occurred, as applicable, by paying $25.00 per share, plus any accumulated and unpaid dividends up to,
but not including, the redemption date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_custom_OctoberFifteenTwentyTwoAndTwentyThreeMember"
      decimals="INF"
      id="Fact001396"
      unitRef="USDPShares">25.75</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_custom_OctoberFifteenTwentyThreeAndTwentyFourMember"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">25.50</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_custom_OctoberFifteenTwentyFourAndTwentyFiveMember"
      decimals="INF"
      id="Fact001398"
      unitRef="USDPShares">25.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_custom_OctoberFifteenTwentyFiveAndAfterFiveMember"
      decimals="INF"
      id="Fact001399"
      unitRef="USDPShares">25.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001401"
      unitRef="USDPShares">25.00</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-08-27_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001403"
      unitRef="Shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <LFMD:CashlessExerciseOfOptionsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">512777</LFMD:CashlessExerciseOfOptionsShares>
    <LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">1630458</LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Shares">86250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001411"
      unitRef="USD">120000</us-gaap:ProceedsFromStockOptionsExercised>
    <LFMD:CashlessExerciseOfOptionsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">74372</LFMD:CashlessExerciseOfOptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Shares">37500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">94500</us-gaap:ProceedsFromStockOptionsExercised>
    <LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">79330</LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Shares">1609960</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact001423"
      unitRef="USD">460000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-062023-02-06_custom_FirstOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001425"
      unitRef="Shares">337895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-172023-04-17_custom_SecondOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">455319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-172023-07-17_custom_ThirdOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">158129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-172023-10-17_custom_FourthOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">117583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-162024-01-16_custom_FifthQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">95821</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssued1
      contextRef="From2024-01-012024-12-31_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact001435"
      unitRef="USD">642000</us-gaap:StockIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001437"
      unitRef="Shares">978500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-02-042023-02-04_custom_StockPurchaseAgreeementMember"
      decimals="-3"
      id="Fact001439"
      unitRef="USD">460000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-062023-02-06_custom_FirstOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001441"
      unitRef="Shares">337895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-172023-04-17_custom_SecondOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001443"
      unitRef="Shares">455319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-172023-07-17_custom_ThirdOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001445"
      unitRef="Shares">158129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-172023-10-17_custom_FourthOfFiveQuarterlyInstallmentMember"
      decimals="INF"
      id="Fact001447"
      unitRef="Shares">117583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001449"
      unitRef="USD">2600000</us-gaap:StockIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_custom_ATMSalesAgreementMember"
      decimals="INF"
      id="Fact001451"
      unitRef="Shares">1009907</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-12-31_custom_ATMSalesAgreementMember"
      decimals="-5"
      id="Fact001453"
      unitRef="USD">6200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_HarborsideMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001457"
      unitRef="USDPShares">5.32</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2023-07-10_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001459"
      unitRef="Shares">2275</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2023-08-14_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001461"
      unitRef="Shares">1225</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-07-10_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001463"
      unitRef="USDPShares">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-14_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001465"
      unitRef="USDPShares">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-07-102023-07-10_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001467"
      unitRef="USD">5100000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-08-142023-08-14_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001469"
      unitRef="USD">5100000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-07-12_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">1010170</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001473"
      unitRef="Shares">550694</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <LFMD:WarrantToPurchaseStockValue
      contextRef="From2023-03-202023-03-21_custom_AvenueMember"
      decimals="-5"
      id="Fact001475"
      unitRef="USD">1200000</LFMD:WarrantToPurchaseStockValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-21_custom_AvenueMember"
      decimals="INF"
      id="Fact001477"
      unitRef="USDPShares">1.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-03-202023-03-21_custom_AvenueMember"
      decimals="-6"
      id="Fact001479"
      unitRef="USD">2000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-03-212023-03-21_custom_AvenueFacilityMember"
      decimals="-6"
      id="Fact001481"
      unitRef="USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-03-21_custom_AvenueMember"
      decimals="INF"
      id="Fact001483"
      unitRef="USDPShares">1.49</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-11-152023-11-15_custom_AvenueMember_us-gaap_CommonStockMember"
      decimals="-6"
      id="Fact001485"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-11-152023-11-15_custom_AvenueMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001487"
      unitRef="Shares">672042</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-11-152023-11-15_custom_AvenueMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001489"
      unitRef="Shares">96773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-11-152023-11-15_custom_AvenueMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">79330</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-12-102023-12-11_custom_MedifastMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001493"
      unitRef="Shares">1224425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-11_custom_MedifastMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001495"
      unitRef="USDPShares">8.1671</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-12-102023-12-11_custom_MedifastMember"
      decimals="-6"
      id="Fact001497"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-01-22_custom_ConversionLabsPRLLCMember"
      decimals="-3"
      id="Fact001499"
      unitRef="USD">376000</us-gaap:NotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-202021-01-22_custom_ConversionLabsPRLLCMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Shares">37531</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-22_custom_ConversionLabsPRLLCMember_custom_OperatingAgreementMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-22_custom_ConversionLabsPRLLCMember_custom_OperatingAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Pure">0.8558</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <LFMD:TrancheeSharesMembershipInterest
      contextRef="AsOf2022-09-30_custom_OptionAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Shares">10300</LFMD:TrancheeSharesMembershipInterest>
    <LFMD:TrancheeSharesMembershipInterest
      contextRef="AsOf2022-09-30_custom_OptionAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001509"
      unitRef="Shares">2100</LFMD:TrancheeSharesMembershipInterest>
    <LFMD:PurchasePricePerMembershipInterest
      contextRef="AsOf2022-09-30_custom_OptionAgreementMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">1.00</LFMD:PurchasePricePerMembershipInterest>
    <LFMD:NumberOfMembershipInterestUnitsRedeemed
      contextRef="From2023-03-312023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001513"
      unitRef="Shares">500</LFMD:NumberOfMembershipInterestUnitsRedeemed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001515"
      unitRef="Pure">0.741</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <LFMD:TrancheeSharesMembershipInterest
      contextRef="AsOf2023-09-30_custom_OptionAgreementMember"
      decimals="INF"
      id="Fact001517"
      unitRef="Shares">889</LFMD:TrancheeSharesMembershipInterest>
    <LFMD:PurchasePricePerMembershipInterest
      contextRef="AsOf2023-09-30_custom_OptionAgreementMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">1.00</LFMD:PurchasePricePerMembershipInterest>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-09-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Pure">0.741</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-09-30_custom_ConversionLabsPRLLCMember_custom_OptionAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001523"
      unitRef="Pure">0.733</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001525"
      unitRef="USD">153000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001527"
      unitRef="USD">2800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001529"
      unitRef="USD">774000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001531"
      unitRef="USD">144000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <LFMD:CashDividend
      contextRef="AsOf2024-03-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001533"
      unitRef="USDPShares">11.20</LFMD:CashDividend>
    <LFMD:CashDividend
      contextRef="AsOf2024-07-01_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001535"
      unitRef="USDPShares">9.05</LFMD:CashDividend>
    <LFMD:CashDividend
      contextRef="AsOf2024-11-15_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001537"
      unitRef="USDPShares">5.66</LFMD:CashDividend>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="-3"
      id="Fact001539"
      unitRef="USD">630000</us-gaap:OtherInterestAndDividendIncome>
    <LFMD:CashDividend
      contextRef="AsOf2023-06-30_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001541"
      unitRef="USDPShares">22.40</LFMD:CashDividend>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="From2023-01-012023-06-30_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q2DividendsMember"
      id="Fact001543">2023-07-03</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <LFMD:CashDividend
      contextRef="AsOf2023-07-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001545"
      unitRef="USDPShares">11.20</LFMD:CashDividend>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="From2023-07-282023-07-28_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q3DividendsMember"
      id="Fact001547">2023-08-01</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <LFMD:CashDividend
      contextRef="AsOf2023-08-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001549"
      unitRef="USDPShares">16.80</LFMD:CashDividend>
    <LFMD:CashDividend
      contextRef="AsOf2023-09-30_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001551"
      unitRef="USDPShares">14.00</LFMD:CashDividend>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="From2023-09-302023-09-30_custom_WorkSimpliSoftwareLlcMember_custom_S2023Q4DividendsMember"
      id="Fact001553">2023-10-05</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <LFMD:CashDividend
      contextRef="AsOf2023-10-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">11.20</LFMD:CashDividend>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="From2023-10-312023-10-31_custom_WorkSimpliSoftwareLlcMember_custom_O2023Q4DividendsMember"
      id="Fact001557">2023-11-08</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <LFMD:CashDividend
      contextRef="AsOf2023-12-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="INF"
      id="Fact001559"
      unitRef="USDPShares">13.44</LFMD:CashDividend>
    <us-gaap:DividendPayableDateToBePaidDayMonthAndYear
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliSoftwareLlcMember_custom_S2024Q1DividendsMember"
      id="Fact001561">2024-01-05</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliSoftwareLlcMember"
      decimals="-5"
      id="Fact001563"
      unitRef="USD">2100000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-01-08_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-01-02_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001567"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-06-24_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001569"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-06-16_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001571"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-14_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001573"
      unitRef="Shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">8100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <LFMD:RemainingAuthorizationOfShares
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001577"
      unitRef="Shares">1940844</LFMD:RemainingAuthorizationOfShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001579">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zQQ5BnNCapAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
the Company had granted service-based stock options and performance-based stock options separate from the Amended 2020 plan. The following
is a summary of outstanding options activity under our Amended 2020 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zC2F6OV3x14j" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zqO3MtJvK82b" style="width: 12%; text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,784,587&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zfDnjKnudgGk" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;2.30&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zkLDJRk8ghx5" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;21.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zZnm1tYjPMXf" title="Weighted Average Remaining Contractual Life, Granted"&gt;6.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zLTuCiUzb6ec" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Ending balance"&gt;9.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z6bq3dFZN4d" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;109,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zbXkYCvi4iVl" title="Exercise Price per Share, Granted"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zLgz6dZLKs5l" title="Exercise Price per Share, Granted"&gt;7.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zvQGqmLbctRh" title="Weighted Average Remaining Contractual Life, Granted"&gt;3.86&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zM4OlkBISvcc" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;3.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zX5r1rBsCmR5" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(37,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zXAuSzsD03Sj" title="Exercise Price per Share, Exercised"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zep960Ip4Vh2" title="Weighted Average Remaining Contractual Life, Exercised"&gt;2.70&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z4bMvYtgIrFe" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zbcwMHZu2GJd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled/Forfeited/Expired"&gt;(1,129,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zDQPd0lacIih" title="Share based compensation exercise price per share forfeited"&gt;2.30&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z6MP2tLWT305" title="Share based compensation exercise price per share forfeited"&gt;21.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z21iP99BQ2Wc" title="Options Outstanding Weighted Average Remaining Contractual Life, Cancelled/Forfeited/Expired"&gt;6.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zslltuXOfuS9" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;10.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zdUR8tJ6n679" style="text-align: right" title="Outstanding number of shares, beginning balance"&gt;726,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zzrIIbvvCzG4" title="Exercise Price per Share, Beginning balance"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zAGCbUuvrxo5" title="Exercise Price per Share, Beginning balance"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zPztwQVHd929" title="Weighted Average Remaining Contractual Life"&gt;4.93&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zEosLek7N0Ki" style="text-align: right" title="Weighted Average Exercise Price per Share, Beginning balance"&gt;8.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z2QE1AFtL7u2" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zKE4IBY6EM84" title="Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1631"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zDyC2osU0ai2" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zv6eparNMngf" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(172,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zV2I2fPbHmkh" title="Exercise Price per Share, Exercised"&gt;6.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice_pid_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_znz8S2sv0xGi" title="Exercise Price per Share, Exercised"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zm95rNGEq7Yh" title="Weighted Average Remaining Contractual Life, Exercised"&gt;5.86&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z2tqk15h4S85" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;6.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zPJFI1wGo3dk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Cancelled/Forfeited/Expired"&gt;(39,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zyoVXp7xlYF6" title="Share based compensation exercise price per share forfeited"&gt;7.44&lt;/span&gt; &#x2013; &lt;span id="xdx_900_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zGMd6MjbjK5j" title="Share based compensation exercise price per share forfeited"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z9uyLqCmwwWe" title="Options Outstanding Weighted Average Remaining Contractual Life, Cancelled/Forfeited/Expired"&gt;5.74&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zsSCIILv8gz2" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;12.77&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zdgVqzG6ZTse" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding number of shares, ending balance"&gt;515,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zTbD6iDznlZ1" title="Exercise Price per Share, Ending balance"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zKWrvIgBOQyj" title="Exercise Price per Share, Ending balance"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_z1fB7fphExO9" title="Weighted Average Remaining Contractual Life, Ending"&gt;4.81&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zRJGRWcV0wmf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price per Share, Ending balance"&gt;8.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zgnm4QN0fpJe" style="text-align: right" title="Number of Options, Exercisable, Ending"&gt;604,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zhpShk4hmf6h" title="Number of Options, Exercise price, Ending"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_zKNP1x6zmIra" title="Number of Options, Exercise price, Ending"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zqZnQg4rbwQc" title="Weighted Average Remaining Contractual Life, Exercisable, Ending"&gt;6.23&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_ztJQ3WGI4UL7" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercisable, Ending"&gt;8.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zO7IANYQ2G1" style="text-align: right" title="Number of Options, Exercisable, Ending"&gt;504,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MinimumMember_zaXQjnsaQOHd" title="Number of Options, Exercise price, Ending"&gt;1.84&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember__srt--RangeAxis__srt--MaximumMember_znXRWIxYcqk6" title="Number of Options, Exercise price, Ending"&gt;13.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_za2zrEXL0OTc" title="Weighted Average Remaining Contractual Life, Exercisable, Ending"&gt;4.84&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zT95aEK8dsr2" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercisable, Ending"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001581"
      unitRef="Shares">1784587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001583"
      unitRef="USDPShares">2.30</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">21.02</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001587">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001589"
      unitRef="USDPShares">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001591"
      unitRef="Shares">109500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001593"
      unitRef="USDPShares">1.84</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001595"
      unitRef="USDPShares">7.44</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001597">P3Y10M9D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001599"
      unitRef="USDPShares">3.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001601"
      unitRef="Shares">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001603"
      unitRef="USDPShares">2.52</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001605">P2Y8M12D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001607"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001609"
      unitRef="Shares">1129698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">2.30</LFMD:ShareBasedCompensationExercisePricePerShareForfeited>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Shares">21.02</LFMD:ShareBasedCompensationExercisePricePerShareForfeited>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001615">P6Y7M13D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001617"
      unitRef="USDPShares">10.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">726889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">1.84</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001623"
      unitRef="USDPShares">13.74</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001625">P4Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001627"
      unitRef="USDPShares">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001635"
      unitRef="Shares">172222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001637"
      unitRef="USDPShares">6.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001639"
      unitRef="USDPShares">7.50</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExcerciseInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001641">P5Y10M9D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001645"
      unitRef="Shares">39000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2024-01-012024-12-31_srt_MinimumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Shares">7.44</LFMD:ShareBasedCompensationExercisePricePerShareForfeited>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2024-01-012024-12-31_srt_MaximumMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001649"
      unitRef="Shares">13.74</LFMD:ShareBasedCompensationExercisePricePerShareForfeited>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001651">P5Y8M26D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedAndExpirationWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001653"
      unitRef="USDPShares">12.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001655"
      unitRef="Shares">515667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001657"
      unitRef="USDPShares">1.84</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001659"
      unitRef="USDPShares">13.74</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001661">P4Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001663"
      unitRef="USDPShares">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001665"
      unitRef="Shares">604758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001667"
      unitRef="USDPShares">1.84</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001669"
      unitRef="USDPShares">13.74</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001671">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001673"
      unitRef="USDPShares">8.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001675"
      unitRef="Shares">504787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001677"
      unitRef="USDPShares">1.84</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001679"
      unitRef="USDPShares">13.74</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePriceBeginning>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      id="Fact001681">P4Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001683"
      unitRef="USDPShares">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001685"
      unitRef="USD">1200000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001687"
      unitRef="USD">4500000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <LFMD:UnamortizedExpense
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="-3"
      id="Fact001688"
      unitRef="USD">30000</LFMD:UnamortizedExpense>
    <LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001690"
      unitRef="Shares">172222</LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001692"
      unitRef="Shares">62781</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyPlanMember"
      decimals="-3"
      id="Fact001694"
      unitRef="USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001696">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKmXcnZJtPQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding service-based options activity (prior to the establishment of the Amended 2020 Plan above):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_z13y98xqNvu8" style="display: none"&gt;SCHEDULE
                                            OF OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zklUBk6nwTtg" style="width: 12%; text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,439,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zF82gtGAoBVd" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z5ZohH8K7Pkd" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;19.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zQTHhxaz5itj" title="Options Outstanding Weighted Average Remaining Contractual Life, Beginning"&gt;5.63&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zOVEVxXXiV0i" style="width: 12%; text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Beginning"&gt;6.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zDTtKRzLugDj" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zrjn3q0TDzRl" title="Options Outstanding Exercise Price Per Share, Granted"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z2Rp1awaShz2" title="Options Outstanding Exercise Price Per Share, Granted"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zDItSrVITUZc" title="Weighted Average Remaining Contractual Life, Granted"&gt;1.94&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zwP6VYxBZjec" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Granted"&gt;1.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKqQNCPaGOHl" style="text-align: right" title="Options Outstanding Number of Shares, Exercised"&gt;(120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_znkksBUd8rp4" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zCikqjW5CL7b" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zcATZyPFhB9b" title="Weighted Average Remaining Contractual Life, Exercised"&gt;4.34&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zpzRM2NEOsDg" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Exercised"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z3xKSFmR0bef" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding Number of Shares, Cancelled/Forfeited/Expired"&gt;(335,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zHg1q57unAIe" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;1.25&lt;/span&gt; &#x2013; &lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zlTLrg3WLVZe" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;19.61&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKr8okVmhAuc" title="Weighted Average Remaining Contractual Life, Granted"&gt;3.90&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zI7t73t7qUIk" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;14.09&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zpEP31AjUGW7" style="text-align: right" title="Options Outstanding Number of Shares, Beginning"&gt;1,124,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_ztnJ12sWyx4e" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zTFYhBB5paVi" title="Options Outstanding Exercise Price Per Share, Beginning"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zqX0GmppfPJ8" title="Options Outstanding Weighted Average Remaining Contractual Life, Beginning"&gt;4.60&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zsmr8g7VGAcf" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Beginning"&gt;3.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zKUI13pxWr6d" style="text-align: right" title="Options Outstanding Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1748"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zaJvzNXzWMEj" style="text-align: right" title="Options Outstanding Number of Shares, Exercised"&gt;(232,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zMlFzofNJCP3" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZuIk03s1Wc" title="Options Outstanding Exercise Price Per Share, Exercised"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zYmdMMf5kDOe" title="Weighted Average Remaining Contractual Life, Exercised"&gt;2.55&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zAkNmU5Di2S1" style="text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Exercised"&gt;2.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zuJG6pRD0jwh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding Number of Shares, Cancelled/Forfeited/Expired"&gt;(210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zKKVZpEQOGKa" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zvU2x29kLuxb" title="Options Outstanding Exercise Price Per Share, Cancelled/Forfeited/Expired"&gt;7.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zBhE0niZEOOc" title="Weighted Average Remaining Contractual Life, Granted"&gt;2.78&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zuH2YYYN5yWd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price per Share, Cancelled/Forfeited/Expired"&gt;2.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zha9ZIW4Faf8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Number of Shares, Ending"&gt;682,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zRi1QVF2uFP5" title="Options Outstanding Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zuPTo1RRrU1j" title="Options Outstanding Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zEODPd1P73Nc" title="Options Outstanding Weighted Average Remaining Contractual Life, Ending"&gt;4.24&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zGonLNVpITm1" style="padding-bottom: 2.5pt; text-align: right" title="Options Outstanding Weighted Average Exercise Price Per Share, Ending"&gt;4.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zvmdmceCGrje" style="text-align: right" title="Options Exercisable Number of Shares, Ending"&gt;1,090,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zAac8lFt9mR6" title="Options Exercisable Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_z8tvUnBmGYv2" title="Options Exercisable Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_z8MrCV5Wt0t7" title="Options Exercisable Weighted Average Remaining Contractual Life, Ending"&gt;4.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zvM7oyHRmfSd" style="text-align: right" title="Options Exercisable Weighted Average Exercise Price Per Share, Ending"&gt;3.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zsv72LGDnFD9" style="text-align: right" title="Options Exercisable Number of Shares, Ending"&gt;682,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zSKOkj6YDoGi" title="Options Exercisable Exercise Price Per Share, Ending"&gt;1.00&lt;/span&gt; &#x2013; &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zujGxwDZGoxf" title="Options Exercisable Exercise Price Per Share, Ending"&gt;11.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zxDQtMtTcaE7" title="Options Exercisable Weighted Average Remaining Contractual Life, Ending"&gt;4.24&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedStockOptionsMember_zQCwPz2vX9Mi" style="text-align: right" title="Options Exercisable Weighted Average Exercise Price Per Share, Ending"&gt;4.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001698"
      unitRef="Shares">1439333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001700"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001702"
      unitRef="USDPShares">19.61</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife
      contextRef="From2022-01-012022-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001704">P5Y7M17D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001706"
      unitRef="USDPShares">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001708"
      unitRef="Shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001710"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001712"
      unitRef="USDPShares">2.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001714">P1Y11M8D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001716"
      unitRef="USDPShares">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001718"
      unitRef="Shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001720"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001722"
      unitRef="USDPShares">1.50</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001724">P4Y4M2D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001726"
      unitRef="USDPShares">1.33</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001728"
      unitRef="Shares">335000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001730"
      unitRef="USDPShares">1.25</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001732"
      unitRef="USDPShares">19.61</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001734">P3Y10M24D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001736"
      unitRef="USDPShares">14.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Shares">1124333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001740"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001742"
      unitRef="USDPShares">11.98</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001744">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001746"
      unitRef="USDPShares">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001750"
      unitRef="Shares">232000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001752"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001754"
      unitRef="USDPShares">6.25</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001756">P2Y6M18D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsExercisedWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001758"
      unitRef="USDPShares">2.19</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001760"
      unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001762"
      unitRef="USDPShares">1.40</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001764"
      unitRef="USDPShares">7.73</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedExpirationInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001766">P2Y9M10D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001768"
      unitRef="USDPShares">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001770"
      unitRef="Shares">682333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001772"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001774"
      unitRef="USDPShares">11.98</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001776">P4Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001778"
      unitRef="USDPShares">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001780"
      unitRef="Shares">1090083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001782"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001784"
      unitRef="USDPShares">11.98</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001786">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001788"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001790"
      unitRef="Shares">682333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001792"
      unitRef="USDPShares">1.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001794"
      unitRef="USDPShares">11.98</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      id="Fact001796">P4Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001798"
      unitRef="USDPShares">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="-3"
      id="Fact001800"
      unitRef="USD">291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="-5"
      id="Fact001802"
      unitRef="USD">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <LFMD:UnamortizedExpense
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">0</LFMD:UnamortizedExpense>
    <LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001806"
      unitRef="Shares">170750</LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001808"
      unitRef="Shares">134302</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="INF"
      id="Fact001810"
      unitRef="Shares">61250</LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_ServiceBasedStockOptionsMember"
      decimals="-5"
      id="Fact001812"
      unitRef="USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001814">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5leMymNwflh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding performance-based options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zNliMHVsguQe" style="display: none"&gt;SCHEDULE
OF OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;br/&gt;

    Outstanding&lt;br/&gt;
    Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;

    Average&lt;br/&gt;
    Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zAnMPEecsjCh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options Outstanding Number of Shares Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;535,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zAo949EWBlWl" title="Exercise Price per Share Beginning"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zU4eXJ94btfi" title="Exercise Price per Share Beginning"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zR60IFbcIzka" title="Weighted Average Remaining Contractual Life Beginning"&gt;4.59&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ziJEaAwmjVD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price per Share Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeJ8pQFzMHbd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBxXtAhTlmFl" title="Exercise Price per Share Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpKhe4ZbHBXk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z1bE3h1U2Ftk" title="Exercise Price per Share Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;-&lt;/span&gt;&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFkLeIqigoGl" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNT1XrmKPXw9" title="Exercise Price per Share Cancelled/Forfeited/Expired"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcq5XnplRkc6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpWSvpFvEva9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;485,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zNN75ORo0iC8" title="Exercise Price per Share Beginning"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zQh9j393Y9bh" title="Exercise Price per Share Beginning"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2O4NC6qsfRk" title="Weighted Average Remaining Contractual Life Beginning"&gt;4.13&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOmi743eT0s4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znLPPtDrr3w" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfJm8T5RvbBc" title="Exercise Price per Share Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHKW7Dyg6Im2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(395,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zr80O1d1xb7b" title="Exercise Price per Share Exercised"&gt;1.50&lt;/span&gt;
    &#x2013; &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zDwOaWDkwxvf" title="Exercise Price per Share Exercised"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsInExercisedWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztV7q6HyCJV2" title="Weighted Average Remaining Contractual Life Exercised"&gt;3.31&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbntfmOV4Qj2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.53&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFbD6xJcZE4h" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Cancelled/Forfeited/Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1864"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationExercisePricePerShareForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z610ImwuU8wb" title="Exercise Price per Share Cancelled/Forfeited/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zainNrYcviGb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zauv1kPclcgb" title="Exercise Price per Share Ending"&gt;1.25&lt;/span&gt;
    &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zjwunWVAf6z6" title="Exercise Price per Share Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZigezOKXz36" title="Weighted Average Remaining Contractual Life"&gt;2.30&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzXkzCtSA6He" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    December 31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmqCuB5hxtYf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;420,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zq5A9tYKbecg" title="Exercise Price per Share Exercisable Ending"&gt;1.50&lt;/span&gt;
    &#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_z9vgqHD3C6Sa" title="Exercise Price per Share Exercisable Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZ9RxMXMt41" title="Weighted Average Remaining Contractual Life Ending"&gt;4.20&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zP6VVynjFzy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLB8A4BIPGs2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Number of Shares Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zBFbIdoadmD5" title="Exercise Price per Share Exercisable Ending"&gt;1.75&lt;/span&gt;
    &#x2013; &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_zRrLK59srKM8" title="Exercise Price per Share Exercisable Ending"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsYGLZUmR1yd" title="Weighted Average Remaining Contractual Life Ending"&gt;1.40&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfJdXhguTDbc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price per Share Exercisable Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001816"
      unitRef="Shares">535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001818"
      unitRef="USDPShares">1.25</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001820"
      unitRef="USDPShares">2.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001822">P4Y7M2D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001824"
      unitRef="USDPShares">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001834"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <LFMD:ShareBasedCompensationExercisePricePerShareForfeited
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001836"
      unitRef="Shares">2.00</LFMD:ShareBasedCompensationExercisePricePerShareForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001838"
      unitRef="USDPShares">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001840"
      unitRef="Shares">485000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001842"
      unitRef="USDPShares">1.25</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001844"
      unitRef="USDPShares">2.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001846">P4Y1M17D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001848"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001854"
      unitRef="Shares">395000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001856"
      unitRef="USDPShares">1.50</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001858"
      unitRef="USDPShares">2.00</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsInExercisedWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001860">P3Y3M21D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsInExercisedWeightedAverageContractualLife>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001862"
      unitRef="USDPShares">1.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001868"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001870"
      unitRef="USDPShares">1.25</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001872"
      unitRef="USDPShares">2.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001874">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001876"
      unitRef="USDPShares">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001878"
      unitRef="Shares">420000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001880"
      unitRef="USDPShares">1.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001882"
      unitRef="USDPShares">2.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001884">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001886"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001888"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001890"
      unitRef="USDPShares">1.75</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001892"
      unitRef="USDPShares">2.50</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      id="Fact001894">P1Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001896"
      unitRef="USDPShares">2.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="Fact001897"
      unitRef="USD">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001899"
      unitRef="Shares">370000</LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001901"
      unitRef="Shares">315694</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash
      contextRef="From2024-01-012024-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001903"
      unitRef="Shares">25000</LFMD:StockIssuedDuringPeriodSharesStockOptionsExercisedOnCash>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandTwentyPlanMember"
      id="Fact001905">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zevMYGJZdx15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding RSUs and RSAs activity under our Amended 2020 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zN7J3Qd2JGKk" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;RSUs and RSAs Outstanding&lt;br/&gt; Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z2OeT7DJNzqb" style="width: 16%; text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;1,028,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z79UtHLteEm3" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;3,625,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zZU6Na0mhjT1" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(674,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_z7DBcCPfdgIb" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(785,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zoz7KmTS1Ahd" style="text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;3,194,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zHVKMVzlAIcd" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;1,759,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zjBbO1OW02tj" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(1,454,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zbuOMjvNwY57" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(450,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyPlanMember_zSKzuMzGYKQ" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU Outstanding Number of Shares, Ending"&gt;3,049,944&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001907"
      unitRef="Shares">1028250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001909"
      unitRef="Shares">3625750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001911"
      unitRef="Shares">674625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001913"
      unitRef="Shares">785000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">3194375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001917"
      unitRef="Shares">1759767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001919"
      unitRef="Shares">1454198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001921"
      unitRef="Shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001923"
      unitRef="Shares">3049944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001925"
      unitRef="Shares">1759767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOfValue
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001927"
      unitRef="USD">12300000</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodOfValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001929"
      unitRef="USD">9900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001931"
      unitRef="USD">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <LFMD:UnamortizedExpense
      contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="-5"
      id="Fact001933"
      unitRef="USD">7100000</LFMD:UnamortizedExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001935"
      unitRef="Shares">1454198</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember_custom_TwoThousandTwentyPlanMember"
      decimals="INF"
      id="Fact001937"
      unitRef="Shares">1359960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001939">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQoNVShTyuZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding RSUs and RSAs activity (outside of our Amended 2020 Plan):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zQ55D4XKLRo8" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;RSUs and RSAs&lt;/b&gt;&lt;b&gt; Outstanding&lt;br/&gt; Number
    of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zbajta5hjzS6" style="width: 16%; text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;715,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_ziX7oTXffBxl" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;725,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zv3TfGBkXpTd" style="text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(390,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zA3y39gFYFT3" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Forfeited"&gt;(500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zRa0KIrcIlv4" style="text-align: right" title="RSU Outstanding Number of Shares, Beginning"&gt;550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zspmYLI54pR3" style="text-align: right" title="RSU Outstanding Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1951"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_z6lbIxQvGina" style="border-bottom: Black 1pt solid; text-align: right" title="RSU Outstanding Number of Shares, Vested"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsAndRestrictedStockAwardsMember_zaxNZMrda2v7" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU Outstanding Number of Shares, Ending"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001941"
      unitRef="Shares">715000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001943"
      unitRef="Shares">725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001945"
      unitRef="Shares">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001947"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001949"
      unitRef="Shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001953"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001955"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="-3"
      id="Fact001957"
      unitRef="USD">809000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="-3"
      id="Fact001959"
      unitRef="USD">885000</us-gaap:AllocatedShareBasedCompensationExpense>
    <LFMD:UnamortizedExpense
      contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="0"
      id="Fact001961"
      unitRef="USD">0</LFMD:UnamortizedExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001963"
      unitRef="Shares">250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockUnitsAndRestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001965"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001967">&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z4Nclr5xRYKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of outstanding and exercisable warrant activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BF_ziuq1gnvjXI7" style="display: none"&gt;SCHEDULE
OF WARRANT OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 Outstanding&lt;br/&gt; Number of&lt;br/&gt;
 Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt;
 Life&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt; Exercise Price&lt;br/&gt;
 per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNXihH1Hg11l" style="width: 12%; text-align: right" title="Outstanding number of shares, beginning balance"&gt;3,859,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z7kOKgmboPsd" title="Exercise price per share"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIkR2mczTX0f" title="Exercise price per share"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDPU0R5iPucl" title="Weighted average remaining contractual life beginning"&gt;4.89&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5bgGQbaOuJl" style="width: 12%; text-align: right" title="Weighted average exercise price per share beginning"&gt;5.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuSEj5TbRQ76" style="text-align: right" title="Outstanding number of shares, granted"&gt;967,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQBOInZWOyx9" title="Exercise price per share, exercised"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedNonOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv1iUFOZz6Vc" title="Weighted average remaining contractual life, granted"&gt;4.22&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zexynFCqryX6" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIKbmQ7yAZQ7" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(96,773&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXxEi2eZ0fd1" title="Exercise price per share, exercised"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrvuH4RRieN7" title="Weighted average remaining contractual life, exercised"&gt;4.22&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGAfMHOtgZzk" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHDOPxZ84zH8" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding number of shares, cancelled/forfeited/expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1995"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBHbpjT1eze" style="text-align: right" title="Outstanding number of shares, beginning balance"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zKl3ikP2xR34" title="Exercise price per share, ending balance"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z1surV1LHS8h" title="Exercise price per share, ending balance"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AJg04gYGB7" title="Weighted average remaining contractual life beginning"&gt;3.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfaLejhUqOjg" style="text-align: right" title="Weighted average exercise price per share beginning"&gt;4.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPbIno2o9gq6" style="text-align: right" title="Outstanding number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2007"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlaJ4ioSGff5" title="Exercise price per share, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2009"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSygIpTtKh05" style="text-align: right" title="Outstanding number of shares, exercised"&gt;(2,986,877&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_znDc83Fv0sA3" title="Exercise price per share, exercised"&gt;1.40&lt;/span&gt; &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvlOfk67VGg7" title="Exercise price per share, exercised"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sfZfp1dLz2" title="Weighted average remaining contractual life, exercised"&gt;3.13&lt;/span&gt; years &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfBTvmVu0JWl" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;4.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEnvPl9NnAIh" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding number of shares, cancelled/forfeited/expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqD1sIIHjV4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding number of shares, ending balance"&gt;1,743,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWItD5jFS3Mk" title="Exercise price per share"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zFWrlBQM4pT9" title="Exercise price per share"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwusgWON7j0f" title="Weighted average remaining contractual life ending"&gt;2.66&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP3KjbixeFag" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price per share beginning"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIZePJy6oSB7" style="text-align: right" title="Outstanding number of shares, exercisable, ending"&gt;4,730,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zp09eoB3dkD" title="Exercise price per share, exercisable, ending"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYzFJx5zCYec" title="Exercise price per share, exercisable, ending"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0osIOvb4w7h" title="Weighted average remaining contractual life, exercisable"&gt;3.95&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbyt0BsCcUC2" style="text-align: right" title="Weighted average exercise price per share exercisable ending"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zocojXGXzXj8" style="text-align: right" title="Outstanding number of shares, exercisable, ending"&gt;1,743,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zgRUc5KKk0Di" title="Exercise price per share, exercisable, ending"&gt;1.24&lt;/span&gt; &#x2013; &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9xWJcFhRAZk" title="Exercise price per share, exercisable, ending"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zb8zq3VLV3Hk" title="Weighted average remaining contractual life, exercisable"&gt;2.66&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcMOTMnD3uCe" style="text-align: right" title="Weighted average exercise price per share exercisable ending"&gt;4.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001969"
      unitRef="Shares">3859638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001971"
      unitRef="USDPShares">1.40</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001973"
      unitRef="USDPShares">12.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="Fact001975">P4Y10M20D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001977"
      unitRef="USDPShares">5.60</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001979"
      unitRef="Shares">967742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001981"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedNonOptionsWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      id="Fact001983">P4Y2M19D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedNonOptionsWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001985"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001987"
      unitRef="Shares">96773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001989"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      id="Fact001991">P4Y2M19D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      decimals="INF"
      id="Fact001993"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001997"
      unitRef="Shares">4730607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001999"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002001"
      unitRef="USDPShares">12.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      id="Fact002003">P3Y11M12D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002005"
      unitRef="USDPShares">4.81</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      decimals="INF"
      id="Fact002011"
      unitRef="Shares">2986877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002013"
      unitRef="USDPShares">1.40</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002015"
      unitRef="USDPShares">5.75</LFMD:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="Fact002017">P3Y1M17D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedExpiredWeightedAverageRemainingContractualTerms>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      decimals="INF"
      id="Fact002019"
      unitRef="USDPShares">4.90</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002023"
      unitRef="Shares">1743730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002027"
      unitRef="USDPShares">12.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="Fact002029">P2Y7M28D</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageContractualLife>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002031"
      unitRef="USDPShares">4.65</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002033"
      unitRef="Shares">4730607</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002035"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002037"
      unitRef="USDPShares">12.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice>
    <LFMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember18578218"
      id="Fact002039">P3Y11M12D</LFMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002041"
      unitRef="USDPShares">4.80</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002043"
      unitRef="Shares">1743730</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableNumber>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002045"
      unitRef="USDPShares">1.24</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002047"
      unitRef="USDPShares">12.00</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableExercisePrice>
    <LFMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      id="Fact002049">P2Y7M28D</LFMD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002051"
      unitRef="USDPShares">4.63</LFMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact002053"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact002055"
      unitRef="USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <LFMD:AvenueExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      decimals="INF"
      id="Fact002057"
      unitRef="Shares">2986877</LFMD:AvenueExercised>
    <LFMD:AvenueWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember18577125"
      decimals="INF"
      id="Fact002059"
      unitRef="Shares">1630458</LFMD:AvenueWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact002061"
      unitRef="USD">4100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_WarrantAndRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact002063"
      unitRef="USD">12200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_WarrantAndRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact002065"
      unitRef="USD">12500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <LFMD:UnamortizedExpenses
      contextRef="From2024-01-012024-12-31_custom_WarrantAndRestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact002067"
      unitRef="USD">7100000</LFMD:UnamortizedExpenses>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002069">&lt;p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_ztWIGoYEotFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82B_zqZ5fwUFvfHk"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office space domestically under operating leases including: (1) the Company&#x2019;s headquarters in New York, New York
for which the lease expires in 2028, (2) a marketing and sales center in Huntington Beach, California for which the lease expires in
2027, (3) a patient care center in Greenville, South Carolina for which the lease expires in 2031, with an additional five year option
to extend, for which the Company expects to utilize, (4) warehouse and fulfillment centers in Columbia, Pennsylvania and Lancaster, Pennsylvania
for which the leases expired in 2024 and (5) a warehouse and pharmacy operations center in Lancaster, Pennsylvania for which the lease
expires in 2029, with an additional five year option to extend, for which the Company expects to utilize. WorkSimpli leases two office
spaces in Puerto Rico for which the leases expire in 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfOperatingRightOfUseAssetTableTextBlock_zNZHukDE8Gld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s operating right-of-use assets and operating lease liabilities as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zYXwFzgn5rwa" style="display: none"&gt;SCHEDULE
OF OPERATING RIGHT OF USE OF ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20241231_zgfnQf9spfEe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zJNzmtO6wGU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,400,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_z0GoYGRprHb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;508,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z22AgLMoG1l9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,265,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z9LPvtgQncP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkbmlCoU8s7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below reconciles the undiscounted future minimum lease payments under the above noted operating leases to the total operating lease
liabilities recognized on the consolidated balance sheet as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zpOChVoSSJW9" style="display: none"&gt;SCHEDULE
OF MATURITY OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20241231_zcB7eCmDMgeb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzduk_zSPamRjUKKU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Fiscal year 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,109,302&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzduk_zHoOykOx9SL1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,339,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzduk_znqNqA4zqwk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,231,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLLzduk_zzFBXelykeil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;931,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maOLLzduk_z0DbgVWg8Qr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;772,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzduk_zXkjV7WzdG83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,676,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzduk_zafQkjhlcPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,288,168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzduk_zXCxm0owCqC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,773,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zXHQHrxgcZZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease expenses were $&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231_zlEuIgGihmJl" title="Operating lease expenses"&gt;1.2&lt;/span&gt; million and $&lt;span id="xdx_909_eus-gaap--OperatingLeaseExpense_pn3n3_c20230101__20231231_zkNJUBKWsDLa" title="Operating lease expenses"&gt;861&lt;/span&gt; thousand for the years ended December 31, 2024 and 2023, respectively, and were included in
other operating expenses in our consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfCashFlowSupplementalInformationrelatedToOperatingLeaseLiabilitiesTableTextBlock_zddGePJ9dQWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to operating lease liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zsd9W1Mt406" style="display: none"&gt;SCHEDULE
OF CASH FLOW INFORMATION RELATED TO OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash paid for operating lease liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeasePayments_c20240101__20241231_zn0p7bNuX5n7" style="width: 16%; text-align: right" title="Cash paid for operating lease liabilities"&gt;831,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeasePayments_c20230101__20231231_z1ohc59Wer8l" style="width: 16%; text-align: right" title="Cash paid for operating lease liabilities"&gt;897,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zcKBnJb7TbDf" title="Weighted average remaining lease term in years"&gt;10.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zcyKHQXwlTH6" title="Weighted average remaining lease term in years"&gt;2.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_z0q8CbenZmgl" style="text-align: right" title="Weighted average discount rate"&gt;10.96&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zbNtK9wFcX6b" style="text-align: right" title="Weighted average discount rate"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zYxPy1cRCz22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have elected to apply the short-term lease exception to the warehouse and fulfillment center spaces we leased in Columbia, Pennsylvania
and Lancaster, Pennsylvania for which the leases expired in 2024. These leases had a term of less than &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20241231_zDfflxCYTfu3" title="Lessee, operating lease, term of contract"&gt;12&lt;/span&gt; months and were not recognized
on the balance sheet, but rather expensed on a straight-line basis over the lease term. Straight-line lease payments are approximately
$&lt;span id="xdx_90C_eus-gaap--ShortTermLeasePayments_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__country--CO_z61PVAgNPkji" title="Short term lease payments"&gt;2&lt;/span&gt; thousand and $&lt;span id="xdx_90D_eus-gaap--ShortTermLeasePayments_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__custom--LancasterMember_zYW9by0C4TC5" title="Short term lease payments"&gt;3&lt;/span&gt; thousand per month, for Columbia, Pennsylvania and Lancaster, Pennsylvania, respectively. Additionally, the Company
utilizes office space in Puerto Rico on a month-to-month basis incurring rental expense of approximately $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pn3n3_c20240101__20241231_zmwEAkHtTjc3" title="Payments for rent"&gt;3&lt;/span&gt; thousand per month.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <LFMD:ScheduleOfOperatingRightOfUseAssetTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002071">&lt;p id="xdx_896_ecustom--ScheduleOfOperatingRightOfUseAssetTableTextBlock_zNZHukDE8Gld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s operating right-of-use assets and operating lease liabilities as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zYXwFzgn5rwa" style="display: none"&gt;SCHEDULE
OF OPERATING RIGHT OF USE OF ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20241231_zgfnQf9spfEe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zJNzmtO6wGU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,400,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_z0GoYGRprHb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;508,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z22AgLMoG1l9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,265,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LFMD:ScheduleOfOperatingRightOfUseAssetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002073"
      unitRef="USD">6400596</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002075"
      unitRef="USD">508537</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002077"
      unitRef="USD">6265192</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002079">&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkbmlCoU8s7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below reconciles the undiscounted future minimum lease payments under the above noted operating leases to the total operating lease
liabilities recognized on the consolidated balance sheet as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zpOChVoSSJW9" style="display: none"&gt;SCHEDULE
OF MATURITY OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20241231_zcB7eCmDMgeb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzduk_zSPamRjUKKU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Fiscal year 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,109,302&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzduk_zHoOykOx9SL1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,339,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLLzduk_znqNqA4zqwk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,231,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLLzduk_zzFBXelykeil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;931,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maOLLzduk_z0DbgVWg8Qr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal year 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;772,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maOLLzduk_zXkjV7WzdG83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,676,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_maOLLzduk_zafQkjhlcPbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,288,168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzduk_zXCxm0owCqC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,773,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002081"
      unitRef="USD">1109302</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002083"
      unitRef="USD">1339435</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002085"
      unitRef="USD">1231623</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002087"
      unitRef="USD">931879</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002089"
      unitRef="USD">772833</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002091"
      unitRef="USD">5676825</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002093"
      unitRef="USD">-4288168</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002095"
      unitRef="USD">6773729</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact002097"
      unitRef="USD">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002099"
      unitRef="USD">861000</us-gaap:OperatingLeaseExpense>
    <LFMD:ScheduleOfCashFlowSupplementalInformationrelatedToOperatingLeaseLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002101">&lt;p id="xdx_890_ecustom--ScheduleOfCashFlowSupplementalInformationrelatedToOperatingLeaseLiabilitiesTableTextBlock_zddGePJ9dQWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to operating lease liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zsd9W1Mt406" style="display: none"&gt;SCHEDULE
OF CASH FLOW INFORMATION RELATED TO OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash paid for operating lease liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeasePayments_c20240101__20241231_zn0p7bNuX5n7" style="width: 16%; text-align: right" title="Cash paid for operating lease liabilities"&gt;831,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeasePayments_c20230101__20231231_z1ohc59Wer8l" style="width: 16%; text-align: right" title="Cash paid for operating lease liabilities"&gt;897,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zcKBnJb7TbDf" title="Weighted average remaining lease term in years"&gt;10.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zcyKHQXwlTH6" title="Weighted average remaining lease term in years"&gt;2.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_z0q8CbenZmgl" style="text-align: right" title="Weighted average discount rate"&gt;10.96&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zbNtK9wFcX6b" style="text-align: right" title="Weighted average discount rate"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LFMD:ScheduleOfCashFlowSupplementalInformationrelatedToOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002103"
      unitRef="USD">831260</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002105"
      unitRef="USD">897883</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact002107">P10Y4M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact002109">P2Y2M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002111"
      unitRef="Pure">0.1096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002113"
      unitRef="Pure">0.0717</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2024-12-31" id="Fact002115">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2024-01-012024-12-31_country_CO"
      decimals="-3"
      id="Fact002117"
      unitRef="USD">2000</us-gaap:ShortTermLeasePayments>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2024-01-012024-12-31_custom_LancasterMember"
      decimals="-3"
      id="Fact002119"
      unitRef="USD">3000</us-gaap:ShortTermLeasePayments>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002121"
      unitRef="USD">3000</us-gaap:PaymentsForRent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002123">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwE26BYZZkzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_825_zwRk0MKD3Eke"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Royalty
Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2016, Conversion Labs PR entered into a sole and exclusive license, royalty and advisory agreement with Pilaris Laboratories, LLC (&#x201c;Pilaris&#x201d;)
relating to Pilaris&#x2019; PilarisMax shampoo formulation and conditioner. The term of the agreement will be the life of the US Patent
held by Pilaris, &lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20161231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zRInRIQMOCy4" title="Finite-lived intangible asset, useful life"&gt;ten years&lt;/span&gt;. &lt;span id="xdx_902_eus-gaap--IntercompanyAgreementsDescription_c20160101__20161231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zz5vzlmUifV" title="Intercompany agreements, description"&gt;As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, &lt;span id="xdx_906_eus-gaap--PremiumsPercentageAssumedToNet_pid_dp_uPure_c20160101__20161231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_z0grtUcyvKp4" title="Percentage of net income"&gt;10&lt;/span&gt;%
of the net income collected by the licensed products based on the following formula: Net Income = total income &#x2013; cost of goods
sold &#x2013; advertising and operating expenses directly related to the marketing of the licensed products.&lt;/span&gt; As of December 31, 2024 and
2023, approximately $&lt;span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zHbRQKKxGRIh" title="Accrued expenses"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_c20231231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zcAhazR7EtC3" title="Accrued expenses"&gt;5&lt;/span&gt; thousand, respectively, was included in accrued expenses in regard to this agreement. The Company paid
Pilaris approximately $&lt;span id="xdx_90A_ecustom--PaymentForAgreement_pn3n3_c20240101__20241231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zrsRipVjIeOe" title="Payment for agreement"&gt;5&lt;/span&gt; thousand and $&lt;span id="xdx_906_ecustom--PaymentForAgreement_pn3n3_c20230101__20231231__dei--LegalEntityAxis__custom--PilarisLaboratoriesLLCMember_zOGXeu5jYWr" title="Payment for agreement"&gt;138&lt;/span&gt; thousand during the years ended December 31, 2024 and 2023, respectively, in regard to this
agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2018, the Company entered into a license agreement (the &#x201c;Alphabet Agreement&#x201d;) with M.ALPHABET, LLC (&#x201c;Alphabet&#x201d;),
pursuant to which Alphabet agreed to license its PURPUREX business which consists of methods and compositions developed by Alphabet for
the treatment of purpura, bruising, post-procedural bruising, and traumatic bruising (the &#x201c;Product Line&#x201d;). Pursuant to the
license granted under the Alphabet Agreement, Conversion Labs PR obtains an exclusive license to incorporate (i) any intellectual property
rights related to the Product Line and (ii) all designs, drawings, formulas, chemical compositions and specifications used or useable
in the Product Line into one or more products manufactured, sold, and/or distributed by Alphabet for the treatment of purpura, bruising,
post-procedural bruising and traumatic bruising and for all other fields of use or purposes (the &#x201c;Licensed Product(s)&#x201d;),
and to make, have made, advertise, promote, market, sell, import, export, use, offer to sell, and distribute the Licensed Product(s)
throughout the world with the exception of China, Hong Kong, Japan, and Australia (the &#x201c;License&#x201d;). &lt;span id="xdx_90F_eus-gaap--IntercompanyAgreementsDescription_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember_zIHIaAl6rkE7" title="Intercompany agreements, description"&gt;The Company shall pay
Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts
were earned or owed as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
execution of the Alphabet Agreement, Alphabet was granted a &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember_zBu1f9YVxBB8" title="Share based compensation arrangement by share based payment award, expiration period"&gt;10&lt;/span&gt;-year stock option to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember_zY8T3kZzRkHe" title="Stock option to purchase shares"&gt;20,000&lt;/span&gt; shares of the Company&#x2019;s common
stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember_zh9yxbVtobw7" title="Stock option exercise price"&gt;2.50&lt;/span&gt;. Further, if Licensed Products have gross receipts of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zM1R7eZlHJzl" title="Proceeds from issuance of common stock"&gt;7.5&lt;/span&gt; million in any calendar year, the Company
will grant Alphabet an option to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zrmUNEHdY7zc" title="Stock option to purchase shares"&gt;20,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zsfoKCA22Ayd" title="Stock option exercise price"&gt;2.50&lt;/span&gt;; (ii) if Licensed
Products have gross receipts of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zzHmtZBw4FA" title="Proceeds from issuance of common stock"&gt;10.0&lt;/span&gt; million in any calendar year, the Company will grant Alphabet an additional option to purchase
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zUy5SEmQzirg" title="Stock option to purchase shares"&gt;20,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zyEulea8lmj" title="Stock option exercise price"&gt;2.50&lt;/span&gt; and (iii) if Licensed Products have gross receipts of
$&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zi5Qthubz5c6" title="Proceeds from issuance of common stock"&gt;20.0&lt;/span&gt; million in any calendar year, the Company will grant Alphabet an option to purchase &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zZyM9AVIzj66" title="Stock option to purchase shares"&gt;40,000&lt;/span&gt; shares of the Company&#x2019;s common
stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180101__20181231__dei--LegalEntityAxis__custom--MALPHABETLLCMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zZZvzSjpNUAh" title="Stock option exercise price"&gt;3.75&lt;/span&gt;. The likelihood of meeting these performance goals for the licensed products are remote and, therefore,
the Company has not recognized any compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Purchase
Commitments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Many
of the Company&#x2019;s vendors require product deposits when a purchase order is placed for goods or fulfillment services related to
inventory requirements. The Company&#x2019;s history of product deposits with its inventory vendors, creates an implicit purchase commitment
equaling the total expected product acceptance cost in excess of the product deposit. As of December 31, 2024, the Company approximates
its implicit purchase commitments to be approximately $&lt;span id="xdx_90B_eus-gaap--PurchaseObligation_iI_pn3n3_c20241231_zbPOlQpHEu0l" title="Purchase obligation"&gt;479&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Matters&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the normal course of business operations, the Company may become involved in various legal matters. As of December 31, 2024, other than
as set forth below, the Company&#x2019;s management does not believe that there are any potential legal matters that could have an adverse
effect on the Company&#x2019;s consolidated financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
August 23, 2023, a purported putative class action complaint captioned Marden v. LifeMD, Inc., Case No. 23-cv-07469, was filed in the
United States District Court for the Southern District of New York (the &#x201c;Marden Complaint&#x201d;) against the Company&#x2019;s RexMD
brand. The Marden Complaint alleges, inter alia, unauthorized disclosure of certain information of class members to third parties. On
November 21, 2023, the plaintiffs amended the Marden Complaint. On March 4, 2024, the Company moved to dismiss the Marden Complaint,
and that motion is pending. On July 12, 2024, the parties attended a mediation. On November 1, 2024, the plaintiffs filed a notice of
voluntary dismissal of the Southern District of New York case. On November 25, 2024, the plaintiffs refiled the case via a new complaint
captioned W.M.F. &amp;amp; Matthew Marden v. LifeMD, Inc., Case No. A-24-906800-C, in the District Court of Clark County, Nevada. The results
of legal proceedings are inherently uncertain, and the best estimate of cost is reflected in the Company&#x2019;s financial results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 5, 2023, the Internal Revenue Service (the &#x201c;IRS&#x201d;) issued a notice of deficiency to the Company in which the IRS
asserted an income tax deficiency of approximately $&lt;span id="xdx_90F_eus-gaap--IncreaseDecreaseInIncomeTaxes_pn5n6_c20230905__20230905_zFSizOSkH7o1" title="Income tax deficiency"&gt;1.9&lt;/span&gt; million for the Company&#x2019;s tax year ending December 31, 2019. The Company
timely filed a petition in the United States Tax Court disputing all of the proposed tax deficiency. The case was subsequently transferred
to the Appeals Division of the IRS. Upon review of the amended return, IRS Appeals agreed to accept the amended return as filed, which
resolves all of the issues asserted in the notice of deficiency. The Company is in the process of finalizing the steps with the IRS to
agree upon a decision document that will be filed by the Tax Court and will resolve all issues in the case in the Company&#x2019;s favor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2016-12-31_custom_PilarisLaboratoriesLLCMember"
      id="Fact002125">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntercompanyAgreementsDescription
      contextRef="From2016-01-012016-12-31_custom_PilarisLaboratoriesLLCMember"
      id="Fact002127">As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10%
of the net income collected by the licensed products based on the following formula: Net Income = total income &#x2013; cost of goods
sold &#x2013; advertising and operating expenses directly related to the marketing of the licensed products.</us-gaap:IntercompanyAgreementsDescription>
    <us-gaap:PremiumsPercentageAssumedToNet
      contextRef="From2016-01-012016-12-31_custom_PilarisLaboratoriesLLCMember"
      decimals="INF"
      id="Fact002129"
      unitRef="Pure">0.10</us-gaap:PremiumsPercentageAssumedToNet>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_PilarisLaboratoriesLLCMember"
      decimals="-3"
      id="Fact002131"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_PilarisLaboratoriesLLCMember"
      decimals="-3"
      id="Fact002133"
      unitRef="USD">5000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <LFMD:PaymentForAgreement
      contextRef="From2024-01-012024-12-31_custom_PilarisLaboratoriesLLCMember"
      decimals="-3"
      id="Fact002135"
      unitRef="USD">5000</LFMD:PaymentForAgreement>
    <LFMD:PaymentForAgreement
      contextRef="From2023-01-012023-12-31_custom_PilarisLaboratoriesLLCMember"
      decimals="-3"
      id="Fact002137"
      unitRef="USD">138000</LFMD:PaymentForAgreement>
    <us-gaap:IntercompanyAgreementsDescription
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember"
      id="Fact002139">The Company shall pay
Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts
were earned or owed as of December 31, 2024.</us-gaap:IntercompanyAgreementsDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember"
      id="Fact002141">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember"
      decimals="INF"
      id="Fact002143"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember"
      decimals="INF"
      id="Fact002145"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockOneMember"
      decimals="-5"
      id="Fact002147"
      unitRef="USD">7500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockOneMember"
      decimals="INF"
      id="Fact002149"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockOneMember"
      decimals="INF"
      id="Fact002151"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockTwoMember"
      decimals="-5"
      id="Fact002153"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockTwoMember"
      decimals="INF"
      id="Fact002155"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockTwoMember"
      decimals="INF"
      id="Fact002157"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockThreeMember"
      decimals="-5"
      id="Fact002159"
      unitRef="USD">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockThreeMember"
      decimals="INF"
      id="Fact002161"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2018-01-012018-12-31_custom_MALPHABETLLCMember_custom_CommonStockThreeMember"
      decimals="INF"
      id="Fact002163"
      unitRef="USDPShares">3.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002165"
      unitRef="USD">479000</us-gaap:PurchaseObligation>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="From2023-09-052023-09-05"
      decimals="-5"
      id="Fact002167"
      unitRef="USD">1900000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002169">&lt;p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ztopmbZkdaW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_82F_zf3XooSC6oJb"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;WorkSimpli
Software&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company utilized CloudBoson Technologies Pvt. Ltd. (&#x201c;CloudBoson&#x201d;), formerly
LegalSubmit Pvt. Ltd. (&#x201c;LegalSubmit&#x201d;), a company owned by WorkSimpli&#x2019;s Chief Software Engineer, to provide software
development services. The Company paid CloudBoson a total of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__custom--SoftwareDevelopmentServicesMember__us-gaap--RelatedPartyTransactionAxis__custom--WorkSimpliSoftwareMember_z1u1h3vfsLOf" title="Stock issued"&gt;3.6&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__custom--SoftwareDevelopmentServicesMember__us-gaap--RelatedPartyTransactionAxis__custom--WorkSimpliSoftwareMember_zobBiiG6WuSk" title="Stock issued"&gt;2.5&lt;/span&gt; million during the years ended December 31, 2024 and
2023, respectively, for these services. The Company owed CloudBoson $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--WorkSimpliSoftwareMember_z8QNaJd0MSK9" title="Stock issued"&gt;56&lt;/span&gt; thousand and $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--WorkSimpliSoftwareMember_zPmyzmHAetmj" title="Stock issued"&gt;226&lt;/span&gt; thousand as of December 31, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company utilized King &amp;amp; Spalding LLP (&#x201c;King &amp;amp; Spalding&#x201d;), a large
international law firm, for which an immediate family member of Robert Jindal, one of the Company&#x2019;s former directors, is the Company&#x2019;s
relationship partner, to provide legal services. The Company paid King &amp;amp; Spalding a total of approximately $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__custom--LegalServicesMember__us-gaap--RelatedPartyTransactionAxis__custom--KingAndSpaldingLLPMember_z2UNJ2d7diV7" title="Stock issued"&gt;830&lt;/span&gt; thousand and $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__custom--LegalServicesMember__us-gaap--RelatedPartyTransactionAxis__custom--KingAndSpaldingLLPMember_zcaFJwV480X1" title="Stock issued"&gt;12&lt;/span&gt;
thousand during the years ended December 31, 2024 and 2023, respectively. The Company owed King &amp;amp; Spalding $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--KingAndSpaldingLLPMember_ztu36WdfKnm6" title="Stock issued"&gt;0&lt;/span&gt; as of December 31,
2024 and $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--KingAndSpaldingLLPMember_zPw6BWe3NlKc" title="Stock issued"&gt;48&lt;/span&gt; thousand as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Director
Consulting Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30, 2023, Will Febbo, a member of the Board of the Company, entered into a consulting services agreement with the Company, pursuant
to which he provides certain investor relations and strategic business development services, in consideration for &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230530__20230530__srt--TitleOfIndividualAxis__custom--WillFebboMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zNxoXvPIogSi" title="Number of restricted shares"&gt;375,000&lt;/span&gt; restricted
shares of the Company&#x2019;s common stock, which vested in quarterly installments from August 30, 2023 through November 30, 2024. The
Company issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20241231__srt--TitleOfIndividualAxis__custom--WillFebboMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zCxIw5a9o2La" title="Number of restricted shares"&gt;250,000&lt;/span&gt; restricted shares of common stock, with a fair value of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--WillFebboMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zbF77muU8xv6" title="Number of restricted shares, value"&gt;525&lt;/span&gt; thousand, related to this agreement during the year
ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 14, 2023, Robert Jindal, a former member of the Board of the Company, entered into a consulting services agreement (the &#x201c;Jindal
Consulting Agreement&#x201d;) with the Company, pursuant to which Mr. Jindal provides certain investor relations and strategic business
development services, in consideration for &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230614__20230614__srt--TitleOfIndividualAxis__custom--RobertJindalMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zSkaBDTe1XEe" title="Number of restricted shares"&gt;225,000&lt;/span&gt; restricted shares of the Company&#x2019;s common stock, which vested in six-month installments
from June 14, 2023 through December 31, 2024. The Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20241231__srt--TitleOfIndividualAxis__custom--RobertJindalMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zBJf2m24qy11" title="Nuimber of restricted shares"&gt;112,500&lt;/span&gt; restricted shares of common stock, with a fair value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--RobertJindalMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zuuLg6mSKkV" title="Nuimber of restricted shares, value"&gt;335&lt;/span&gt;
thousand, related to the Jindal Consulting Agreement during the year ended December 31, 2024. On July 17, 2024, Mr. Jindal entered into
the First Amendment to the Jindal Consulting Services Agreement with the Company (the &#x201c;Jindal First Amendment&#x201d;), pursuant
to which the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240717__20240717__srt--TitleOfIndividualAxis__custom--NaveenBhatiaMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zSkPqmwxbHBj" title="Number of restricted shares"&gt;24,835&lt;/span&gt; restricted shares of common stock, with a fair value of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240717__20240717__srt--TitleOfIndividualAxis__custom--NaveenBhatiaMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zsCKfSXJSCNc" title="Number of restricted shares, value"&gt;168&lt;/span&gt; thousand, all of which vested on September
14, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 14, 2023, Naveen Bhatia, a former member of the Board of the Company, entered into a consulting services agreement with the Company,
pursuant to which Mr. Bhatia provides certain investor relations and strategic business development services, in consideration for &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240614__20240614__srt--TitleOfIndividualAxis__custom--NaveenBhatiaMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_z2vfvcKH6dfl" title="Nuimber of restricted shares"&gt;225,000&lt;/span&gt;
restricted shares of the Company&#x2019;s common stock, which vested in six-month installments from June 14, 2023 through December 31,
2024. The Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NaveenBhatiaMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_zViLkltlUwn3" title="Nuimber of restricted shares"&gt;56,250&lt;/span&gt; restricted shares of common stock, with a fair value of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NaveenBhatiaMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingServicesAgreementMember_z4sXzASEBZCh" title="Nuimber of restricted shares, value"&gt;168&lt;/span&gt; thousand, related to this agreement during
the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amended
Employment Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
May 1, 2024, Brian Schreiber, Logistics &amp;amp; Fulfillment Advisor, and a relative of the Company&#x2019;s Chief Executive Officer, entered
into an amended employment agreement. Mr. Schreiber&#x2019;s compensation package was adjusted to reflect the increased scope of his responsibilities.
The compensation adjustment, approved by the Compensation Committee of the Board, includes a base salary increase to $&lt;span id="xdx_90E_eus-gaap--SalariesAndWages_pn3n3_c20240501__20240501_zM3mdA3KssUh" title="Salary"&gt;240&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patient
Care Director&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stacey
Roberts, spouse of former Chief Operating Officer, Brad Roberts, was previously employed by the Company as Patient Care Director. The
Company paid Ms. Roberts a total of approximately $&lt;span id="xdx_90C_eus-gaap--PostemploymentBenefitsPeriodExpense_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StaceyRobertsMember_ztIlfYR5ocl3" title="Postemployment benefits"&gt;85&lt;/span&gt; thousand and $&lt;span id="xdx_904_eus-gaap--PostemploymentBenefitsPeriodExpense_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StaceyRobertsMember_zvjtxuzSb1Yh" title="Postemployment benefits"&gt;117&lt;/span&gt; thousand during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_SoftwareDevelopmentServicesMember_custom_WorkSimpliSoftwareMember"
      decimals="-5"
      id="Fact002171"
      unitRef="USD">3600000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_SoftwareDevelopmentServicesMember_custom_WorkSimpliSoftwareMember"
      decimals="-5"
      id="Fact002173"
      unitRef="USD">2500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliSoftwareMember"
      decimals="-3"
      id="Fact002175"
      unitRef="USD">56000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliSoftwareMember"
      decimals="-3"
      id="Fact002177"
      unitRef="USD">226000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_LegalServicesMember_custom_KingAndSpaldingLLPMember"
      decimals="-3"
      id="Fact002179"
      unitRef="USD">830000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_LegalServicesMember_custom_KingAndSpaldingLLPMember"
      decimals="-3"
      id="Fact002181"
      unitRef="USD">12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_KingAndSpaldingLLPMember"
      decimals="-3"
      id="Fact002183"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_KingAndSpaldingLLPMember"
      decimals="-3"
      id="Fact002185"
      unitRef="USD">48000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-05-302023-05-30_custom_WillFebboMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002187"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_WillFebboMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002189"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_WillFebboMember_custom_ConsultingServicesAgreementMember"
      decimals="-3"
      id="Fact002191"
      unitRef="USD">525000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-06-142023-06-14_custom_RobertJindalMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002193"
      unitRef="Shares">225000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_RobertJindalMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002195"
      unitRef="Shares">112500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_RobertJindalMember_custom_ConsultingServicesAgreementMember"
      decimals="-3"
      id="Fact002197"
      unitRef="USD">335000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-07-172024-07-17_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002199"
      unitRef="Shares">24835</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-172024-07-17_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember"
      decimals="-3"
      id="Fact002201"
      unitRef="USD">168000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-142024-06-14_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002203"
      unitRef="Shares">225000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember"
      decimals="INF"
      id="Fact002205"
      unitRef="Shares">56250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_custom_NaveenBhatiaMember_custom_ConsultingServicesAgreementMember"
      decimals="-3"
      id="Fact002207"
      unitRef="USD">168000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SalariesAndWages
      contextRef="From2024-05-012024-05-01"
      decimals="-3"
      id="Fact002209"
      unitRef="USD">240000</us-gaap:SalariesAndWages>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="From2024-01-012024-12-31_custom_StaceyRobertsMember"
      decimals="-3"
      id="Fact002211"
      unitRef="USD">85000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="From2023-01-012023-12-31_custom_StaceyRobertsMember"
      decimals="-3"
      id="Fact002213"
      unitRef="USD">117000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002215">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zY098zXuBDjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_822_z6phj3Wep4q7"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zmmrpPDHaUF" title="Operating loss carryforwards"&gt;102.8&lt;/span&gt; million of operating loss carryforwards for federal income tax reporting purposes
that may be applied against future taxable income. All remaining net operating loss carryforwards were generated after 2017 and can be
carried forward indefinitely. The net operating loss carryforwards could be subject to limitation in any given year in the event of a
change in ownership as defined by Internal Revenue Code Section 382.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation allowance overall increased by approximately $&lt;span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zme93wapIuFc" title="Valuation allowance increased"&gt;4.8&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_znCWyjPdDCNl" title="Valuation allowance increased"&gt;5.4&lt;/span&gt; million during the years ended December 31, 2024 and 2023,
respectively. The Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zCJkh8IAoYn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision charged to continuing operations for the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z6pRufj8kgt7" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION CHARGES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240101__20241231_zhZGhjo17FTi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230101__20231231_zmxA1sTV1Wq2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zoqfZOwRSxR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzflE_zlGj7jQWVrdk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;144,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzflE_zDjuHRqgjt4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_maCFSALzflE_zwpd8tHqqZ16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;317,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzflE_maITEBzFfO_zPd02odUnsIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zex4UWOoLHc3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzvkn_zixqzicmQNEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzvkn_z3MKG2CzIbMa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2246"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_maDFSALzvkn_zK2kcArN5bBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_mtDFSALzvkn_maITEBzFfO_zneEfgV9xoGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2252"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzFfO_zuwZhmUHGwCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z2NeKNhoGeYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zG5cuWUplWYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
provision for income taxes differs from the expected amount of income tax benefit determined by applying the U.S. federal income tax rate of 21% to pretax income (loss) for the years ended December 31, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BF_zEYojqgWX2bi" style="display: none"&gt;SCHEDULE
OF PROVISION DIFFERS FROM THE AMOUNT OF INCOME TAX&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240101__20241231_zQMKjZ7sbac7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230101__20231231_z9bHQSlOmsS" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExpectedTaxExpenseBenefit_maITEBzcoG_zOhKJ11oGui5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,848,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,951,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Increase (decrease) in income taxes resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzcoG_zOeFtOUqG06l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(397,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(440,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzcoG_znzLT1IJpNu3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome_maITEBzcoG_zg2kUjocG0T" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Apportionment of Puerto Rico income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(133,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzcoG_z000DacH4AFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Nondeductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_maITEBzcoG_ztcIgdmcVih8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;GILTI, net of 250 deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,855,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDeductionsDividends_iN_di_msITEBzcoG_z9MlH8wkCYgj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Dividends received deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,224,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzcoG_zQxdoIZNQGhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,846,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,361,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationRateDifferential_maITEBzcoG_zxrxjbC0SMH4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationDeferredTrueUp_maITEBzcoG_zDPbb58l5Uoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Deferred true up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(515,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzcoG_zXjBxB3U53md" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;155,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(471,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzcoG_zJ6kKJfMyqB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zkWTLHSdncX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zaTE5vcVHPmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
deferred tax liabilities consist of the following components as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BC_zVa8LWm5vVhc" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zt5gD1kctsod" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zNmYGlCXwNGd" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzskU_z98uF2Noh1M" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetSoftwareDevelopment_iI_pp0p0_maDTAGzskU_zXK66SVwvNU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Sec 174 &#x2013; software development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;915,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTAGzskU_z0Ei7RBFnzbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;976,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;521,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pp0p0_maDTAGzskU_zJHPVA1CUas6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,569,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;145,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsDeferredBusinessInterestLimitation_iI_pp0p0_maDTAGzskU_zFyFCl5JGc27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Business interest limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,324,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,044,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzskU_zKq1X3Z6cZ08" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,026,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;957,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzskU_zSrpnXWC42j8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,634,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,057,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzskU_maDTALNzsVA_zu5IFc7UFXP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,425,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,122,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLz7K0_zWtU0LRaUrOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,478,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLz7K0_zGarA9IqxxAf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(181,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLz7K0_msDTALNzsVA_zxEosbZdX3n2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(1,659,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(202,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNTI_pp0p0_di_msDTALNzsVA_zml3XrOzfXk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(45,766,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(40,920,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzsVA_zDThk9J0OA8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2334"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2335"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zKXdAEYNRAJ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact002217"
      unitRef="USD">102800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact002219"
      unitRef="USD">4800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact002221"
      unitRef="USD">5400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002223">&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zCJkh8IAoYn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision charged to continuing operations for the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z6pRufj8kgt7" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION CHARGES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240101__20241231_zhZGhjo17FTi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230101__20231231_zmxA1sTV1Wq2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zoqfZOwRSxR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzflE_zlGj7jQWVrdk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;144,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzflE_zDjuHRqgjt4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_maCFSALzflE_zwpd8tHqqZ16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;317,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzflE_maITEBzFfO_zPd02odUnsIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zex4UWOoLHc3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzvkn_zixqzicmQNEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2244"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzvkn_z3MKG2CzIbMa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2246"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_maDFSALzvkn_zK2kcArN5bBe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_mtDFSALzvkn_maITEBzFfO_zneEfgV9xoGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2252"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzFfO_zuwZhmUHGwCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002228"
      unitRef="USD">144000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002231"
      unitRef="USD">196000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002232"
      unitRef="USD">111000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002234"
      unitRef="USD">62000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002235"
      unitRef="USD">317000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002237"
      unitRef="USD">402000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002238"
      unitRef="USD">428000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002255"
      unitRef="USD">402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002256"
      unitRef="USD">428000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002258">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zG5cuWUplWYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
provision for income taxes differs from the expected amount of income tax benefit determined by applying the U.S. federal income tax rate of 21% to pretax income (loss) for the years ended December 31, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BF_zEYojqgWX2bi" style="display: none"&gt;SCHEDULE
OF PROVISION DIFFERS FROM THE AMOUNT OF INCOME TAX&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240101__20241231_zQMKjZ7sbac7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230101__20231231_z9bHQSlOmsS" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExpectedTaxExpenseBenefit_maITEBzcoG_zOhKJ11oGui5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,848,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,951,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Increase (decrease) in income taxes resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzcoG_zOeFtOUqG06l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(397,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(440,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzcoG_znzLT1IJpNu3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome_maITEBzcoG_zg2kUjocG0T" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Apportionment of Puerto Rico income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(133,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzcoG_z000DacH4AFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Nondeductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2272"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_maITEBzcoG_ztcIgdmcVih8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;GILTI, net of 250 deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,855,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDeductionsDividends_iN_di_msITEBzcoG_z9MlH8wkCYgj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Dividends received deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,224,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzcoG_zQxdoIZNQGhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,846,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,361,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationRateDifferential_maITEBzcoG_zxrxjbC0SMH4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationDeferredTrueUp_maITEBzcoG_zDPbb58l5Uoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Deferred true up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(515,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzcoG_zXjBxB3U53md" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;155,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(471,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzcoG_zJ6kKJfMyqB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;402,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;428,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <LFMD:ExpectedTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002260"
      unitRef="USD">-3848000</LFMD:ExpectedTaxExpenseBenefit>
    <LFMD:ExpectedTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002261"
      unitRef="USD">-1951000</LFMD:ExpectedTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002263"
      unitRef="USD">-397000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002264"
      unitRef="USD">-440000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002266"
      unitRef="USD">56000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002267"
      unitRef="USD">71000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <LFMD:EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002269"
      unitRef="USD">-13000</LFMD:EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome>
    <LFMD:EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002270"
      unitRef="USD">-133000</LFMD:EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002275"
      unitRef="USD">69000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002276"
      unitRef="USD">1855000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:IncomeTaxReconciliationDeductionsDividends
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002279"
      unitRef="USD">1224000</us-gaap:IncomeTaxReconciliationDeductionsDividends>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002281"
      unitRef="USD">4846000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002282"
      unitRef="USD">5361000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <LFMD:IncomeTaxReconciliationRateDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002284"
      unitRef="USD">-108000</LFMD:IncomeTaxReconciliationRateDifferential>
    <LFMD:IncomeTaxReconciliationRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002285"
      unitRef="USD">-2125000</LFMD:IncomeTaxReconciliationRateDifferential>
    <LFMD:IncomeTaxRateReconciliationDeferredTrueUp
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002287"
      unitRef="USD">-358000</LFMD:IncomeTaxRateReconciliationDeferredTrueUp>
    <LFMD:IncomeTaxRateReconciliationDeferredTrueUp
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002288"
      unitRef="USD">-515000</LFMD:IncomeTaxRateReconciliationDeferredTrueUp>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002290"
      unitRef="USD">155000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002291"
      unitRef="USD">-471000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002293"
      unitRef="USD">402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002294"
      unitRef="USD">428000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002296">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zaTE5vcVHPmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
deferred tax liabilities consist of the following components as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BC_zVa8LWm5vVhc" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zt5gD1kctsod" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zNmYGlCXwNGd" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzskU_z98uF2Noh1M" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetSoftwareDevelopment_iI_pp0p0_maDTAGzskU_zXK66SVwvNU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Sec 174 &#x2013; software development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;915,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTAGzskU_z0Ei7RBFnzbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;976,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;521,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pp0p0_maDTAGzskU_zJHPVA1CUas6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,569,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;145,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsDeferredBusinessInterestLimitation_iI_pp0p0_maDTAGzskU_zFyFCl5JGc27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Business interest limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,324,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,044,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzskU_zKq1X3Z6cZ08" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,026,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;957,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzskU_zSrpnXWC42j8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,634,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,057,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzskU_maDTALNzsVA_zu5IFc7UFXP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,425,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,122,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLz7K0_zWtU0LRaUrOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,478,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLz7K0_zGarA9IqxxAf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(181,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLz7K0_msDTALNzsVA_zxEosbZdX3n2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(1,659,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(202,000&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNTI_pp0p0_di_msDTALNzsVA_zml3XrOzfXk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(45,766,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(40,920,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzsVA_zDThk9J0OA8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2334"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2335"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002298"
      unitRef="USD">17981000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002299"
      unitRef="USD">15100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <LFMD:DeferredTaxAssetSoftwareDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002301"
      unitRef="USD">915000</LFMD:DeferredTaxAssetSoftwareDevelopment>
    <LFMD:DeferredTaxAssetSoftwareDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002302"
      unitRef="USD">298000</LFMD:DeferredTaxAssetSoftwareDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002304"
      unitRef="USD">976000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002305"
      unitRef="USD">521000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <LFMD:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002307"
      unitRef="USD">1569000</LFMD:DeferredTaxAssetsOperatingLeaseLiabilities>
    <LFMD:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002308"
      unitRef="USD">145000</LFMD:DeferredTaxAssetsOperatingLeaseLiabilities>
    <LFMD:DeferredTaxAssetsDeferredBusinessInterestLimitation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002310"
      unitRef="USD">1324000</LFMD:DeferredTaxAssetsDeferredBusinessInterestLimitation>
    <LFMD:DeferredTaxAssetsDeferredBusinessInterestLimitation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002311"
      unitRef="USD">1044000</LFMD:DeferredTaxAssetsDeferredBusinessInterestLimitation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002313"
      unitRef="USD">1026000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002314"
      unitRef="USD">957000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002316"
      unitRef="USD">23634000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002317"
      unitRef="USD">23057000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002319"
      unitRef="USD">47425000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002320"
      unitRef="USD">41122000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002322"
      unitRef="USD">1478000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002323"
      unitRef="USD">125000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002325"
      unitRef="USD">181000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002326"
      unitRef="USD">77000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002328"
      unitRef="USD">1659000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002329"
      unitRef="USD">202000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002331"
      unitRef="USD">45766000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002332"
      unitRef="USD">40920000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002337">&lt;p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zLCgu1pSCjS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_82F_z6NqwOIuiI18"&gt;SEGMENT DATA&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
portfolio of brands are included within &lt;span id="xdx_90A_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zq9U957mYN11" title="Number of operating segments"&gt;two&lt;/span&gt; operating segments: Telehealth and WorkSimpli. Our CODM, is our Chief Executive Officer.
The CODM uses segment operating income or loss to determine segment profitability in order to assess performance and allocate resources
for the Company&#x2019;s operating segments based on monitoring of budgeted versus actual results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relevant
segment data as of December 31, 2024 and December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zyCKdRG0ozxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BC_zWggW8H9Urye"&gt;SCHEDULE OF RELEVANT SEGMENT DATA&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z0ZxkcN6D8Qb" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z8DXjLnW5Gsa" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zPUFJSXthHLh" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z3pJMjIIEsMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Revenue, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;158,438,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,015,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;212,453,838&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfRevenue_z3TWGfC3QE86" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,440,799&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,627,680&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,068,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_iT_zps4XhlpR9r9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,997,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,387,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,385,359&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Significant Segment Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SellingAndMarketingExpense_i01_zAFHbU8pgdnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,102,961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,917,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,020,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LaborAndRelatedExpense_i01_zPAuieMo3Dnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,486,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,015,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,501,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--MerchantProcessingFees_i01_zbrUAVJckPu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Merchant processing fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,188,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,245,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,433,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_zCJy4GQrlFYh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,582,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,264,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,847,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SegmentReportingOtherItemAmount_i01_zPp8Ip4t0ykf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other segment items&lt;sup id="xdx_F42_ztwb1xtw1Gx8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,424,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,302,160&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,726,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_ztlhv2XSoAG8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Segment operating (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,787,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;642,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,144,681&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_iT_zFlL9CfwHeT1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Interest expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,175,405&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,181,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_zlySnjBG4wr5" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zrSxy9ahZW86" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;(Loss) income from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,962,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;636,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,326,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zwlfarbrTd6b" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zwnIXRbp2tRl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDuk6QI62Bni" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31, 2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKV456nRJjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Revenue, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;98,152,919&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,394,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;152,547,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CostOfRevenue_zGUekAk9kjB2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,480,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,419,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,900,464&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GrossProfit_iT_mtCzUSw_maCzyZ7_zD083wTGLX3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,672,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,974,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,646,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Significant Segment Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_i01_maCz1v1_zIoSahMas4kl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,589,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,861,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,451,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_i01_zHoIIfkClGWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,370,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,986,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,357,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--MerchantProcessingFees_zCbfxl9ymMj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Merchant processing fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,054,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,551,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,605,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_zqm34iUmFQB3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,140,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,491,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,632,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_zlySyI0vJb2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other segment items&lt;sup id="xdx_F49_zpQwDc974lhb"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,778,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,311,054&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,089,569&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingExpenses_iT_zLypa7UbyWIf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Segment operating (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,261,021&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,771,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,489,273&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpense_iN_di_zMFPchve7gX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,591,416&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596,586&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GainsLossesOnExtinguishmentOfDebt_zCQCwMqtgtA7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2432"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zFuCjWprjiN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;(Loss) income from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,177,635&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,766,578&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,411,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F08_zljKhSn9rp06"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zgcehwPkSHm3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items include stock-based compensation and depreciation and amortization. Stock-based compensation expense for our Telehealth
    segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zZGsrHLlmpb" title="Stock compensation expense"&gt;12.2&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcxQTe7KGASb" title="Stock compensation expense"&gt;12.5&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively. Depreciation and amortization
    for our Telehealth segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zdYLMWmwrkxa" title="Depreciation and amortization"&gt;6.2&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z7bfWnsiX78a" title="Depreciation and amortization"&gt;4.3&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively, and for
    our WorkSimpli segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Tmqa36n0Pc" title="Stock compensation expense"&gt;3.3&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zEsyztH9zCNj" title="Stock compensation expense"&gt;2.3&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_z2F4fP0uEiFf" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zWfn2jh0aEad" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 0in"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zjYMGsHstFs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%"&gt;Telehealth&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;62,340,390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;48,126,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zvVo5Oi0fuAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;WorkSimpli&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,119,636&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,354,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Assets_iI_zupw3x4yXA5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 2.5pt"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;72,460,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;58,480,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Assets_iI_zXUysruTALhg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;72,460,026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;58,480,709&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zA1FADLsphrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
expenditures for purchases of capitalized software, equipment, and intangible assets, which are reported on the Company&#x2019;s consolidated
statements of cash flows totaled $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcLHgBrYnxCb" title="Net cash used in investing activities"&gt;8.2&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zz4B4SjYmGl5" title="Net cash used in investing activities"&gt;5.4&lt;/span&gt; million for our Telehealth segment during the years ended December 31, 2024 and
2023, respectively, and $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zDcMmHExIVUd" title="Net cash used in investing activities"&gt;3.3&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zRNOKupyrKqh" title="Net cash used in investing activities"&gt;3.3&lt;/span&gt; million for our WorkSimpli segment during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;International net revenues totaled
$&lt;span id="xdx_903_eus-gaap--Revenues_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zYzsCLjapqNd" title="Revenues"&gt;14.9&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--Revenues_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zwmXbhyVuWq3" title="Revenues"&gt;14.0&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively, and relate to our WorkSimpli segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002339"
      unitRef="Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002341">&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zyCKdRG0ozxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BC_zWggW8H9Urye"&gt;SCHEDULE OF RELEVANT SEGMENT DATA&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z0ZxkcN6D8Qb" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z8DXjLnW5Gsa" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zPUFJSXthHLh" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z3pJMjIIEsMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Revenue, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;158,438,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,015,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;212,453,838&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfRevenue_z3TWGfC3QE86" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,440,799&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,627,680&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,068,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GrossProfit_iT_zps4XhlpR9r9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,997,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,387,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,385,359&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Significant Segment Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SellingAndMarketingExpense_i01_zAFHbU8pgdnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,102,961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,917,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,020,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LaborAndRelatedExpense_i01_zPAuieMo3Dnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,486,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,015,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,501,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--MerchantProcessingFees_i01_zbrUAVJckPu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Merchant processing fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,188,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,245,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,433,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_zCJy4GQrlFYh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,582,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,264,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,847,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SegmentReportingOtherItemAmount_i01_zPp8Ip4t0ykf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other segment items&lt;sup id="xdx_F42_ztwb1xtw1Gx8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,424,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,302,160&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,726,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_ztlhv2XSoAG8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Segment operating (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,787,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;642,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,144,681&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_iT_zFlL9CfwHeT1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Interest expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,175,405&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,181,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_zlySnjBG4wr5" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zrSxy9ahZW86" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;(Loss) income from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,962,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;636,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,326,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zwlfarbrTd6b" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zwnIXRbp2tRl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDuk6QI62Bni" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31, 2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Telehealth&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;WorkSimpli&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKV456nRJjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Revenue, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;98,152,919&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,394,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;152,547,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CostOfRevenue_zGUekAk9kjB2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,480,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,419,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,900,464&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GrossProfit_iT_mtCzUSw_maCzyZ7_zD083wTGLX3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,672,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,974,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,646,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Significant Segment Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_i01_maCz1v1_zIoSahMas4kl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Selling and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,589,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,861,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,451,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_i01_zHoIIfkClGWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Payroll expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,370,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,986,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,357,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--MerchantProcessingFees_zCbfxl9ymMj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Merchant processing fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,054,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,551,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,605,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_zqm34iUmFQB3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,140,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,491,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,632,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_zlySyI0vJb2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other segment items&lt;sup id="xdx_F49_zpQwDc974lhb"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,778,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,311,054&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,089,569&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingExpenses_iT_zLypa7UbyWIf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Segment operating (loss) income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,261,021&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,771,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,489,273&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpense_iN_di_zMFPchve7gX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,591,416&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596,586&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GainsLossesOnExtinguishmentOfDebt_zCQCwMqtgtA7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2432"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(325,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zFuCjWprjiN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;(Loss) income from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,177,635&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,766,578&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,411,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F08_zljKhSn9rp06"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zgcehwPkSHm3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items include stock-based compensation and depreciation and amortization. Stock-based compensation expense for our Telehealth
    segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zZGsrHLlmpb" title="Stock compensation expense"&gt;12.2&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcxQTe7KGASb" title="Stock compensation expense"&gt;12.5&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively. Depreciation and amortization
    for our Telehealth segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zdYLMWmwrkxa" title="Depreciation and amortization"&gt;6.2&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z7bfWnsiX78a" title="Depreciation and amortization"&gt;4.3&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively, and for
    our WorkSimpli segment was $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Tmqa36n0Pc" title="Stock compensation expense"&gt;3.3&lt;/span&gt; million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zEsyztH9zCNj" title="Stock compensation expense"&gt;2.3&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_z2F4fP0uEiFf" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&lt;b style="display: none"&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zWfn2jh0aEad" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;&lt;b style="display: none"&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 0in"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zjYMGsHstFs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%"&gt;Telehealth&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;62,340,390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;48,126,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zvVo5Oi0fuAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1pt"&gt;WorkSimpli&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,119,636&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,354,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Assets_iI_zupw3x4yXA5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 2.5pt"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;72,460,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;58,480,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Assets_iI_zXUysruTALhg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; padding-left: 0.125in; padding-bottom: 2.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;72,460,026&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;58,480,709&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002343"
      unitRef="USD">158438631</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">54015207</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002345"
      unitRef="USD">212453838</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002347"
      unitRef="USD">21440799</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002348"
      unitRef="USD">2627680</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002349"
      unitRef="USD">24068479</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002351"
      unitRef="USD">136997832</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002352"
      unitRef="USD">51387527</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002353"
      unitRef="USD">188385359</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002355"
      unitRef="USD">70102961</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002356"
      unitRef="USD">32917064</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002357"
      unitRef="USD">103020025</us-gaap:SellingAndMarketingExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002359"
      unitRef="USD">30486701</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002360"
      unitRef="USD">3015136</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002361"
      unitRef="USD">33501837</us-gaap:LaborAndRelatedExpense>
    <LFMD:MerchantProcessingFees
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002363"
      unitRef="USD">7188539</LFMD:MerchantProcessingFees>
    <LFMD:MerchantProcessingFees
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002364"
      unitRef="USD">3245429</LFMD:MerchantProcessingFees>
    <LFMD:MerchantProcessingFees
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002365"
      unitRef="USD">10433968</LFMD:MerchantProcessingFees>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002367"
      unitRef="USD">27582905</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002368"
      unitRef="USD">8264986</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002369"
      unitRef="USD">35847891</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002371"
      unitRef="USD">18424159</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002372"
      unitRef="USD">3302160</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002373"
      unitRef="USD">21726319</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002375"
      unitRef="USD">-16787433</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002376"
      unitRef="USD">642752</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002377"
      unitRef="USD">-16144681</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002379"
      unitRef="USD">-2175405</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002380"
      unitRef="USD">-6412</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002381"
      unitRef="USD">-2181817</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002383"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002385"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002387"
      unitRef="USD">-18962838</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002388"
      unitRef="USD">636340</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002389"
      unitRef="USD">-18326498</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002391"
      unitRef="USD">98152919</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002392"
      unitRef="USD">54394087</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002393"
      unitRef="USD">152547006</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002395"
      unitRef="USD">17480533</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002396"
      unitRef="USD">1419931</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002397"
      unitRef="USD">18900464</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002399"
      unitRef="USD">80672386</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002400"
      unitRef="USD">52974156</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002401"
      unitRef="USD">133646542</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002403"
      unitRef="USD">48589567</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002404"
      unitRef="USD">27861899</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002405"
      unitRef="USD">76451466</us-gaap:SellingAndMarketingExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002407"
      unitRef="USD">19370268</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002408"
      unitRef="USD">1986775</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002409"
      unitRef="USD">21357043</us-gaap:LaborAndRelatedExpense>
    <LFMD:MerchantProcessingFees
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002411"
      unitRef="USD">3054336</LFMD:MerchantProcessingFees>
    <LFMD:MerchantProcessingFees
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002412"
      unitRef="USD">3551247</LFMD:MerchantProcessingFees>
    <LFMD:MerchantProcessingFees
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002413"
      unitRef="USD">6605583</LFMD:MerchantProcessingFees>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002415"
      unitRef="USD">18140721</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002416"
      unitRef="USD">6491433</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002417"
      unitRef="USD">24632154</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002419"
      unitRef="USD">16778515</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002420"
      unitRef="USD">2311054</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002421"
      unitRef="USD">19089569</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002423"
      unitRef="USD">-25261021</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002424"
      unitRef="USD">10771748</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002425"
      unitRef="USD">-14489273</us-gaap:OperatingExpenses>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002427"
      unitRef="USD">2591416</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002428"
      unitRef="USD">5170</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002429"
      unitRef="USD">2596586</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002431"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002433"
      unitRef="USD">-325198</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_TelehealthMember"
      decimals="0"
      id="Fact002435"
      unitRef="USD">-28177635</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002436"
      unitRef="USD">10766578</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact002437"
      unitRef="USD">-17411057</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002440"
      unitRef="USD">12200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002442"
      unitRef="USD">12500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002444"
      unitRef="USD">6200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002446"
      unitRef="USD">4300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002448"
      unitRef="USD">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002450"
      unitRef="USD">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_TelehealthMember"
      decimals="0"
      id="Fact002452"
      unitRef="USD">62340390</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_TelehealthMember"
      decimals="0"
      id="Fact002453"
      unitRef="USD">48126006</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002455"
      unitRef="USD">10119636</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_WorkSimpliMember"
      decimals="0"
      id="Fact002456"
      unitRef="USD">10354703</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002458"
      unitRef="USD">72460026</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002459"
      unitRef="USD">58480709</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002461"
      unitRef="USD">72460026</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002462"
      unitRef="USD">58480709</us-gaap:Assets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002464"
      unitRef="USD">8200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31_custom_TelehealthMember"
      decimals="-5"
      id="Fact002466"
      unitRef="USD">5400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002468"
      unitRef="USD">3300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002470"
      unitRef="USD">3300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002472"
      unitRef="USD">14900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_custom_WorkSimpliMember"
      decimals="-5"
      id="Fact002474"
      unitRef="USD">14000000.0</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002476">&lt;p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zJOX8Zg0gjE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &#x2013; &lt;span id="xdx_82E_zdgEobbmKhxc"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Issued for Service&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January and February 2025, the Company issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBhgdAPYKUd7" title="Number of shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSYpzQfZRJY6" title="Number of shares issued"&gt;831,238&lt;/span&gt;&lt;/span&gt; shares of common stock related to vested RSUs and RSAs with a total fair value
of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1EKidScTT4g" title="Fair value total"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWoACiS7FALh" title="Fair value total"&gt;4.1&lt;/span&gt;&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cashless
Exercise of Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2025, the Company issued an aggregate of &lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesCashLessWarrantsExercised_pid_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z11KZfZR2FZa" title="Number of cash less warrants exercised"&gt;56,139&lt;/span&gt; shares of common stock related to the cashless exercise of &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCashLessWarrantsExercised_pid_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsm3ATRnstKj" title="Number of cashless warrants issued"&gt;95,000&lt;/span&gt; stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;LillyDirect
Pharmacy Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 6, 2025, the Company announced its integration with LillyDirect&#x2019;s (&#x201c;Lilly&#x201d;) pharmacy provider, Gifthealth, to
offer streamlined access of single-dose vials of Lilly&#x2019;s prescription obesity treatment Zepbound&#xae;&#160;(tirzepatide) to the
Company&#x2019;s eligible patients.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002478"
      unitRef="Shares">831238</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2025-02-012025-02-28_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002480"
      unitRef="Shares">831238</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002482"
      unitRef="USD">4100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-02-012025-02-28_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002484"
      unitRef="USD">4100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised
      contextRef="From2025-02-012025-02-28_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002486"
      unitRef="Shares">56139</LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised>
    <LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised
      contextRef="From2025-02-012025-02-28_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002488"
      unitRef="Shares">95000</LFMD:StockIssuedDuringPeriodSharesCashLessWarrantsExercised>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact002371"
          xlink:label="Fact002371"
          xlink:type="locator"/>
        <link:footnote id="Footnote002438" xlink:label="Footnote002438" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    segment items include stock-based compensation and depreciation and amortization. Stock-based compensation expense for our Telehealth
    segment was $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zZGsrHLlmpb"
  title="Stock compensation expense">12.2</xhtml:span> million and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zcxQTe7KGASb"
  title="Stock compensation expense">12.5</xhtml:span> million for the years ended December 31, 2024 and 2023, respectively. Depreciation and amortization
    for our Telehealth segment was $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_904_eus-gaap--DepreciationAndAmortization_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_zdYLMWmwrkxa"
  title="Depreciation and amortization">6.2</xhtml:span> million and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90D_eus-gaap--DepreciationAndAmortization_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TelehealthMember_z7bfWnsiX78a"
  title="Depreciation and amortization">4.3</xhtml:span> million for the years ended December 31, 2024 and 2023, respectively, and for
    our WorkSimpli segment was $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_z9Tmqa36n0Pc"
  title="Stock compensation expense">3.3</xhtml:span> million and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEVWQU5UIFNFR01FTlQgREFUQSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--WorkSimpliMember_zEsyztH9zCNj"
  title="Stock compensation expense">2.3</xhtml:span> million, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002371"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002372"
          xlink:label="Fact002372"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002372"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002373"
          xlink:label="Fact002373"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002373"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002419"
          xlink:label="Fact002419"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002419"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002420"
          xlink:label="Fact002420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002420"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002421"
          xlink:label="Fact002421"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002421"
          xlink:to="Footnote002438"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
